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ABSTRACT
Part A: Studies towards total synthesis of an antifungal and anticancer agent, Pseudolaric
acid B
Marked by the uncontrolled cell proliferation, cancer is one of the deadliest diseases,
accounting for about 7.0 million deaths in 2007. Cancer is second leading cause of death
worldwide, according to the American Cancer Society. Cancer chemotherapy has evolved
through many years of painstaking research, and as a result, today we are able to cure at least
some of cancers. One of the major impediments in the development of new drugs for treating
cancer is that most of the approved drugs are themselves toxic and produce drug resistance
during the initial exposure of these drugs. Thus there is a continued need to search for new/better
drugs. Over the years, numerous natural products have been identified as leads for the drug
discovery and development process. Some of the most well-known examples are Taxol,
vincristine, vinblastine, Camptothecin and Etoposide
Pseudolaric acid B is a diterpenoidal natural product isolated from the extract of the root
bark of Pseudolarix kaempferi, is a Chinese herbal medicine called Tu Jin Pi, which has been
used for many years against fungal infections of the skin and nails. Studies of the bark of this
plant have led to the isolation of several novel diterpene acids, namely pseudolaric acids A
(PLAA, 1), B (PLAB, 2), C (PLAC, 3) and B-Glycoside (PLAB-Gly, 4)4-6.
We hereby report our studies towards the synthesis of PLAB using a model substrate. We
have accomplished the synthesis of the model system, which can now be applied to the total
ii

synthesis of PLAB. Key steps of our approach include Lewis acid mediated Diels Alder (DA)
cycloaddition to give a bicyclo [2.2.2] acid, and a cationic 1,2- rearrangement. Series of
functional group transformation reactions of the DA adduct, epoxidation, a tandem ring-openingring closing event, decarboxylation, and an enhanced Wagner-Meerwein rearrangement afforded
a bicyclo [3.2.1] core 3.22. Unfortunately, X-ray analyses of the bicyclo derivative revealed an
inverted relative configuration. All the approaches to solving this end stage problem will be
presented in the dissertation. Finally, we were able to obtain the crucial intermediate 3.22, with
the desired relative stereochemistry. With this intermediate in hand we have started efforts to
complete the total synthesis of PLAB.
Part B: Synthesis and biological evaluation of Berkeleyamide A and its derivatives
Interleukin-1β converting enzyme (ICE), also known as caspase-1, responsible for the
cleavage and activation of interleukin-1β (IL-1β) to its active form (17K), is involved in the
pathogenesis of several auto immune inflammatory disorders. Subsequent research over the years
suggests that ICE plays a pivotal role in regulation of proinflammatory cytokines and its
inhibition can be a potential therapeutic target for the treatment of immune-mediated
inflammatory diseases.
Recently several interesting secondary metabolites have been isolated from the rare
microbes evolved in extreme ecosystems such as a Berkeley Pit Lake in search of potential
anticancer and antimicrobial agents. One such natural product, Berkeleyamide A, isolated from
the fungi Pencillium rubrum, inhibited caspase-1 (ICE) and the signal transducing enzyme
iii

matrix metalloproteinase-3 (MMP-3) in a low micromolar range. Herein we report an efficient
total synthesis of (-)-berkeleyamide A. The total synthesis was accomplished in overall 18%
yield, starting from N-Boc-L-leucinal, employing Evans’ syn-aldol reaction of N-acyl-4R-benzyl
oxazolidin-2-one as the key step. Excellent enantioselectivity (more than 95% ee) was obtained
with a good yield (75%) for the crucial C-C bond formation key reaction step. In summary, our
synthetic endeavor of (-)-berkeleyamide A is very efficient, scalable and highly
diastereoselective with the flexibility to develop various analogues of the natural product. Using
this modular approach, we accomplished syntheses of four other diastereomers. We have also
carried out molecular docking studies to predict the binding mode of berkeleyamide A in the ICE
active site. Furthermore, we designed a library of compounds as potential caspase-1 inhibitors
based on berkeleymide A scaffold.
Finally we carried out biological evaluation of Berkeleyamide A and its dervivatives. We
tested these compounds for caspase-1 inhibition, antfungal, antimalarial, antileishmanial and
cytotoxic activities. However, berkeleyamide A and its derivatives failed to show promise in any
of these assays.
.
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CHAPTER 1
PSEUDOLARIC ACID B-INTRODUCTION

Cancer is one of the deadliest diseases, accounting for about 7.0 million deaths in 2007.
Cancer is, in fact, the second leading cause of death worldwide, according to the American
Cancer Society.1 Cancer chemotherapy has evolved through many years of painstaking research,
and as a result, today we are able to cure at least some types of cancers. One of the major
impediments in the development of new drugs for treating cancer is that most of the approved
drugs are themselves toxic, and over a period of time, cancers develop resistance to existing
drugs. Thus there is a continued need to search for new and better anti-cancer drugs. By far,
chemotherapy is one of the most important and effective methods to treat or control cancer.
Over the years, numerous natural products have been identified as leads in various drug
discovery programs

2, 3

The past two decades have seen a considerable number of new chemical

entities either derived from natural products or that are natural product themselves. Newman and
Crags published a critical review on the impact of natural products on developing novel anticancer agents. In this review, they analyzed sources of new chemical entities (NCE) reported in
the literature from 1981-2008. Their analysis suggests that between 1981-2008, more than 50%
of the sources of NCE’s had natural product origins (natural product, natural product derivatives
or natural product inspired). Moreover, almost 80% of anti-cancer agents and 68% of
antiinfective agents are from natural product sources. Some of the well-known examples are:
Taxol, rapamycin, statins and several -lactam antibiotics.2-4
Our research group is involved in the total synthesis of biologically important natural
products. Our aim is to explore natural product leads, build natural product derived library and
study their structure activity relationship in quest of potent inhibitors of several important
biological targets.
1

Pseudolaric acids are novel diterpenoidal acids isolated from the root and trunk bark of
Pseudolarix kaempfer. Gordon (Pinaceae). The crude alcoholic extract of the plant (called ‘‘Tujin-pi’’) has been used for decades in China for the treatment of the fungal infections of skin and
nail.5 The antifungal activity of Pseudolarix kaempferi was reported in the literature in late
1950’s, and later detailed investigation of the extract led to the isolation and identification of the
major antifungal component, pseudolaric acids. To date, more than 20 diterpenoids have been
isolated with unique tricyclic scaffold. Up until March 2011, over 170 publications have been
reported in the literature covering different aspect of studies on the pseudolaric acids. The
pseudolaric acids and its derivatives have exhibited an array biological properties such as
antifungal, anti-fertility, cytotoxic and anti-angiogenic.5, 6
Pseudolaric acids, with their diverse biological properties and unusual tricyclic structures, have
attracted the attention of a number of research groups, resulting in several studies directed
towards the total synthesis of the natural product.
1.1 Isolation of various pseudolaric acids:
The Cortex pseudolaricis was extracted with either benzene or percolated with 95% ethanol.7
Over 20 Pseudolaric acids have been reported in the literature with Pseudolaric acid A and B
being the first ones to be isolated and characterized. Most of the pseudolaric acids have a
common scaffold, with variations only at either of R1, R2 and R3 positions. Few of them were
derivatives of pseudolaric acid A with modifications mainly on the seven membered ring and a
couple of them were pseudolaric acid B derivative with truncated side chain (Figure 1.1).6 A
comparative study analyzing the composition of the extracts of ‘‘tu jin pi’’ from different regions
in the Republic of China showed some variation in the ratio of components. However, the major
2

components in crude extract were in the following order; pseudolaric acid B (PLAB) (1.2) and its
glycoside derivative, pseudolaric acid A PLAA (1.1) and its glycoside derivative 1.5, pseudolaric
acid C.8 One of the common protocols for isolation of pseudolaric acids was extraction of the
benzene extract with sodium bicarbonate solution followed by acidification of the aqueous
extract with hydrochloric acid leading to precipitation of the mixtures of pseudolaric acids. Pure
pseudolaric acids can then be obtained via silica gel column chromatography.7, 9

Figure 1.1. Common scaffold of pseudolaric acid
Table 1.1: Structures of various Pseudolaric acids till date 6, 9-17
Name

R1

R2

R3

1.1

Pseudolaric acid A

Me

Ac

H

1.2

Pseudolaric acid B

CO2Me Ac

H

1.3

Pseudolaric acid C1

CO2Me H

H

1.4

Pseudolaric acid C2

CO2H

Ac

H

1.5

Pseudolaric acid A O--D-glucopyranoside

Me

Ac

-D-glucose

1.6

Pseudolaric acid B O--D-glucopyranoside

CO2Me Ac

-D-glucose

1.7

Demethoxydeacetoxypseudolaric acid B

CO2H

H

1.8

Pseudolaric acid B 2,3-dihydroxypropyl ester

CO2Me Ac

1.9

Pseudolaric

acid

B

H

6-O-acetyl-O--D- CO2Me Ac

glucopyranoside

CH2CH(OH)CH2OH
6-O-acetyl-b-Dglucose

3

1.10 Deacetylpseudolaric acid A

Me

H

H

1.11 Pseudolaric acid A methyl ester

Me

Ac

Me

1.12 Pseudolaric acid B methyl ester

CO2Me Ac

Me

1.13 Deacetylpseudolaric

acid

A

O--D- Me

H

-D-glucose

glucopyranoside
1.14 Deacetylpseudolaric

acid

A

2,3- Me

H

CH2CH(OH)CH2OH

acid

B

2,3- CO2Me H

CH2CH(OH)CH2OH

dihydroxypropyl ester
1.15 Deacetylpseudolaric
dihydroxypropyl ester

Figure 1.2: Pseudolaric acids with modified seven membered ring

4

1.2 Structure Elucidation:
Zhou’s research group18 performed thorough structural elucidation studies, including degradation
analysis, functional group transformations, NMR, mass spectroscopy and IR on pseudolaric
acids.19,

20

Lin et al21, using X-ray crystallographic analysis, unambiguously assigned relative

stereochemistry and structure of 1.1 (Figure 1.1) while absolute configuration of 1.2 was
confirmed to be 3S, 4S,10R,11R by use of the circular dichroism method. Hamburger et al22
carried out NMR(1D&2D) and molecular modeling studies to investigate the conformation of
1.2. Their NOEs studies revealed close spatial relationship of H3, H12 and H13. Furthermore,
their molecular modeling studies were in corroboration with NOE studies suggesting that the
lactone ring adopting a half-planar conformation.22 Recently the absolute chemistry and
structures of both 1.1 and 1.2 were also confirmed by total synthesis.23, 24

1.3 Biological properties and Mechanism of Action of Pseudolaric acid B
1.3.1 Antifungal Activity
The extract of Pseudolarix kaempferi has long been used in China traditionally to treat fungal
infections of skin.5 Hufford et al led a systematic investigation into the bioactivity-guided
fractionation of P. kaempferi to identify the active constituents responsible for its antifungal
activity.25 The authors recognized Pseudolaric acid B as the major constituent responsible for
antifungal activity of P. kaempferi. In their study, PLAB was found to be particularly active
against Trichophyton mentagropbytes, Twrtlopsispetrophiium, Mirrospwum gypseum, and
Candida species and the in vitro efficacy of PLAB was found to be comparable to amphoterecin
B, a well known antifungal compound. In order to identify the structural features required for
antifungal activity, the authors further synthesized various methylated and hydrolyzed
5

derivatives of PLAB. The SAR studies demonstrated that neither the methylated nor the
hydrolyzed compounds showed any antifungal activity. This led to the conclusion that acetoxyl
group and the C-18 free acid in PLAB moiety are necessary for antifungal activity. Compound 3,
as well as its monopotassium and monosodium salts of PLAB exhibited marginal micromolar
level antifungal activity against C. albicans. PLAB was evaluated for its ability to reduce the C.
albicans infection in murine kidney candidiasis model. PLAB was found to exhibit significant
antifungal activity against C. albicans in murine kidney candidiasis model.25
Avery et al demonstrated the concentration-dependent activation effect of PLAB for the nuclear
peroxisome proliferator-activator (PPAR) α, γ and δ isoforms in CV-1 and H4IIEC3 cell lines.
Since the peroxisome proliferator- activated receptors (PPARs) are important for the membrane
integrity and lipid metabolism of Candida species, it was speculated by the authors that the
activation of PPAR isoforms may be the plausible mechanism of anti-fungal activity of PLAB.26

1.3.2 Antifertility Activity
In a study by Zhang et al, Pseudolaric acid B has demonstrated anti-fertility activity by
decreasing the fertilization rate of hamster ova. But no effect of PLAB on spermatozoa activity
or fertilizing ability of hamster was observed in this study. 27 Anti-fertility activity of PLAB was
evaluated in several animal models, including rats, dogs, and hamsters. Although there was a
transient reduction in the progesterone levels of the animals treated with PLAB, termination of
pregnancies were not observed in these cases.27
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1.3.3 Anti-cancer activity
Apart from antifungal and anti-fertility activities of PLAB, it was shown to exhibit cytotoxicity
towards several cancer cell lines including those of the lung, colon, breast, brain and kidney by
Pan et al.28 It was discovered that minor structural modifications of the functional groups led to
significant reduction in cytotoxic activity of PLAB. The target for anticancer activity of PLAB
and PLAA was also not known and elucidated.

1.3.4 Angiogenesis
Angiogensis is a pivotal factor in tumor progression, and it is known that inhibition of
angiogensis is a potential anti-cancer target. Recently, studies have shown that PLAB exerted
potent anti-angiogenic effects in vitro, which was evaluated by vascular endothelial cell
proliferation, migration and tube formation assays. Moreover, PLAB also showed repression of
in vivo angiogenesis in the Matrigel plug and chicken chorioallantoic membrane assay.29-32 Antiangiogenetic activity of PLAB was the result of a dual mechanism. First, PLAB blocked vascular
endothelial growth factor (VEGF) mediated anti-apoptotic effect and induced cell death in
endothelial cells. The increased apoptosis of endothelial cell was due to the inhibition of VEGF
stimulated tyrosine kinase phosphorylation of the kinase insert domain-containing receptor/fetal
liver kinase-1 (KDR/flk-1), resulting in the inhibition of Akt and ERK phosphorylation.31
Second, PLAB inhibited the secretion of the angiogenic factor VEGF from breast tumor cells via
reduction of hypoxia-inducible factor-1HIF-1) protein by inducing its ubiquitin-proteasome
mediated degradation. Hypoxia inducible factor-1 is a heterodimer composed of HIF-1 and
HIF-1. HIF-1 is a key transcription factor responsible for angiogenesis in hypoxic conditions.
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Overepression of HIF-1 protein is demonstrated in several types of cancers and its degradation
can be considered as a promising target in anti-angiogenesis.30, 31
Molecular target of PLAB has been recently identified as microtubules which have been proved
to be one of the most validated targets for anticancer drug development.33 Microtubles are
polymers of -tubulin and -tubulin heterodimers playing an essential role in the organization,
development and preservation of cell shape, transport of important components of cells, cell
signaling, in cell division and mitosis. Microtubles are long filamentous tubeshaped protein
polymers present in all eukaryotic cells which undergo dynamic polymerization (two nonequilibrium dynamic states; dynamic instability and treadmilling) to facilitate cell mitosis and
division.34, 35 Wong et al demonstrated that PLAB is a novel microtubule destabilizing agent in
vitro as well as in vivo, and more importantly, it circumvents the P-glycoprotien overexpression
induced drug resistance.36, 37 Consistent with previous reports38, they also found PLAB displayed
significant cytotoxicity (Table 1) (mean IC50 0.9 g/ml) against various human cell lines.
Furthermore, with the use of NIH-3T3 cells transfected with V1 isoform, the authors
demonstrated that PLAB selectively halts the progression of actively proliferating cancer cells.
PLAB induced G2-M cell cycle arrest for cell types from different tissues liver (HepG2), breast
(MCF-7), colon (SW620), and cervical (HeLa) in a time dependant manner. To completely
understand the mechanism of PLAB induced cell cycle arrest, HepG2 cells were treated with
PLAB along with other G2-M cell cycle arrest agents etopside (topoisomerase II inhibitors) and
nocodazole (microtubule-targeting agent). PLAB and nocodazole, unlike etopside, did not have
any effect on G2 checkpoint proteins and upregulated cyclin B1, a marker for mitotic arrest. This
suggests that PLAB may arrest mitotic phase of the cell cycle which was further confirmed by
examining the effect of PLAB on microtubules organization by use of immunofluorescence
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staining of -tubulin. Wong and associates treated HeLa cells and umbilical vascular endothelial
cells with PLAB (2 mol/L) which resulted in the disruption of microtubule fibres, abnormal
formation of multipolar spindles and subsequent cell cycle arrest at prometaphase in a time
dependent manner. This study suggests that PLAB is a microtubule destabilizing agent and
exerts its cytotoxicity in a manner similar to that of colchicine and vinblastine. PLAA also shows
similar microtubule destabilization leading to apoptosis but is far less potent than PLAB.36, 37
Table 1.2 Cytotoxic activity of PLAB on different human cancer cells (IC50 ) 38
Cancer Cells

Cancer Cells

IC50 (mol/L)

IC50 (mol/L)

BGC-823

1.13 ± 0.24

Ketr3

3.58 ± 2.42

HeLa

0.50 ± 0.19

A-2780

0.87 ± 0.08

A549

5.20 ± 0.26

Skov3

0.74 ± 0.28

HCT-8

1.20 ± 0.02

Mcf-7

4.25 ± 1.37

HT-29

0.68 ± 0.03

EJ

1.04 ± 0.50

KB

0.17 ± 0.035

HKC

5.77 ± 0.65

(Table 1.2 adapted from reference no. 38)
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1.4 PLAB binding site
Wong et al examined the microtubule polymerization in vitro in the presence of PLAB,
paclitaxel and colchicine. 36, 37 As expected, paclitaxel increased tubulin polymerization due to its
stabilizing effects on the microtubules. On the other hand, PLAB and colchicine treatment
reduced the microtubule assembly in dose dependent manner suggesting that PLAB directly
interacts with tubulin. Furthermore, most of the known microtubule-disrupting agents interact
with either the vinca domain or the colchicine site of tubulin. Hence they carried out further
studies to probe the binding site of PLAB with the aid of [3H]colchicine and [3H]vinblastine
competition-binding assays. PLAB was able to displace [3H]colchicine from the binding site
when its concentration was increased gradually while [3H]vinblastine remained bounded to the
binding site. This study implies that PLAB may interact with the colchicines binding domain in a
competitive fashion and does not interact with the vinblastine binding domain. The fact that
PLAB only displaced colchicine at a higher concentration and given their structural disparity,
suggest that PLAB binds to a distinct novel binding site on tubulin that induces conformational
changes to the colchicine site and weakens colchicine binding. The observations that PLAB may
bind to a distinct tubulin binding site corroborated with research findings from Tong’s research
group32. They carried out the studies to probe the effects on the dynamics and conformation of
tubulin induced by binding of PLAB. To confirm that PLAB interacts directly with tubulin,
investigations were carried out to see the effects of PLAB on intrinsic tryptophan fluorescence of
tubulin. The tubulin has eight tryptophan residues in its primary structure and intrinsic
tryptophan fluorescence is a measure of conformational state of tubulin. PLAB enhanced the
intrinsic fluorescence, while vinblastine and colchicine decreased the intrinsic tryptophan
fluorescence of tubulin. Also, the far-UV CD showed some change in the secondary helical
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structure of the protein suggesting that PLAB binds to tubulin which brings a unique change in
its conformation.

Furthermore, unlike vinblastine and colchicine, PLAB increased the

fluorescence intensity of the tubulin bis-ANS (bis-ANS binds stoichiometrically with tubulin and
the complex is used to probe the conformational status of tubulin) complex. Additionally, PLAB
did not have any effects on the tubulin cysteine residues, which was measured by 2, 4
Dinitrothiocyanobenzene (DNTB) titration assay. Tubulin has reactive sulphydryl groups (of
Cysteine residues) located in the area, which is especially crucial for polymerization, and any
changes in reactivity of these functional group is a measure of conformational change of the
protein. DNTB is used to titrate the number of sulphydryl groups in a protein. While colchicine
and vinblastine caused a decrease in the number of reactive thiol groups, PLAB did not have any
effect on the accessibility of sulfhydryl groups on tubulin. Both these studies (bis-ANS-Tubulin
complex and DNTB titration of thiol groups) together indicate that PLAB indeed binds to a
novel, distinct binding site different than that of colchicine and vinblastine, However, the exact
binding site is yet to be determined. It is safe to conclude that neither vinblastine nor colchicine
competitively inhibits PLAB binding to tubulin.32
1.5 Explanation of other biological properties of PLAB
The identification of tubulin as the molecular target of the pseudolaric acids has helped to solve
the puzzle regarding mechanisms for their other biological activities. Though there is no direct
evidence, a plausible mechanism of antimicrobial activity of pseudolaric acids can be
microtubule destabilization in the microbes. There is a high structural similarity between tubulins
of lower and higher organisms, which makes the above assumption more logical. Along the same
lines, the anti-fertility activities of 1.1 and 1.2 can be explained and is most probably due to the
suppression of angiogenesis and inhibition of cell division during formation and development of
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the embryo. Lastly, the reduction of HIF-1 protein and subsequently inhibition of angiogenesis
can be attributed to their effect on the depolymerization of microtubules as other microtubuletargeting molecules, such as 2-methoxyestradiol or phenyl-3-(2-chloroethyl) urea have shown
similar outcomes.37
1.6 PLAB as a potential Anticancer agent:
Acquired drug resistance is one of the major hurdles in anti-infective and anti-cancer drug
development. Multi drug resistant tumour cells are characterized by the overexpression of the Pglycoprotein (P-gp) efflux pump. These P-gp efflux pumps are responsible for the development
of resistance in tumor cells to many drugs including tubulin-binding agents. Wong et al
demonstrated that PLAB’s cytotoxicity was only slightly reduced (2 fold) compared to
cytotoxicity of doxorubicin (17 fold decrease) in cells that ectopically overexpressed P-gp
proteins. Furthermore, PLAB also showed a better cytotoxicity profile than taxol in a paclitaxelselective P-gp overexpressing cell line and multidrug-resistant liver cancer cell line from the
parental cell line. These results suggest that PLAB is not a P-gp substrate and able to circumvent
P-gp mediated drug resistance in tumor cells. Furthermore, Wong and coworkers also
demonstrated in vivo efficacy of PLAB by using a xenograft mouse model. In this study, PLAB
treatment resulted in tumor suppression in a dose-dependent manner. Moreover, PLAB treatment
not only reduced the tumor growth of a taxol-resistant liver cancer but also did not show any
signs of toxicity or weight loss in the animals, indicating that PLAB is selective against tumors
in vivo.36, 37
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In summary, it is quite clear that PLAB, with its multiple modes of action, inhibition of
angiogenesis, as well as microtubule destabilization, and by virtue of its ability to circumvent Pgp mediated drug resistance, is a good lead in anti-cancer drug development.
1.7 Structure Activity Relationship of Pseudolaric acid B

Figure 1.3: Structure activity relationship of pseudolaric acids. The portion of molecule shown
in red indicates forbidden modifications and the one displayed in green indicates allowed
modification
Several research groups have synthesized numerous derivatives of PLAB and PLAA in an effort
to identify their SAR which ultimately will aid in the design of more potent analogs of
pseudolaric acid. They have tested PLAB, PLAA, other naturally occurring pseudolaric acids as
well as synthetic derivatives for antifungal and antiangiogenic activities. Interestingly, the SAR
profile of PLAB and PLAA for all the above mentioned activities is nearly the same. Core
structure of pseudolaric acid (PLAB and PLAA), along with its functional group, is absolutely
necessary for the activity. Most of the chemical modifications resulted in reduced or completely
abolished activity with exception of derivatives, which were either equipotent or more potent
than parent natural products (PLAB and PLAA)
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1.7.1 Antifungal SAR 25, 39, 40
1) The compounds exhibiting antifungal activity have amphipathic properties. All of them have a
hydrophobic polycyclic rigid carboskeleton and a hydrophilic region of an unsaturated
carboxylic acid chain.
2) R1 tolerates some lipophilic substituents, but overall, carboxylic methyl ester and methyl
functional groups as found in PLAB and PLAA respectively were the most active compounds.
Substitution at R1 with CO2Et, –CO2(n-Pr) and –CO2(n-Bu) decreased the antifungal activity.
3) The double bond at C-7 position is important for antifungal activity and any modification of
the double bond, even migration renders the resulting compound inactive.
4) The side chain is absolutely essential for the activity. Saturation of the two double bonds or
modification of the double bonds resulted in diminished activity. Shortening of lengthening of
the side chain had a similar fate.
5) The free carboxylic acid group in the side chain was found to be necessary for antifungal
activity. Ester, amide and even naturally occurring glycoside had little to no activity, however,
the sodium and potassium salts of PLAB retain the activity. Surprisingly, the NH-(thiazol-2-yl)
amide derivative exhibited better antifungal profile than the parent natural product against
Epidermophyton floccosum40
6) Finally, C-4 acetyl group is optimal for antifungal activity
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1.7.2 Antiangiogenic SAR41
Same research group carried out SAR studies for antiangiogenic activity, and the SAR is as
follows:
1) All the compounds that showed antiangiogenic activity were amphipathic in nature same as is
the case for antifungal activity. All derivatives shared this common feature: presence of a
hydrophobic domain comprising of constrained tricylic ring on the western hemisphere and a
relatively hydrophilic (E)-methylpentadienoic acid side chain on the eastern hemisphere of the
molecule.
(2) Major difference in the antiangiogenic and antifungal SAR for PLAB was seen at R1
substitution. A bulky hydrophobic R group at C-7 increased the antiangiogenic and/or anticancer
activity by almost 3-4 folds. Table 1.3 shows the amide and ester derivatives of PLAB tested
against human microvascular endothelial cells (HMEC-1), human premyelocytic leukemia (HL60), human lung cancer cell (A-549), human breast cancer cells (MB-MDA-468), human liver
cells (BEL-7402), human colon cell HCT116 and human cervical cancer cell (HeLa) in vitro.
4) Presence of ∆7 is crucial for antiangiogenic activity and saturation or modification of the
double bond leads to loss of activity. This probably suggests that the double between C-7 and C8 might lock the molecule in a favorable bioactive conformation (Not supported by any data).
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5) The side chain is absolutely essential for the activity and either saturation of the two double
bonds or shortening or lengthening of the side chain resulted in analogs to greatly decrease or no
activity.
6) Several research groups have made numerous ester and amide analogs with different degrees
of structural complexities; however, no substitution is tolerated and the free carboxylic acid
functional group is critical for antiangiogenic activity
7) Any other structural changes in the seven-membered ring, like saturation or migration of the
∆7 double bond and/or oxygenation at C-7 or C-8 will render the analogs inactive.
8) Finally, as in the case of antifungal SAR, the acetoxy group at C-4 is crucial for the activity.
The replacement, hydrolysis or the elimination of the acetoxy group, significantly attenuated the
antiangiogenic and anticancer activity.

The SAR studies PLAB showed that most of the structural feature must be retained in order to
preserve the antifungal, antiangiogenic and cytotoxic activity. To obtain significantly more
potent analogs from PLAB, studies are warranted to identify the exact target site on tubulin.
Once the active site is known, molecular modeling studies (docking) can be used to study the
binding interactions of PLAB and PLAA with tubulin active site. After understanding the key
protein-ligand interactions, better analogs can be designed with improved biological as well as
pharmacokinetic profile.
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Table 1.3: Biological evaluation of ester derivatives of PLAB against several cancer
cell lines41
R1

IC50 (µM)
HMEC-1

HL-60

A-549

HCT116

Hela

1.162±0.36

MB-MDA468
0.596±0.22

0.803±0.00

0.235±0.07

0.136±0.03

0.497±0.15

1.1a

>5.00

>5.00

>5.00

-

-

-

1.1b

1.047±0.01

0.5±0.266

1.992±0.02

0.587±0.11

0.670±0.02

0.756±0.11

1.1c

0.199±0.00

0.242±0.01

0.608±0.01

0.332±0.04

0.367±0.04

0.427±0.23

1.1d

0.238±0.04

0.190±0.03

0.677±0.11

0.243±0.02

0.234±0.03

0.262±0.01

1.1e

0.278±0.09

0.171±0.00

0.649±0.00

0.239±0.02

0.243±0.03

0.262±0.01

1.1f

0.195±0.00

0.198±0.05

0.567±0.02

0.245±0.07

0.257±0.04

0.163±0.08

1.1g

0.757±0.03

0.316±0.01

0.726±0.01

0.27±0.098

0.394±0.06

0.426±0.25

1.1h

0.216±0.01

0.264±0.00

0.676±0.11

0.298±0.08

0.304±0.03

0.212±0.05

1.1i

0.569±0.14

0.658±0.02

0.756±0.00

0.657±0.08

0.641±0.00

0.565±0.15

1.1j

0.562±0.04

0.459±0.31

0.74±0.03

0.377±0.07

0.419±0.09

0.550±0.12

1.1k

0.335±0.02

0.421±0.24

0.666±0.06

1.973±0.12

1.563±0.59

2.291±0.38

1.1l

>5.00

>5.00

>5.00

-

-

-

1.1m

>5.00

>5.00

>5.00

-

-

-

1.1n

>5.00

>5.00

>5.00

-

-

-

1.1

(Plab)

(This table is adapted from Yang et.al. J Med Chem 2008, 51, 77-85)
1.8 Synthetic studies on Pseudolaric acid (A and B):
To date, several efforts towards the total synthesis of pseudolaric acids have been published in
the literature by few research groups. However, only Chiu’s group and Trost’s group have
succeeded in completing the total synthesis of 1.1 and 1.2 respectively.
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1.8.1 Pan’s PLAA synthetic studies 6, 42:
First synthetic study towards pseudolaric acid A was reported by Pan and associates in 1989. In
their retrosynthetic analysis given below they envisioned intermediate 1.22 to be crucial for the
completion of total synthesis of PLAA. Their approach was to construct all the rings in the
tricyclic core sequentially starting from the -keto ester derivative 1.23

Scheme 1.1: Pans retrosynthetic plan
The synthesis of seven membered ring beta ketoester began with nucleophilic ring opening of the
vinyl epoxide by the dianion of ethyl acetoacetate to give a hemiketal. The hemiketal was
subsequently dehydrated using tosic acid to give tetrahydrofuran derivative 1.26, which under
thermal conditions underwent claisen rearrangement to give 1.23. -ketoester 1.23 was alkylated
to give compound 1.28, which was then subjected to base-mediated aldol reaction to give 1.29.
Aldol adduct was treated with organolithium reagent to give diol, which was treated with sodium
hydride to give lactone 1.30. The eventual completion of synthesis of PLAA and determination
of relative stereochemistry was reported by this group. Later on, Chiu et al proved that the aldol
adduct formed was actually 1.29 instead of the 1.22 and had undesired cis-fused ring junction.
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Scheme 1.2: Synthesis of lactone 1.30
Reagents and conditions: (a) Tosic acid (b) heat (c) K2CO3, toluene, 18-crown ether (d)dil. Acetic
acid (e) 0.5 equiv. KOtBu, 1 : 1 THF–tBuOH, 70%; (f)1.27, nBuLi, THF, -78°C, (g) NaH, RT, 1
h, 83%.

1.8.2 Chiu’s initial studies 43
Chiu and associates decided to revisit the strategy employed by Pan, i.e. sequential construction
of the three rings of PLAA. However, Pan’s earlier aldol reaction could not be reproduced
instead a carbocyle was obtained. Further analysis suggested that aldol adduct formed which
degraded under basic condition in a retro aldol fashion.
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Scheme 1.3: Chiu’s synthesis of 1.35 using reductive aldol.
Reagents and condition Reagents and conditions: (a) 0.5 equiv. KOtBu, 1 : 1 THF (b)
[Ph3PCuH]6, PhMe, -23 °C, 0.5 h, 66% : 16% (1.34:1.35).
After this failure, Chiu’s research group investigated a reductive aldol cyclization of unsaturated ketone 1.34 catalyzed by copper reagent [Ph3PCuH]6 (Scheme 1.3). Primarily two
aldol products were formed; 1.35 and 1.36 (66:16 %) in good yields and the relative
stereochemistry of both the products were determined by X-ray crystallographic analysis.
Unfortunately, none of them had the desired relative stereochemistry required to complete the
total synthesis of PLAA
1.8.3 Bai’s studies44, 45
Bai was the first one to explore an asymmetric route for the construction of tricyclic core of
PLAA using chiral pool synthesis starting with D (-)-mannitol. Their retro synthetic approach is
delineated in the scheme given below
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Scheme 1.4: Bai’s retrosynthesis of PLAA
The key step employed by Bai was Harmata’s generation of allyic cation for tandem Pummerer
rearrangement and intramolecular [4+3] cycloaddition to build the 5,7 fused ring system. 
unsaturated ester 1.39 derived from D-(-)-mannitol was subjected to furyllithium conjugate
addition in highly diastereoselcetive fashion, and the resultant ester was reduced using LAH to
give alcohol 1.40 in moderate yields over two steps. The alcohol was converted to iodide 1.41
and was alkylated with methyl acetoacetate furnishing 1.42. Compound 1.42 was deprotonated
and quenched with diphenyl disulfide to give sulfide 1.43, which was then oxidized and
alkylated in situ to give E-enol ether 1.44. The enol ether was reduced using dibal, and the
obtained alcohol was subjected to tandem Pummerer rearrangement and intramolecular [4+3]
cycloaddition. The thionium ion formed in situ in the Pummerer rearrangement undergoes
intramolecular [4 + 3]
cycloaddition with furan moiety of 1.45b affording a trans fused 5,7 fused ring compound 1.46.
The absolute stereochemistry at C-1 and C-2 was established by NOESY experiments to be
trans; similar to that of PLAA. However, stereochemistry at center 3 required inversion to
advance the synthesis of PLAA and was done in the following manner. Reduction of double
bond, desulfurization, hydrolysis of enol ether and detrifluoroacetylation of 1.46 were carried out
in one pot using H2 - Raney Ni affording acetonide 1.47 which cleaved in oxidative fashion to
furnish aldehye. Aldehyde (1.47a) was epimerized to enol, which underwent intramolecular
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hemiacetalization in acidic environment to give hemiacetal 1.48 in very moderate yield.
Completion of the total synthesis is yet to be reported.44, 45

Scheme 1.5: Bai’s synthesis of hemiacetal intermediate 1.48 for synthesis of PLAA
Reagents and conditions: (a) i) 2-furyllithium, dr > 20:1; ii) LAH (b) I2, PPh3 (c) methyl
acetoacetate, NaH; (d) Oxidation (e) (CF3CO)2O, 2, 6-lutidine, CH2Cl2, RT, overnight, 50% (dr
> 95%); (f) CF3COOH, CHCl3, reflux, 12 h, 33% (60% of 85 recovered).

1.8.4 Chiu’s total synthesis
Chiu’s group reported the first total synthesis of PLAA in 2006. Given below is their
retrosynthetic scheme 1.6, which relies on cleavage of lactone and HWE disconnection of PLAA
to give a crucial aldehye intermediate 1.49. They envisioned the aldehyde from a octahydro
epoxyazulene intermediate 1.50, which, in turn, can be visualized from a intramolecular carbine
cyclization cycloaddition (CCCC) cascade reaction starting from the diazo ketone 1.51. They
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proposed the synthesis of diazo ketone from compound 1.52 via asymmetric Evans aldol reaction
and homologation.

Scheme 1.6: Chiu’s retrosynthetic analysis for synthesis of PLAA
Retrosynthetic Analysis
Synthesis began by p-methoxy benzyloxy monosubstitution of commercially available allyl
dichloride to give ally chloride 1.53, which was then alkylated with zinc homoenolate of methyl
3-iodopropionate affording ester 1.54.

The ester was converted to thioester and further

transformed into silyl enol ether. The enol ether was then subjected to a [Cu][OTf]2 catalyzed
asymmetric aldol reaction with methyl pyruvate giving aldol adduct in 76% yield and more
importantly with 88% ee. Tertiary hydroxy group generated having required absolute
configuration was protected by TBS and the thioester group is reduced to aldehyde 1.55. The
aldehye was then submitted to reduction with LAH giving a triol 1.56. The 1,3 diol of 1.56 was
protected as dioxalane and the remaining primary alcohol was oxidized using DMP to give
aldehyde 1.57.
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Scheme 1.7: Synthesis of compound 1.59
Reagents and conditions: a) NaH, PMBOH, THF, reflux, 61%; b) ICH2CH2CO2Me, Zn(Cu),
CuCN, 91%; c) NaOH, MeOH d) EtSH, DCC, DMAP, CH2Cl2 e) i) LDA, TESCl, THF, -78ºC;
ii). [Cu{(S,S)-tBu-box}][OTf ]2 , methyl pyruvate, 88% ee; f) TBSOTf, 2,6-lutidine, DCM, RT,
g) Et3SiH, Pd/C, CH2Cl2, h) LAH followed by TBAF, THF, i) 3,3-dimethoxypentane, PTSA, ; j)
Dess–Martin periodinane, k) ClMgO(CH2)3MgCl, THF l) 3% [Rh2{(S)-bptv}4], PhCF3, 408C,
82% yield (50% 21a, 32% 21b).
PMB

=

p-methoxybenzyl,

dicyclohexylcarbodiimide,

DMA

DMAP

=

=

N,N-dimethylacetamide,

4-dimethylaminopyridine,

DCC
LDA

=
=

N,Nlithium

diisopropylamide, TES = triethylsilyl, tBu-box = 2,20-methylenebis(4-tert-butyl-2-oxazoline), Tf
=

trifluoromethanesulfonyl, TBS = tert-butyldimethylsilyl, TBAF = tetrabutylammonium
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fluoride, PTSA = p-toluenesulfonic acid, DMP = Dess–Martin periodinane, bptv = a-(tertbutyl)-1,3-dihydro-1,3-dioxo-2H-benz[f]isoindole-2-acetato, DMPU = 1,3-dimethylhexahydro2-pyrimidinone, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, CSA = camphorsulfonic
acid.
The aldehyde 1.57 was homologated with Grignard reagent ClMgO (CH2)3MgCl developed by
Normant et al; to give a diol, which was subjected to series of steps to give the crucial chiral
diazoketone intermediate. The diazoketone 1.58, was converted into the required cylcoadduct
1.59 utilizing Hashimoto’s chiral rhodium catalyst; [Rh2{(S)-bptv}4] catalyzed CCCC cascade
reaction. Mechanistically, an electrophilic carbene generated from diazoketone 1.58 cyclized
with the tethered carbonyl group to form a carbonyl ylide, which instantaneously undergoes
intramolecular [5 + 2] cycloaddition.
In this key reaction, cycloadduct obtained had all the requisites of stereochemistry; however, this
reaction suffered from moderate diastereoselectivity (1.6:1). Ketone in the cycloadduct 1.60 was
subjected to nucleophilic methyl magnesium bromide addition giving single diastereomer 1.61.
Tertiary alcohol containing compound 1.61 was treated with thionyl chloride giving mixture of
chlorides 1.62. This mixture was subjected to a reductive protocol that resulted in cleavage of
oxygen bridge and installation of the double bond to give compound 1.63 with perhydroazulene
core. Simple functional group transformation and deprotection furnished mixed acetal 1.64. The
primary alcohol in 1.64 was oxidized and homologated by a HWE reaction developed by Avery
research group. Four routine functional group transformations yielded pseudolaric acid A in 26
linear step in 1.4% overall yield.23, 46, 47
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Scheme 1.8: Completion of Total synthesis of PLAA
Reagents and conditions: a) MeMgCl, THF, b) SOCl2, DMPU, 0ºC–RT; c) Na, Et2O, reflux,
78% d) DDQ e) Dess–Martin periodinane, f) MeOH, CSA, RT, 95%; g) Dess–Martin
periodinane; h) (E)-(EtO)2POCH2CH=C(CH3)CO2MEM , nBuLi, THF, 83%; i) 60% AcOH, j)
Dess–Martin periodinane; k) 3N HCl/THF, RT, 66%; l) AcCl, DMAP, 80%. DMPU=1,3dimethylhexahydro-2-pyrimidinone,

DDQ=2,3-dichloro-5,6-dicyano-1,4-benzoquinone,

CSA=camphorsulfonic acid, MEM=2-(methoxyethoxy)methyl.
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1.8.5 Trost’s synthesis of PLAB:

Scheme 1.9 : Trost’s retrosynthetic approach
Trost’s retrosynthetic approach
Trost’s group reported the first asymmetric total synthesis of Pseudolaric acid B. Their synthetic
approach (scheme 1.10) relies on building the polyhydroazulene scaffold via the Ru catalyzed
intramolecular cycloaddition reaction of an alkyne and a vinylcyclopropane. The scaffold 1.66
can be further transformed into important precursor 1.65, which, then can be subjected to a free
radical mediated cyclization yielding the tricyclic core. The synthesis of vinylcyclopropane 1.67
was carried out in 10 steps in a modular fashion. Optically pure iodide 1.71 was obtained in 5
steps from 2-acetylbutyrolactone wherein the stereogenic center were set by use of Noyori
reduction. To this end, the cyclopropyl aldehyde derivative was synthesized in three steps from
cis-butenediol using Charette cyclopropanation. The iodide was homologated using
triphenylphosphoniummethylide, and the resulting in phosphonium salt (not isolated) was
immediately subjected to Schlosser-Wittig olefination with the aldehyde to give TMS protected
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alkyne. Alkyne was subjected to deprotection to give the crucial intermediate required for [5+2]
the cyclodaddition reaction. The key cycloaddition reaction was carried out successfully using
both by ruthenium based catalyst as well as rhodium based catalyst. However, with ruthenium
(23 mol%) based catalyst only 48% yield was obtained, while in the case of rhodium catalyst (11
mol%) 88% yield was obtained for the required regioisomer. Lower yields obtained in the case
of ruthenium based catalyst may be a result insertion of ruthenium in to labile bisallyl C-H bond
leading to formation of Ru-cyclopentadienyl complex, finally, deactivating the catalyst.

Scheme 1.10: Trost’s synthesis of crucial intermediate 1.66
Reagents and Conditions: Conditions: (a) Noyori asymmetric reduction (b) TBSCl, imidazole,
DMAP, DMF; (c) DIBAL-H, -78 °C; (d) TMSCHN2, LDA, THF, -78 °C, then TMSCl, (e)
PPh3, I2, imidazole, (f) TBDPSCl, imidazole, THF, 92%; (g) S Charette’s auxiliary, CH2Cl2 (h)
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Swern (i) (1) MePh3P+Br-, PhLi (2) 71, PhLi/LiBr; (3) 74, -78 °C, then PhLi/ LiBr, (4) HCl, -78
°C, then KOtBu, 23 °C; (j) K2CO3, MeOH, 58% (k) 11 mol % 1.76

Scheme 1.11 Trost’s completion of total synthesis of PLAB
Reagents and Conditions: (a) i) TBAF, 3 Å MS, ii) TESCl, imidazole, DMAP, DMF, 85%; (b)
m-CPBA, (c) LDA, THF, (d) DDQ, pH 7 buffer, DCM; (e) MnO2, KCN, (f) TBAF (g) CDI,
THF, quant; (h) Ph2Se2, NaBH4, DMF, 92%; (i) PMBOC(NH)CCl3, 2 mol % Sc(OTf)3, (j)
Bu3SnH, 1,1-azo(biscyclohexanecarbonitrile),(k) KOTMS, toluene, 120 °C, Me2SO4, (l) DessMartin periodinane, NaHCO3, (m) DDQ (n) TMSCtCCeCl2.2LiCl, THF, -78 °C (o) Otera’s
catalyst,12 toluene, 130 °C, 94%; (p) TBAF,
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The diene was isomerized as well as deprotected by molecular sieve activated TBAF, and the
diol obtained was protected with TES group. The use of TES protecting group allowed for
diastereoselective epoxidation of the tetrasubstituted double bond using mCPBA. The
eliminative epoxide opening by LDA afforded the tert-alcohol with required stereochemistry at
C-4. Series of functional group transformation and deprotection gave the diol 1.81 in good
yields. Next, alkoxy carbonyl radical mediated cyclization was used for formation of the lactone
ring. Initial attempts of use of intermediate 1.82 with side chain precursor attached to it did not
furnish any cyclized product due to predominant tertiary propargyl radical formation.
Alternatively, use of the secondary alkoxycarbonyl selenium compound in radical cyclization
protocol resulted in mixtures of double-bond isomers, which were treated then with DBU to give
only the desired ester.24, 48
Finally, to install the side chain, it was imperative that the lactone be hydrolyzed and that the
total synthesis of the natural product be completed. Lactone was hydrolyzed by using KOTMS,
the acid was immediately esterified and the secondary alcohol was oxidized to give compound
1.84. The PMB group was removed before mounting the side chain to prevent -elimination.
TMS-acetylene was added on to the ketone in the form of TMS(C)2CeCl2.2LiCl to afford a
felkin-anh model favored alcohol at C-11 with required stereochemistry. The tert alcohol was
then subjected to lactonization to form tricyclic core using Otera’s catalyst. Finally PLAB was
assembled by deprotection, scandium triflate catalyzed acetylation, hydrostannylation, and Stille
coupling with the iodide.
In summary, Trost’s group completed the total synthesis of plab using rhodium catalyzed [5+2]
cycloaddition in 28 steps with overall 1.4% yield.
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Chiu’s and Trost’s research group completed the total synthesis of PLAA and PLAB
respectively. However, both the routes are very laborious and lengthy. A novel short route for
synthesis of pseudolaric acids is warranted in order to carry out detailed structure activity
relationship studies. The route should be amenable to scale-up in order to make several analogs
of pseudolaric acid B in search of potent anticancer and antifungal agent.
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CHAPTER 2
PRIOR WORK IN OUR LAB

PLAB is one of the exciting natural products with intriguing biological properties and is a
challenging synthetic target. We have been engaged in the semi-synthesis and total synthesis of
PLAB, with the goal of performing structure-activity relationships in the pursuit of potent
antifungal and anticancer agent. Our total synthetic plan was based on the fact that the tricyclic
core of PLAB could be accessed through a Wagner-Meerwein-type (WM) rearrangement from
intermediate 2.4, followed by an oxidative ring opening and subsequent rearrangement of 2.2 to
give an aldehdye 2.1(Scheme 2.1). In order to test the validity of intermediate 2.1 in completion
of the total synthesis of PLAB, we decided to carry out degradation analysis of the natural
product. In degradation analysis a natural product is broken down in a systematic manner until a
crucial intermediate (in this case intermediate 2.1) is indentified and then from the crucial
intermediate, the natural product is reconstructed.49

Scheme 2.1: Retrosynthetic Scheme for PLAB
Intermediate 2.6 could be obtained by degradation of PLAC as shown in Scheme 2.2.
(We chose PLAC for degradation to 2.6 over PLAB because it was found in higher yields during
isolation of Pseudolarix kaempferi bark). Acid functional group in 2.6 was converted to acid
chloride, which was reduced selective to alcohol in the presence of an ester using
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LiAlH(OCMe3)3 (72%, 2 steps) and the endo double bond was reduced by using magnesium to
give intermediate 2.7.

Scheme 2.2 : Degradation of PLAC
Reagents and conditions: (a) (i) SOCl2, 70°C (ii) THF, −78°C, LiAlH(OCMe3)3; (b) Mg, MeOH,
rt, (c) Ozonolysis (d) 2,4-(NO2)2C6H3NHNH2,cat. HCl; (e) THF, −78oC, 1.1 equiv.
LiAlH(OCMe3)3.
Ozonolysis, followed by reductive workup of diene 2.7, provided two aldehydes; aldedhye 2.8
(major) and aldehyde 2.1 (minor). To confirm the absolute stereochemistry of the intermediate
2.8, the aldehyde intermediate was transformed into a 2,4-dinitrophenyl hydrazone 2.9. Single
crystal obtained was resolved using X-ray crystal analysis. (scheme 2.2). Aldehyde intermediate
2.8 was converted to the required aldehdye 2.1 in two steps; reduction of aldehdye to allylic
alcohol and ozonolysis of the allylic alcohol.
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With intermediate 2.1 in hand, the next important task was to rebuild PLAB from the crucial
intermediate 2.1. The first step involving acetylation of the sterically hindered tertiary hydroxyl
group proved to be difficult as anticipated. After few initial attempts, treatment of 2.1 with
scandium triflate and Ac2O in acetonitrile afforded acetate 2.13, albeit with poor yield. The
Aldehyde was subjected to a Wittig reaction to install the side chain, furnishing diene 2.11

Scheme 2.3: Reconstruction of pseudolaric acid B from crucial intermediate 2.1.
Reagents and conditions: (a) Ac2O, MeCN, Sc(OTf)3, −20 to 0°C; (b) (EtO)2P(O)CH2CHC(Me)COOMEM , n-BuLi, THF, −20 to 0°C; (c) KHMDS, THF, −78°C, then PhSeCl, −23°C, then
AcOH, H2O2; (d) AcOH, THF, H2O, rt.

Final steps in total synthesis of PLAB were the regeneration of the endo double bond and
the deprotection of the acid functional group. The endo double bond was reinstated by trapping
potassium hexamethyldisilazane (KHMDS) mediated anion of ester with PhSeCl and the
subsequent oxidative elimination of the selenium compound to give pseudolaric acid B as the
major product. 49(scheme 2.3)
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In summary, crucial intermediate 2.1 was indentified for the completion total synthesis of
PLAB. Furthermore, it was demonstrated that PLAB could be constructed from these
intermediate aldehdye 2.1 in four steps. The key steps in the completion of the total synthesis
were installation of acetyl group onto the hindered tertiary hydroxyl group, the building of side
chain via a Horner-Wadsworth-Emmons reaction and reinstatement of the desired endo double
bond by Selenylation and oxidative elimination sequence. The synthetic approach developed in
our group is not only important for completion of total synthesis of PLAB but also for the
synthesis of PLAB analogs (generation of diverse libraries). This route can also used for
radiolabeling of PLAB to probe its mechanism of action, especially useful in identifying the
tubulin binding site.

Scheme 2.4. More detailed Retrosynthetic Analysis for Pseudolaric Acid B
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With encouraging results from degradation analysis, the next task was to devise a strategy
for synthesis of the crucial intermediate 2.1, via Wagner-Meerwein arrangement of highly
oxygenated species 2.4 (retrosynthetic 2.4 scheme detailed version).
An unreported aspect of the proposed [2.2.2]→[3.2.1] WM rearrangement, of having the
bridgehead sp3-C of the bicyclo[2.2.2]octanyl core surrounded by  and -O atoms, a
COOR moiety and possibly a fourth electron withdrawing -X group, was to be quickly
ascertained.

While it is accepted that the bridgehead -:O:- atom in WM rearrangements

provides a rate accelerating effect (due to the contribution of lone pair electrons towards
stabilization of the WM intermediates), a -carboxyl group would be less likely to exert electron stabilization as this would require the prior enolization of the carboxyl moiety. In the
model system chosen, the second -carboxyl group would roughly mimic the electron
withdrawing capacity of an X group, thus suggesting that 2.14 should provide useful information
regarding the likelihood of a successful rearrangement for 2.4 (or congener). In order to test
these hypotheses, synthesis of 2.14 was smoothly accomplished as follows in Scheme 2.5. Diels
Alder (DA) addition of diethylfumarate to 1-trimethylsilyoxy-3-methylcyclohexadiene 2.16
afforded a 1:1 mixture of [4+2] cycloadducts 2.17 and 2.18. After chromatographic separation,
2.17 was arbitrarily chosen for allylic bromination to provide the allylic bromide 2.19 in 90%
yield. Treatment of 2.19 with AgClO4 in benzene resulted in the immediate precipitation of
AgBr and concomitant formation of the desired exocyclic product 2.20, thus confirming our
presumption that the bicyclic diester would undergo a Wagner-Meerwein shift. 50
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Scheme 2.5: Synthesis of the model system
Reactions and conditions: a) diethyl fumarate, heat; b) NBS, h, and c) AgClO4·H2O, benzene.

These results were suggestive that the key rearrangement step in the retrosynthetic
analysis (Scheme 2.4) would be successful despite the electron withdrawing ester group(s). With
this important finding in hand, we embarked upon the more complex ring-fused system intended
to lead us to the natural product PLAB.
With success of Wagner-Meerwien rearrangement in the model system, next step was to
test our hypotheses in actual substarte. After few initial attempts, the synthesis of diene 2.5 was
successfully carried out with good yields starting from napthalone derivative 2.15. Key steps is n
this conversion were; dimsyl anion mediated one carbon Wittig reaction, Thallic (III) nitrate
mediated oxidative ring expansion and birch reduction.

Scheme 2.6: Synthesis of diene derivative 2.5.

37

A more appealing approach to the DA adduct 2.14 involved the possibility of achieving
an intramolecular Diels-Alder (IMDA) via the 7-membered ring R group tethered to the X
position. To accomplish this 1,3 diene was acylated with appropriate acid chloride or silyl
chloride (e.g. when R = -SiMe2CH=CH2; -SiMe2CH2CH=CH2; E-COCH=CHCOOEt; ECOCH=CHCl). Unfortunately, of the several precursors synthesized and differen reaction
conditions attempted, all failed to successfully undergo IMDA reaction under a variety of
cycloaddition conditions. It was felt that the IMDA precursors were not stable due to impurities
catalyzing rapid thermal decomposition.

Scheme 2.7 Intramolecular Diels-Alder approach
After the difficulties encountered in the intramolecular approach, it was assumed that
intermolecular reaction with maleic anhydride, a highly reactive dienophile, could at least serve
to provide access to the ring system. Gratifyingly, the silyl-protected 1,4-diene 2.22 undergwent
cycloaddition with maleic anhydride in presence of glass wool to give the diastereomers 2.25 and
2.26, in a ratio of 4:1, respectively. It was postulated that the dicarboxylic acids from hydrolysis
of anhydride diastereomers 2.25 or 2.26 would undergo literature precedented decarboxylative
olefin formation upon treatment with Pb(OAc)4, leading to a bicyclo[2.2.2]octadienyl functional
arrangement as in 2.27, Scheme 2.9.
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Scheme 2.8: DA using maelic anhydride

Scheme 2.9: Decarboxylation and lactonization using NaOH and Pb(OAc)4

However, surprisingly, a single decarboxylation and lactone ring formation occurred in a good
yield to provide the highly stable tetracyclic lactone 2.28. In review of the mechanism of the
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reaction, it was noted that the anhydride was hydrolyzed first with hydroxide ion to a
dicarboxylate salt, which was treated directly in vitro with lead tetraacetate. The reaction was
rapid and clean, and when stopped early, did not demonstrate the presence of mechanistically
suggestive intermediates like the dilactone 2.32.

Instead, the product structure implies a

mechanism, possibly radical, in which the bridging carboxyl radical 2.31 can undergo cyclization
by a 5-endo-tet closure, with either simultaneous or stepwise bridge migration (WMR) leading to
the enol ether intermediate 2.33. Ensuing decarboxylation of 2.33 then finally gives the product
di-ether 2.34, or after in situ desilylation, the enol-ether alcohol 2.28.

Scheme 2.10 lead tetraacetate decarboxylation, mechanistic insights
In an effort to make use of this remarkable reaction, elimination of water from 2.28 (acid
treatment) was attempted but was not successful, the sole product being the stable keto-lactone
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2.36, formed again in high yield. Attempts to reduce the lactone of 2.34 or 2.35 were also
unsuccessful. The reticent behavior of the lactones 2.28 and 2.34-2.36 led to their eventual
abandonment in order to explore similar Pb(IV) chemistry on the corresponding epoxide, which
had the virtue of not having an available double bond to undergo lactone formation. Thus,
epoxidation of the anhydride 2.25 gave the expected epoxide 2.37. Upon exposure to NaOH, it
was hoped that the other lactone would form by SN2 ring opening from the less hindered
secondary epoxide carbon to give lactone 2.38.

Scheme 2.11 Synthesis of lactone 2.41
Reactions and conditions a) m-CPBA, CH2Cl2; b) NaOH; H+; c) Me2SO4, Na2CO3, acetone.

While 2.37 did lead to a 5-membered ring lactone-acid as hoped, once again bridgehead
lactonization was the sole ring-opening product, lactone 2.40. Unfortunately, all the approaches
to make use of the remarkable lead tetracetate catalyzed reaction were futile.50
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Finally, we decided to examine was the use of an intermolecular DA reaction with methyl
acrylate. This route would remove the second carboxyl moiety at the outset, thus eliminating the
need for complicated interconversions.

As before, the 1,4-diene was elected as a starting

material using glass wool to effect in situ Lewis-Acid catalyzed isomerization of the 1,4-diene to
the 1,3-diene. While this approach had been successfully employed with maleic anhydride,
acrylates were polymerized before DA reaction could occur. While the possibility existed of
returning to the earlier protocol of hydrolysis of the 1,4-dieneol ether to a -unsaturated enone
which could then be enolized and trapped as the silyl 1,3-dieneol ether, we decided to set this
system aside for the time being and work with a slightly simpler decalin system. Once details of
the rearrangement could be solved, we felt we could more confidently return to the suberone like
scaffold.

42

CHAPTER 3
STUDIES TOWARDS TOTAL SYNTHESIS OF
PSEUDOLARIC ACID B

3.1 Synthetic Approach 1:
With the failure of IMDA and succinic anhydride intermolecular DA, we focused our attention
on the methyl acrylate DA reaction. Given below is our revised retrosynthetic, scheme 3.1. Our
synthetic plan is based on the fact that the tricyclic core of PLAB could be accessed through an
oxidative ring opening and ensuing rearrangement of 3.2. Intermediate 3.2 can be visualized via
Wagner-Meerwein (WM) or a pinacol type rearrangement of highly oxygenated species51 3.4.,
which in turn can be envisioned as a Diels-Alder adduct 3.5. The adduct 3.5 can be obtained via
a Diels-Alder reaction between the electron rich diene 3.6 and appropriate deinophile.

Scheme 3.1: Retrosynthetic Analysis for Pseudolaric Acid B
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Diene 3.6 can be prepared from 2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene. With our
relay system established and crucial intermediates indentified, we wanted to quickly test our
hypothesis. To facilitate this study, we chose to begin with a model system (Scheme 3.2), which
can be accessed via readily available and inexpensive starting materials and which would
provide quick access to the necessary Wagner-Meerwein precursor. With this precursor in hand,
we could then determine the necessary conditions to bring about the molecular rearrangement.

Scheme 3.2 : Retrosynthetic scheme for model system
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3.2 Synthesis of Model system:
Synthesis of the model system commenced with Birch reduction of commercially
available 6-methoxy-1,2,3,4-tetrahydronaphthalene 3.13 to give the cross-conjugated diene 3.14
in 91% yield. Compound 3.14 readily underwent hydrolysis in the presence of catalytic amounts
of oxalic acid in methanol/water mixture furnishing the unconjugated enone 3.15 in 78% yield
(Scheme 6). The kinetically formed lithium enolate of 3.15 mediated by lithium diisopropyl
amide, was trapped with tert-butyldimethylsilyl chloride in THF affording the TBS-protected,
conjugated dienol ether 3.16, in 82% yield. After screening through several protocols, DielsAlder cycloaddition of methyl acrylate with 3.16 in the presence of trimethyl aluminum and
diethyl aluminum chloride52 in THF at -20°C proceeded smoothly. It resulted in an 81% yield of
a 9:1 mixture of endo:exo regioisomers 3.18 and 3.19, respectively, which were readily separated
by silica gel flash column chromatography.53

Scheme 3.3 : Synthesis of diene 20
Reagents and conditions a) Li/NH3, EtOH, Et2O, -78°C, 91%; b) oxalic acid (cat.), MeOH/H2O,
RT, 78%; c) LDA, TBSCl, THF, -78°C-RT, 82%; d) methyl acrylate, Me3Al, Et2AlCl, THF, 20°C, 81%, 9:1.
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Once the tricyclic architecture had been established, the next mission was to carry out the
molecular rearrangement to obtain the crucial enone, which can then be oxidatively opened and
rearranged to obtain the crucial aldehdye intermediate 3.9.

The classic Wagner-Meerwein

rearrangement involves the use of free hydroxyls under acidic conditions. We subjected the
tricyclic alkene 3.18 to mCPBA epoxidation (obtained exclusively only one isomer) followed by
treatment with aqueous sodium hydroxide resulting in the opening of the epoxide and hydrolysis
of the ester to give dihydroxy acid 3.20. We believed that compound 3.20 had the right
architecture required for Wagner-Meerwein type or a pinacol type rearrangement. Our initial
attempts to rearrange 3.20 under Lewis acid or protic acid conditions proved to be unsuccessful.
The dihydroxy acid was relatively unstable and instantaneously cyclized to the lactone under
acidic conditions. To block this pathway and to accelerate or initiate the rearrangement, we
decided to activate the hydroxyl group using a methane sulfonyl group. Treatment of the
carboxylic acid 3.20 with methane sulfonyl chloride and triethylamine in dichloromethane at 0°C
yielded compound 3.21. After a quick filtration column, mesylate was dissolved in toluene and
heated to 180°C for 4 hours in a sealed tube providing the rearranged tricyclic -hydroxy ketone
(either 3.22 or 3.23), while yielding only a small amount of the lactone. The structure of the
ketone was confirmed by NMR (1D and 2D) and spectroscopic techniques. There was a
possibility of two isomers from this rearrangement; either it can be desired ketone 3.22 or
undesired ketone 3.23. At this time, it was crucial to investigate the relative stereochemistry of
the product of rearrangement. Extensive 2D NMR studies conducted were inconclusive and
could ascertain the relative stereochemistry of the product. Fortunately, we were able to
crystallize the ketone from ethyl acetate and the single crystal obtained was submitted for X-ray
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analysis. X-ray of ketone revealed that the tricyclic -hydroxy ketone had undesired relative
stereochemistry and indeed we had obtained ketone 3.24 instead of 3.23 (figure 3.1).

Scheme 3.4: Synthesis of rearranged ketone 3.23
Reagents and conditions a) m-CPBA, NaHCO3, CH2Cl2, 99%; b) NaOH (aq), 5:1 MeOH/H2O,
RT, 70% c)

MsCl, Et3N, CH2Cl2, 0 °C; d) toluene, 180 °C, 56% (2 steps) e) IBX,

DMSO/Toluene, 75°C, 59%
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Figure 3.1: ORTEP plot of the X-ray crystal structure of the ketone 3.23 depicting the relative
stereochemistry
To explain this unanticipated result, we postulated a step-wise mechanism pathway, as
demonstrated in scheme 6. The reaction can proceed via two distinct pathways: Pathway A,
where migration of bond B is favored or pathway B, where migration of bond A is preferred. In
order to obtain our desired compound the course of the reaction should have been pathway A. In
pathway A, migrating bond B is antiperiplanar to the leaving group suggesting a S N2 type one
step mechanism. Unfortunately, it seems that the rearrangement of the trihydroxy acid occurred
via pathway B. In Pathway B, the leaving group is in the same plane as the migrating group,
suggesting two step SN1 type mechanism (formation of carbocation followed by migration of
bond A, with sp3 hybridized carbon almost getting sp2 character). In our case, pathway B was
favored, either due to a predominant SN1 type mechanism, or due to higher migratory aptitude of
carboxy substituted bond. Later we also calculated the total energies of both the ketones. The
molecules were sketched using Maestro graphical user interface from Schrodinger. The two
molecules were then subjected to energy minimization using OPLS2005 force-field. The
minimized conformation were then used as a starting conformation for the geomtery
optimization using Jaguar module available in Schrodinger Suite. Jaguar is well-known and well48

established module for quantum chemical calculations. We used Hybrid Density Finctional
Theory (B3LYP) method with split basis set function (6-31G**) for geometry optimization. The
energies of the two molecules were calculated and the energy difference is reported. These
calculations also (slightly) supported the formation of more stable ketone 3.23. The relative
energy of isomer 3.22 was higher by (ΔE= E[3.23-3.22]= -3.0kcal/mol) 3.0 kcal/mol (figure 3.2
and 3.3)

Scheme 3.5: Mechanistic insights in to Wagner-Meerwien type rearrangement
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=

Figure 3.2: Molecular energy calculation for the ketone 3.22 T.E = 33.5599 kcal/mol (Chem3D)

=

Figure 3.3: Molecular energy calculation for the ketone 3.23 T.E = 30.1534 kcal/mol (Chem 3D)
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Though we were able to successfully accomplish a novel Wagner-Meerwien [2.2.2]→[3.2.1]
type rearrangement, its application to the completion of total synthesis needed some fine tuning.
Our strategy was to change the migratory aptitude in the rearrangement reaction to obtain ketone
with required relative stereochemistry. In the next section, several approaches en route to
obtaining the correct ketone will be described in details.
3.3 Strategies to obtain the desired rearranged compound
3.3.1 Strategy I
With the aim obtain ketone 3.22, we decided to carry out the rearrangement without the
carboxylic acid functional group attached to the tricyclic core 3.18. After scrutinizing several
protocols for decarboxylation, we planned to employ Barton decarboxylation on the tricyclic
core (Scheme 3.6). However, Barton’s decarboxylation did not proceed as smoothly as
anticipated. When the reaction was carried out with only 1.0 equivalent of the radical quenching
agent, tert-buty thiol, compound 3.27 with a [3.2.1] rearranged core was obtained in about 50%
yield, with the required [2.2.2] decarboxylated system 3.28 present in only around 10%. We
rationalized the formation of 3.27 based on formation of cyclopropyl radical type intermediate
3.33. The cyclopropyl intermediate then formed disintegrates to give more stable tertiary radical
3.34. Reaction mechanism for decarboxylation as well as for unanticipated product 3.27 is given
below (scheme 3.7 and 3.8)
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Scheme 3.6 : Barton decarboxylation
Reagents and conditions a) NaOH, 5:1 MeOH:H2O, 69% b) isobutryl chlorformate, TEA, 2Mercaptopyridine N-oxide c) AIBN, t-Bu3SnH, hν 200 watt benzene d) AIBN, tBuSH, hν 200W,
benzene.
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Scheme 3.7: Barton decarboxylation mechanism

Scheme 3.8: Mechanistic insights for formation of [2.2.2] intermediate
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After ascertaining the mechanism of the rearrangement, we carried out the
decarboxylation reaction with with 20 equivalents of tert-buty thiol (radical scavenger).54, 55 As
anticipated, we were able to obtain the required [2.2.2] decarboxylated tricyclic system. With
compound 3.28 in hand, treatment with mCPBA in DCM gave the epoxide 3.36. The next step
was the opening of this epoxide by a hydroxide nucleophile to give the tri hydroxy compound
3.37. However, the epoxide was stable to alkaline hydrolysis conditions and highly unstable to
acidic epoxide opening conditions. We are in the process of synthesizing more of alkene 3.28
and investigating conditions necessary to obtain the trihydroxy compound 3.37, which will be
further subjected to a Wagner-Meerwein/ pinacol type rearrangement.

Scheme 3.9: Attempted synthesis of the trihydroxy derivative 3.37
Reagents and Conditions: a) mCPBA, NaHCO3, DCM b) NaOH, MeOH:water, 5:1 c) HClO4,
Acetone, water.
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3.3.2 Strategy II
We then investigated the epoxide 3.19, which was set up for a classic semi-pinacol type
rearrangement. In a classical semi- pinacol type rearrangement, an epoxy alcohol in presence of a
Lewis acid rearranges to give a pinacol type product.56 The stereochemistry of the products
generally depends on the Lewis acid catalysts used (however is hard to predict). When we
subjected our epoxide to various lewis acid conditions, a mixture of products were obtained with
majority of allylic alcohol 3.38, TBS deprotected allylic alcohol 3.40 and some other
unrecognizable compounds. However, none of the required compound was obtained

Scheme 3.10: Attempts to rearrange the epoxide 3.19 to give desired ketoester 3.39
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3.3.3. Strategy III
Next, we thought that the lactone would provide an efficient route to the WagnerMeerwein rearrangement. Our initial thoughts were that the lactone would provide a efficient
route to the Wagner-Meerwein rearrangement when treated with various Lewis or protic acids as
the lactone oxygen atom (leaving group) was properly oriented (orientation such that the
backside sp2 LUMO orbital would be facing the forming sp2 HOMO orbital of the migrating ring
methylene.

While the reaction was certainly set-up stereoelectronically for a successful

rearrangement, some unforseen aspect of using an intramolecularly tethered leaving group
interfered with the prospective rearrangement reaction. Thus, treatment of 52 with externally
supplied reagent Lewis or protic acids resulted in some cases in dehydration by tertiary hydroxy
group elimination, or alternatively, TBS deprotection from the angular hydroxyl moiety.
However, no evidence of WM rearrangement reaction products (i.e. [2.2.2]→[3.2.1]) were seen.

Scheme 3.11: Acid mediated Rearrangement of lactone 3.41
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3.3.4. Strategy IV
Further, it was deliberated that the desired ketone 3.22 may actually have formed, but
because of the harsh conditions, there is a possibility of opening of the cyclic ketone 3.22 in a
retro-aldol fashion and recyclization, in aldol fashion to yield the rearranged ketone 3.23.
Generally, such aldol reactions gives rise syn product. To test our hypothesis, the tertiary alcohol
of the lactone 3.41 was protected with benzyl protecting group in a hope that the benzyl group
would survive the harsh rearrangement condition. Benzylation of tertiary alcohol xx was a
challenging task and was achieved using sodium hydride and benzyl bromide (surprisingly a
very clean reaction). Then the benzyl lactone obtained was hydrolyzed with aqueous sodium
hydroxide to hydroxy acid. The hydroxyl acid was then mesylated using mesyl chloride and
triethyl amine to give mesylate 3.43. Compound 3.43 was then subjected to the rearrangement
conditions developed earlier, heating in a sealed tube in toluene at 180 °C. Surprisingly, an
unanticipated  unsaturated ketone 3.44 (desired product was -benzyloxy ketone 41) and
considerable amount of benzyl lactone 3.42 was isolated in the reaction (scheme 3.12)
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Scheme 3.12: Attempted synthesis of Benzyloxy Ketone 3.45
Reagents and Conditions: a) BnBr, NaH, DMF b) NaOH, MeOH:H2O 68% c) MsCl, TEA,
DCM d) Toluene, 180°C 48%.
3.3.5. Strategy V
So far all the strategies adopted by us for fixing the relative stereochemistry of the obtained
rearranged product 25 were futile. Hence, we decided to take an alternate route to complete our
model. In strategy IV we had obtained unsaturated ketone 3.44.

This ketone can be

epoxidized to give (probably) a mixture of epoxides 3.45 and 3.46. After isolation and
identification of the required epoxide 3.46, it can be subjected hydride mediated ring opening to
yield a diol 3.48. Later the diol xx can be subjected to oxidation using Dess-Martin-Periodinane
to yield required ketone 3.22.
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Scheme 3.13. Proposed synthetic route for strategy V
With the proposed route (scheme 3.13) in mind, we began the synthetic scheme with birch
reduction the naphthalene derivative. As described earlier, the naphthalene derivative was
converted in to endo DA adduct 3.18 in four steps. It is important to note that starting from the
naphthalene derivatve up until DA adduct no chromatographic purification were required. The
DA adduct was converted to an -epoxide 3.19, which was subsequently hydrolyzed to give
trihydroxy acid derivatve. The compound 3.20 was converted into mesylate and converted to hydroxy ketone derivative xx using our novel Wagner-Meerwien type rearrangement. Once the
tert-hydroxy ketone was obtained, several alcohol dehydration protocols were examined to
obtain the ketone 3.44. Exposing the ketone to amberlyst or tosic acid gave the desired product,
albeit with poor yields. Hence we decided to explore relatively mild dehydration agents like
Martin sulfurane reagent or Burgess reagent. Martin sulfurane afforded the required compound,
however, the reaction did not go to completion. Finally, refluxing the tert-alcohol in anhydrous
benzene in presence of burgess reagent furnished the trisubstituted alkene 3.44 in over 80%
yield.
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Scheme 3.14: Synthesis of ene-ketone 3.44
Reagents and conditions a) m-CPBA, NaHCO3, CH2Cl2, 99%; b) NaOH (aq), 5:1 MeOH/H2O,
RT, 70% c) MsCl, Et3N, CH2Cl2, 0 °C; d) toluene, 180 °C, 66% e) Burgess reagent, Benzene
reflux 87%
Mechanism of dehydration using burgess reagent in given in scheme given below

Scheme 3.15: Mechanism of dehydration of tertiary alcohol using burgess reagent
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Once the alkene was obtained, it was submitted to the mCPBA mediated epoxidation.
Unfortunately, the epoxidation of ketone did not proceed in a clean fashion. This may due to
possibility of a Baeyer-Villiger Oxidation of ketone functionality giving rise to multiple
products. In the lieu of this failure, we decided to convert the ketone functionality in 3.44 into a
secondary alcohol. This was achieved by treating the ketone with sodium borohydride at 0 ºC to
give mixtures of alcohols 3.48 and 3.49 in 3:1 ratio. Each isomer was separated by flash column
chromatography and fully characterized by 1D and 2D NMR. Alcohol 3.49 was carried forward
in the epoxidation reaction producing a mixture of epoxide with moderate diastereoselctivity of
4:1. The moderate diastereoselectivity can be explained by the figure given below. The molecule
3.44 was sketched in Chem 3D and minimized using MM2 minimization. It can be seen from the
figure 3.4 that the face of the alkene is only slightly more sterically hindered ( presence of
bridge methylene group) than the -face of the molecule.

Figure 3.4: Ball and stick representation of 3.44
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Scheme 3.16 : Completion of synthesis of crucial intermediate 3.10
Reagents and conditions a) NaBH4 THF, 89%; b) m-CPBA, NaHCO3, CH2Cl2, 89%; c) LAH,
THF 90% d) DMP, DCM 89 % e) IBX, DMSO:Toluene 1:2 80 °C 80% f) MeLi 1.6M in Ether,
THF 91% g) O3 DCM, DMS h) DMP, DCM 70% (2 steps)
The epoxide mixture obtained was purified using column chromatography and the alpha epoxide
was forwarded in the scheme. Although pure diastereoselectivities were obtained at the ketone
reduction and epoxide formation step, the unrequired isomers can be easily recycled and overall
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of the -epoxide can be increased. The epoxide 3.51 was ring opened using lithium aluminium
hydride to give a diol and the diol was subsequently oxidized using Dess Marton periodinane
oxidation to give the desired ketone 3.22. The relative stereochemistry of the ketone was
confirmed by X-ray crystal analysis of the ketone as well as of the precursor diol (Figure 3.5 and
3.6)

Figure 3.5: Ortep diagram for Diol

Figure 3.6: ORTEP representation of ketone 3.22
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Gratifyingly, the relative stereochemistry of the ketone is as desired. With ketone successfully
synthesized, according to our synthetic plan, next task was introduction of unsaturation followed
by methyl metal to give tert-Diol 3.9. Introduction of unsaturation proved to be more
difficult than anticipated, with routine sequence of phenylselenation followed by in situ
oxidation/elimination resulted in very low yields. After few attempts, unsaturation was
obtained in acceptable yields using IBX in a solvent mixture of DMSO/toluene at 75°C for 2
hours (65-70% yield). Nucleophilic 1,2 Methyl lithium addition on the carbonyl group proceeded
very smoothly at room temperature, giving rise to a single isomer. The relative stereochemistry
was established by COSY and NOSEY 1H-NMR (scheme 3.16) experiments and was found to be
in accordance to our scheme. With the relative stereochemistry and structure of diol confirmed,
final task was ozonolysis of the diene and subsequent lactol formation. Ozonloysis using
standard conditions and reductive workup afforded lactol (not shown). The lactol without
purification was immdediately oxidized to give lactone 3.10, the crucial intermediate. The
structure and relative stereochemistry was confirmed using 2DNMR and other spectroscopic
technique. Though the relative stereochemistry of intermediate 3.10 was confirmed by 2D NMR
technique we still want to carry out X-ray crystal structure analysis to eliminate any doubts about
the correctness of the structure.
3.4 Alternative route retrosynthesis
Simultaneously, we have designed an alternative route for synthesis of PLAB. It is
known from several earlier approaches and Trost’s completion of total synthesis of PLAB that
the intermediate 3.56 is crucial for completion of the total synthesis of PLAB. We decide to use a
model system to quickly investigate our hypothesis of constructing the intermediate 3.56 in
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following manner. Delineated below, scheme 3.17, is our alternative retrosynthetic approach
towards synthesis of the crucial intermediate. The crucial intermediate can be visualized from the
trans fused 7+5 polyhydroazulene ring 3.57. The epoxide can be prepared from the - keto ester
3.60 in about 3 steps.

Scheme 3.17: Route 2 retrosynthetic analysis
3.5 Progress for alternative route
As per our retrosynthetic scheme, we began with synthesis

of ethyl 2-

oxocycloheptanecarboxylate 3.60 from cycloheptone in 75% yield. Then compound 3.61 was
alkylated57 using homoallyl bromide and potassium tert-butoxide to give compound 3.59 in 70%
yield.58,
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The next step was one carbon witting to obtain the diene 3.62. Initial attempts to

convert 3.61 to 3.62, utilizing n-BuLi in THF to generate the triphenylphosphonium methylide,
resulted in relatively low yield. Recovery of starting material in this reaction suggested that
enolization of the substrate was competing with the addition process. Changing solvents in the
Wittig reaction from THF to DMSO and using dimsyl anion as the deprotonating species
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(NaCH2SOCH3) allowed for a more selective addition to occur relative to unwanted
deprotonation of the carbonyl, and improved the yield to about 70%. With diene 3.62 in hand, we
subjected it to intramolecular ring closing metathesis using 10 mol% of Grubbs II generation
catalyst. Gratifyingly, the reaction proceeded smoothly, giving alkene 3.63 in almost quantitative
yield.60 Epoxidation of alkene with mCPBA in DCM gave separable mixture of two epoxides;
6:4 (trans:syn) in 85% yield (3.64:3.65). Using examples from literature and 1D and 2D NMR
spectroscopy, the non-polar epoxide 3.64 was identified as the required epoxide with trans
relationship with the ester. With the required epoxide in hand, we decided to carry out opening of
the epoxide with various nucleophiles. After using several different nucleophiles and different
epoxide opening protocols61-69 we were unable to obtain any desired product. The epoxide was
either stable to most of the conditions or opened to give allylic alcohol or in some cases ester was
attacked by the nucleophile with epoxide still intact. This suggests the epoxide is hindered and
not susceptible to opening with nucleophiles.

66

Scheme 3.18: Route 2; attempted synthesis of intermediate 3.66
Reagents and conditions a) Diethyl carboxylate, NaH, DMF 75% b) 4-bromobut-1-ene, KtOBu,
DMSO 70% c) methyltriphenylphosphonium bromide, NaH, DMSO, 70% d) Grubbs II
generation catalyst, DCM reflux 95% e) mCPBA, DCM, RT 85% f) alkyl, alkenyl, alkynyl
grignards, or akenyl, alkynyl lithium etc.
In summary, we have successfully accomplished the model studies directed toward the total
synthesis of pseudolaric acid B starting from a commercially available naphthalene derivative.
We demonstrated that our novel Wagner-Meerwien rearrangement can indeed be applied to
completion of total synthesis of PLAB. However, a setback in our synthetic scheme was that the
undesired ketone formation was favored over the desired ketone. Gratifyingly, we were able to
invert the stereochemistry of the ketone in relatively acceptable yields in five steps. Currently we
are in a process of streamlining our synthetic route, and then it will be applied towards the
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synthesis of the natural product, PLAB. Furthermore, we also demonstrated a quick assembly of
5+7 membered ring using ring closing metathesis. The success of this route depends upon the
ring opening of the epoxide with appropriate nucleophile. As this route is relatively short and
elegant, more studies directed towards opening of sterically hindered epoxide are warranted.

3.6 Future Direction
With the route 2 failing to give desired product, we wish to investigate an alternative route to
obtain the crucial intermediate 3.71. The proposed route is delineated in scheme 3.19. The ethyl
caorboxylate cycloheptanone derivative can easily be alkylated with allyl bromide to give
intermediate 3.67, which in turn can be subjected to alkynyl metal addition to give corresponding
tertiary alcohol 3.68. This step is going to determine the stereochemistry of polyhydroazulene
framework which will be formed in next step.
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Scheme 3.19: Future directions
We intend to use an intramolecular delivery of the alkynyl species which will be tethered to the
carboxylic acid, ensuring the attack of alkyne from the same side as that of carboxylic acid
resulting in correct stereoisomer required for completion of total synthesis of PLAB. Once the
correct stereoschemistry is obtained, next crucial step is eneyne-metathesis, which can be carried
out using Grubbs II catalyst. With appropriate X group (TMS or OTIPS) it is possible to envision
crucial intermediate 3.70 in few steps from 3.68. Currently, to test our hypothesis synthesis of
intermediate is being carried out in our laboratory and will be reported in due course.
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CHAPTER 4
EXPERIMENTAL- PSEUDOLARIC ACID B

General Experimental
1

H and

13

C NMR spectra were measured in CDCl3 or C6D6 on Bruker 400 MHz (100 MHz) or

500 MHz (125 MHz) machines. Chemical shifts were reported in ppm downfield from
tetramethylsilane (δ) as the internal standard and coupling constants are in hertz (Hz).
Assignment of proton resonances were confirmed by correlated spectroscopy. IR spectra were
recorded using a universal attenuated total reflection sampling accessory with a Zinc Selenide
crystal on a Perkin-Elmer Spectrum 100 FT-IR spectrometer. The high-resolution mass spectra
(HRMS) were recorded on a Micromass Q-Tof Micro mass spectrometer with lock spray source.
Optical rotations were measured on an Autopol V automatic polarimeter, from Rudolph
Research Analytical in a 1 dm or a 5 dm cell. Melting points were measured on an OptiMelt®
V.1.061 (Stanford Research systems) instrument and were uncorrected. The reaction progress
was monitored on precoated silica gel G or GP Analtech TLC plates. Spots were visualized
under 254 nm UV light and/or by dipping the TLC plate into a solution of 2 ml anisaldehyde and
10 ml glacial acetic acid and 5 ml H2SO4 in 340 ml MeOH followed by heating with a hot gun.
Column chromatography was performed with Dynamic Adsorbents Inc. silica gel 60 (230-400
mesh). All the solvents (hexane, ethyl acetate, CH2Cl2, Et2O) were distilled prior to use. All
reactions were performed under an atmosphere of argon using oven-dried glassware and standard
syringe/septa techniques. The solvents THF and Et2O were distilled from sodium-benzophenone,
toluene, cyclohexane, benzene from sodium. CH2Cl2 was dried over P2O5. DMF, NEt3, iPr2NH
and iPr2NEt and were distilled from CaH2.

70

6-Methoxy-1,2,3,4,5,8-hexahydronaphthalene (3.14)
Ammonia (350 mL) was condensed into a 3-neck round-bottom flask at –78°C. Dry ether (50
mL) and dry ethanol (125 mL) were added via syringe followed by a solution of 6-methoxy1,2,3,4-tetrahydronaphthalene (10g, 61.7 mmol, in 10 mL dry ether). Lithium metal (2.78g, 6.5
eq) was added piecewise. After the blue color faded (~1 hour), the cooling bath was removed,
and the ammonia was allowed to evaporate overnight. Ether (200 mL) was added, and the
mixture was washed with water (2 x 200 mL) and brine (100 mL). The ether layer was dried
(MgSO4) and concentrated to give 9.21g (91%) of a clear oil, which was mostly pure by TLC
(20% EtOAc:hexanes). The product 3.14 was used in the next step without further purification.
An aliquot was purified rapidly by column chromatography (silica gel, hexanes). IR (neat) 2924,
2827, 1703, 1671, 1218 cm–1; 1H NMR (400 MHz, CDCl3) δ 4.65 (d, J = 3.1 Hz, 1H), 3.78 (s,
1H), 3.56 (s, 3H), 2.79 – 2.53 (m, 5H), 1.91 (s, 4H), 1.74 – 1.56 (m, 5H). 13C NMR (CDCl3) 
13

C NMR (101 MHz, CDCl3) δ 153.04, 125.86, 124.74, 90.54, 77.35, 77.03, 76.72, 53.74, 33.85,

31.96, 29.64, 29.25, 23.17, 22.92. HRMS (ESI) calcd. for C11H17O: 165.1279 [M+H]+, found
165.1273.
3,4,5,6,7,8-Hexahydro-1H-naphthalene-2-one (3.15)
The dienol ether (8.83g, 54 mmol) was added to a solution of MeOH (47 mL) and H2O (15 mL)
followed by oxalic acid (486 mg, 0.1 eq). The mixture was stirred for 3 hours until no starting
material remained by TLC (20% EtOAc/hexanes). The MeOH was removed by vacuum. EtOAc
(60 mL) was added. The organic layer was washed with aqueous NaHCO3 (saturated). The
organic layer was dried (MgSO4) and evaporated.

The residue was purified by column

chromatography (5% EtOAc:hexanes) to give 6.3g (78%) of the pure enone as a clear oil. IR
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(neat) 3413, 2922, 1715, 1440, 815, 740 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.74 (s, 2H), 2.49
(t, J = 6.9 Hz, 2H), 2.33 (s, 2H), 1.98 (s, 2H), 1.90 (s, 2H), 1.63 (dd, J = 6.2, 3.2 Hz, 4H)

13

C

NMR (101 MHz, CDCl3) δ 210.99, 128.60, 125.77, 77.43, 77.11, 76.79, 44.42, 38.96, 30.69,
29.73, 29.62, 22.85, 22.38. HRMS (ESI) calcd. for C10H14OK:

189.0677 [M+K]+, found

189.0669.
tert-Butyl-(3,4,5,6,7,8-hexahydronaphthalene-2-yloxy)-dimethylsilane. (3.16)
Freshly distilled diisopropylamine (0.98 mL) was added to dry THF (10 mL) in a round-bottom
flask under argon. The solution was cooled to –18C with a MeOH/ice bath. n-BuLi (2.79 mL,
2.5M) was added dropwise over 10 minutes. After an additional 15 minutes at –18C, the
solution was cooled to –78ºC. The enone (3.15) (952 mg, 6.35 mmol) was dissolved in dry THF
(2 mL) and added dropwise over 10 minutes to the LDA solution. After 30 minutes at –78ºC,
TBDMSCl (1.14g, 1.5 eq) in THF (1.5 mL) was added over 5 minutes via syringe. After 1 hour
at –78ºC, the solution was allowed to warm to RT overnight. After 24 hours the solvent was
evaporated. Pentane was added, and the mixture was filtered through Celite to remove LiCl.
Evaporation of the pentane gave a clear, yellow oil. The product was used without further
purification. An aliquot was purified by column chromatography (silica, hexanes). The column
was washed with 1% Et3N:hexanes prior to purification. The product was isolated as a clear oil
(1.37g, 82%). IR (neat) 2928, 2858, 1668, 1622, 1247, 838 cm-1; 1H NMR (CDCl3) s 4.90 (s,
1H), 2.18 (m, 4H), 1.95 (m, 4H), 1.61 (m, 4H), 0.93 (s, 9H), 0.17 (m, 6H); 13C NMR (CDCl3) 
151.5, 126.6, 122.3, 106.6, 32.0, 30.2, 29.8, 29.5, 29.3, 26.1, 23.6, 23.5, 18.5; HRMS (ESI)
calcd. for C16H29OSi: 265.1981 [M+H]+, found, 265.1975.
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endo-8-(tert-Butyl dimethylsilanyloxy) tricyclo[6.2.2.01,6] dodec-6-ene-9-carboxylic acid
methyl ester (3.18) and exo-8-(tert-Butyl dimethylsilanyloxy) tricyclo[6.2.2.01,6] dodec-6ene-9-carboxylic acid methyl ester.(3.17)
Methyl acrylate (858 L, 820 mg, 2.5 eq) was dissolved in dry toluene (1.5 mL) and cooled to
0ºC. Al(Me3)3 (170 L) was added dropwise. After 15 minutes the temperature was lowered to
–20ºC, and Et2AlCl (3.42 mL, 1.0 eq, 1M in hexanes) was added dropwise via syringe and
syringe pump. After 15 minutes the diene (1g, 3.8 mmol) in dry toluene (9 mL) was added
dropwise. The reaction was completed in 3 hours at –20ºC. Water (5 mL) was added to quench
the reaction, followed by HCl (10 mL, 2N). The aqueous layer was extracted with EtOAc. The
organic layer was washed with brine and dried over MgSO4. The crude mixture was purified by
column chromatography (silica, 3% EtOAc:hexanes) to give two products (1.07g, 81% total
yield) in a 9:1 ratio as clear oils. Major isomer (endo): IR (neat) 2928, 2857, 1737, 1433, 1359,
1250, 1197, 837 cm-1; 1H NMR (CDCl3)  5.73 (s, 1H), 3.60 (s, 3H), 2.80 (dd, 1H, J = 6.0 Hz, J
= 9.5 Hz), 2.31-2.21 (m, 2H), 1.70-1.29 (m, 12H), 0.86 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H);

13

C

NMR (CDCl3)  176.2, 143.8, 127.0, 51.7, 51.3, 39.5, 36.8, 36.5, 32.3, 32.3, 26.9, 25.9, 21.7,
19.8, 18.4, -1.8, -2.0; HRMS (ESI) calcd. for C20H35O3Si: 351.2349 [M+H]+, found, 351.2348;
Anal. calcd. for C20H34O3Si: C, 68.52, H, 9.78; found: C, Minor isomer (exo): IR (neat) 2930,
2859, 1732, 1460, 1354, 1261, 1203, 1163, 1105, 867, 834, 791 cm-1; 1H NMR (CDCl3)  5.83
(s, 1H), 3.67 (s, 3H), 2.55 (ddd, 1H, J = 10.9 Hz, J = 5.9 Hz, J = 1.3 Hz), 2.21 (m, 2H), 1.60-1.47
(m, 10H), 1.34-1.25 (m, 2H), 0.87 (s, 9H), 0.12 (s, 3H), 0.05 (s, 3H); 13C NMR (CDCl3)  176.1,
144.9, 130.3, 51.7, 50.7, 37.4, 36.6, 33.3, 32.3, 30.3, 27.0, 26.0, 21.8, 19.7, 18.4, -1.9, -2.1;
HRMS (ESI) calcd. for C20H35O3Si: 351.2349 [M+H]+, found, 351.2352.
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(1aR,8aR)-methyl

2-((tert-butyldimethylsilyl)oxy)octahydro-2,4a-ethanonaphtho[1,8a-

b]oxirene-3-carboxylate (3.19)
The ester (5g, 1.4 mmol) was dissolved in CH2Cl2 (100 mL) and treated with NaHCO3 (2.06g)
with stirring. The suspension was cooled to 0ºC and treated with m-CPBA (4.24g, 1.5 eq, 70%).
The cooling bath was removed.

The reaction was completed within 2 hours (TLC; 20%

EtOAc:hexanes). The mixture was filtered, and the white solid was washed with CH2Cl2 (10
mL).

The filtrate was washed with NaHCO3 (sat, 2 x 20 mL) and dried over MgSO4.

Evaporation of the solvent gave a pale, yellow oil (5.21g, 99%). NMR showed none of the isomer. IR (neat) 2932, 2864, 1734, 1433, 1361, 1263, 1186, 1143, 871, 824, 781 cm-1; 1H NMR
(CDCl3)  3.67 (s, 3H), 3.11 (d, 1H, J = 0.8 Hz), 2.83 (dd, 1H, J = 10.5 Hz, J = 5.3 Hz), 2.33 (m,
1H), 2.22-2.14 (m, 1H), 1.89 (dt, 1H, J = 11.4 Hz, J = 4.3 Hz), 1.67 (m, 2H), 1.58-1.27 (m, 8H),
1.16 (dt, 1H, J = 12.1 Hz, J = 4.4 Hz), 0.86 (s, 9H), 0.17 (s, 3H), 0.10 (s, 3H); 13C NMR (CDCl3)
 176.6, 75.9, 61.9, 61.6, 51.9, 51.4, 36.6, 35.2, 34.1, 33.4, 32.6, 29.6, 25.9, 23.7, 22.5, 18.2, 2.1, -2.8; HRMS (ESI) calcd. for C20H35O4Si: 367.2298 [M+H]+, found, 367.2302. Anal. for
C20H34O4Si: calcd: C, 65.53, H, 9.35; found: C, 65.91, H, 9.39.
8-(tert-Butyl dimethylsilyloxy)-6,7-dihydroxy tricyclo[6.2.2.01,6]dodecane-9-carboxylic acid
(3.20)
Method A. The lactone (200 mg, 0.57 mmol) was dissolved in dry EtOH (16 mL) and treated
with KOH (640 mg). The mixture was stirred overnight until no starting material remained
(TLC, 20% EtOAc:hexanes). The solution was neutralized with HCl (1N). The product was
extracted with EtOAc (4 x 15 mL). After drying with MgSO4, the solvent was evaporated by
vacuum to give the product as a white amorphous solid (196 mg, 93%).
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Method B. The epoxide (5.2g, 1.4 mmol) was dissolved in MeOH (52 mL) and treated with a
solution of NaOH (2.86g, 5eq. in 10 mL H2O) with stirring. The solution was heated to reflux
for 5 hours or until no starting material remained by TLC (20% EtOAc:hexanes). The MeOH
was removed by vacuum. The residue was dissolved in CH2Cl2 (100 mL). HCl (3N) was added
slowly with vigorous stirring until the reaction mixture was neutralized. Fast addition of the HCl
leads to formation of a sticky mass. The aqueous layer was separated, and the organic layer was
filtered. The white solid was washed with CH2Cl2 and ether (2.94g, 56%). mp ºC; IR (KBr)
3509, 3288, 3269, 2942, 2919, 2858, 2641, 2621, 1681, 1470, 1260, 1143, 1004, 835, 773 cm-1;
1

H NMR (DMSO-d6)  4.35 (s, 1H), 4.04 (bs, 1H), 2.77 (t, 1H, J = 10.0 Hz), 1.97 (t, 1H, J =

11.4 Hz), 1.84 (m, 1H), 1.71 (m, 1H), 1.58-1.33 (m, 8H), 1.28-1.10 (m, 2H), 1.06 (d, 1H, J =
12.7 Hz), 0.81 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H); 13C NMR (DMSO-d6)  178.6, 90.0, 84.5, 76.5,
75.7, 75.6, 49.6, 34.9, 34.1, 33.6, 30.7, 30.2, 26.5, 22.0, 21.4, 18.7, -1.2, -1.7; HRMS (ESI)
calcd. for C19H33O5Si: 369.2103 [M-H]-, found, 369.2095. Anal. calcd. for C19H34O5Si: C,
61.58, H, 9.25; found: C, 61.57, H, 9.40.
(1S,4aS,8aS)-8a-hydroxyhexahydro-1H-1,4a-ethanonaphthalen-2(5H)-one (3.23)
The hydroxy acid (1.0 g, 2.7 mmol) was suspended in dry CH2Cl2 (30mL) and cooled to 0 °C.
Et3N (800 L, 2.1 eq) was added dropwise. After 5 minutes, freshly distilled MsCl (440 L, 2.1
eq) was added dropwise. After stirring at 0 °C for 30 minutes, the solution was allowed to warm
to RT. The solvent was removed under vacuum, and the residue was dissolved in EtOAc (35
mL) and washed with 1M HCl (25 mL). The organic layer was washed with water (2 x 20 mL).
The organic layer was washed with brine (20 mL) and dried with MgSO4. Removal of the
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solvent and filtration through a short pad of silica (3% MeOH/Chloroform) gave the mesylate,
which was used without further purification.
The mesylate was dissolved in 800 mL of dry toluene and heated in an oil bath to 180 °C in a
glass, high-pressure reaction vessel (Ace Glass, Inc., PN 8648-157) for 8 hours. The solvent was
removed under vacuum, and the product was purified by column chromatography (silica, 15%
EtOAc/Hexanes) to give 352 mg (67%, 2 steps) of a light tan solid.
IR (KBr) 3401, 2925, 2852, 1694, 1444, 1177, 1033, 1006, 800 cm-1; 1H NMR (CDCl3)  2.532.45 (m, 1H), 2.36 (m, 2H), 2.25 (dd, 1H, J = 16.2 Hz, J = 7.0 Hz), 2.12 (m, 1H), 1.98 (m, 1H),
1,86 (m, 1H), 1.68-1.35 (m, 10H); 13C NMR (CDCl3)  13C NMR (126 MHz, CDCl3) δ 211.19,
80.85, 77.28, 77.02, 76.77, 61.58, 42.76, 35.37, 34.88, 34.06, 29.85, 29.08, 23.47, 21.28, 20.46.;
HRMS (ESI) calcd. for C12H19O2: 195.1379 [M+H]+, found, 195.1393. anal. for C12H18O2:
calcd. C, 74.19, H, 9.34; found: C, 74.20, H, 9.52.

endo-8-(tert-Butyl dimethylsilyloxy) tricyclo[6.2.2.01,6]dodec-6-ene-9-carboxylic acid (3.25)
The endo ester (3.83g, 1.1 mmol) was dissolved in MeOH (100 mL) at RT. An aqueous solution
of NaOH (3.57g in 7 mL H2O) was added slowly. The solution was heated to reflux for 12 hours
or until no starting material remained by TLC (20% EtOAc:hexanes).

(Prolonged heating

resulted in substantial loss of product due to desilylation). The product mixture was acidified to
pH 3 with HCl (2N), and the MeOH was removed by vacuum. The product was extracted with
EtOAc (3 x 50 mL). The organic layer was dried (MgSO4), and the solvent was removed by
vacuum. The residue was purified by column chromatography (silica, 10% EtOAc:hexanes) to
give 1.97g (67%) of the pure acid as a white solid. mp 61-63 ºC (dec.); IR (KBr) 3473, 2934,
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2859, 1761, 1703, 1256, 1197, 1109, 836, 775 cm-1; 1H NMR (CDCl3)  11.10 (bs, 1H), 5.66 (s,
1H), 2.67 (dd, 1H, J = 9.9 Hz, J = 4.0 Hz), 2.18 (m, 2H), 1.93 (td, J = 9.2 Hz, J = 3.7 Hz), 1.801.73 (m, 1H), 1.64-1.31 (m, 10H), 0.93 (s, 9H), 0.21 (s, 3H), 0.20 (s, 3H);
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C NMR (CDCl3)

175.5, 147.5, 124.8, 78.5, 50.6, 36.6, 35.8, 35.3, 33.9, 31.9, 26.9, 26.0, 21.5, 19.4, 18.3; HRMS
(ESI) calcd. for C19H32ClO3Si: 371.1815 [M+Cl]-, found, 371.1849;
Synthesis

of

(3.28) tert-butyl(((2s,4ar)-3,4,5,6,7,8-hexahydro-2H-2,4a-ethanonaphthalen-2-

yl)oxy)dimethylsilane
To stirred suspension of (2S,4aR)-2-((tert-butyldimethylsilyl)oxy)-3,4,5,6,7,8-hexahydro-2H2,4a-ethanonaphthalene-3-carboxylic acid 3.25(50mg, 0.149 mmol) in Benzene (5.0 ml) was
charged N-Methylmorpholine (0.033 ml, 0.297 mmol) at -30°C resulting in a pale yellow
solution. To this after 15 mins was charged DCC (30.7 mg, 0.149 mmol) followed by 2Mercapto pyridineoxide (37.8 mg, 0.297 mmol). The reaction mixture was brought to 0°C and
stirred for 2-3 hrs. After 2 hrs t-Butylthiiol (0.329 ml, 2.53 mmol) was charged to reaction
mixture (suspension) slowly. The reaction mixture was then exposed to 300 h light for 2 hrs.
(Note The temperature was maintained 0-10 °C by ice water bath). Reaction was monitored by
TLC. Reaction mixture was diluted with water and extracted with ether. The aqueous extract was
carefully quenched with bleach in the hood. The organic layer was quickly washed with bleach
followed by brine. The organic layer was dried over magnesium sulfate and evaporated under
vacuum to give crude oil. The crude was purified by column chromatography using pentane to
afford

3.28

tert-butyl(((2s,4ar)-3,4,5,6,7,8-hexahydro-2H-2,4a-ethanonaphthalen-2-

yl)oxy)dimethylsilane (25.0mg, 0.085 mmol, 57.5 % yield) 2927.36 2866.22, 1477.98, 1448.69,
1253.83, 1069.83, 1008.05,860.72, 772.99, 673.18 cm-1 1H NMR (400 MHz, CDCl3) δ 5.77 (s,
1H), 2.21 (dt, J = 6.7, 3.5 Hz, 2H), 1.67 (td, J = 10.1, 4.1 Hz, 2H), 1.57 (dd, J = 6.6, 3.2 Hz, 4H),
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1.45 (t, J = 5.7 Hz, 2H), 1.41 – 1.24 (m, 5H), 1.01 – 0.78 (m, 9H), 0.20 – 0.02 (m, 5H). 13C NMR
(101 MHz, CDCl3) δ 143.29, 129.80, 77.30, 76.99, 76.67, 75.38, 36.02, 35.63, 33.26, 32.24,
26.66, 25.82, 21.63, 19.50, 17.96, -2.10. APCI (M+1) 293.21; (M+Na) 315.21

Synthesis

of

(3.27)

tert-butyldimethyl(((4aR,7R)-1,2,3,4,5,6,7,8-octahydro-4a,8-

methanobenzo[7]annulen-7-yl)oxy)silane
Same procedure was followed. Instead of using 17.0eq of t-Butly thiol only 1.0 equivalent was
used.Colorless oil I.R 2856, 1471, 1461.78, 1253.84, 1051.73, 772.99, 673.18 cm-1 1H NMR
(500 MHz, CDCl3) δ 5.49 (s, 1H), 3.65 (ddd, J = 9.3, 6.0, 2.9 Hz, 1H), 2.46 – 2.36 (m, 2H), 2.02
– 1.95 (m, 1H), 1.78 – 1.54 (m, 7H), 1.38 – 1.21 (m, 6H), 1.00 (td, J = 12.8, 5.5 Hz, 1H), 0.90 (s,
9H), 0.09 – 0.02 (m, 6H).
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C NMR (126 MHz, CDCl3) δ 146.62, 121.27, 77.27, 77.02, 76.77,

70.02, 49.69, 46.55, 44.55, 36.77, 29.66, 26.88, 26.38, 26.36, 25.95, 22.86, 18.22, -4.60. APCI
(M+1) 293.24
(3R,5aR,9aR,9bS)-3a-((tert-butyldimethylsilyl)oxy)-9a-hydroxydecahydro-2H-3,5amethanonaphtho[1,2-b]furan-2-one (3.41)
The acid (226 mg, 0.67 mmol) was dissolved in CH2Cl2 (2 mL) and treated with m-CPBA (249
mg, 1.5 eq, 70%) at RT. The solution was stirred at RT for 3 hours, until no starting material
remained by TLC (5% MeOH:CHCl3). CH2Cl2 (10 mL) was added, and the mixture was
washed with NaOH (1N, 4 x 20 mL) until no meta-chlorobenzoic acid remained. After drying
(MgSO4), the solvent was removed by vacuum to give the product as an amorphous white solid
(110 mg, 46%). mp 204-205ºC; IR (KBr) 3474, 2934, 2860, 1764, 1473, 1343, 1104, 994, 836,
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774 cm-1; 1H NMR (CDCl3)  3.97 (s, 1H), 2.45 (d, 1H, J = 10.9 Hz), 2.07-1.96 (m, 2H), 1.921.79 (m, 2H), 1.60-1.48 (m, 5H), 1.47-1.39 (m, 2H), 1.29-1.18 (m, 3H), 0.83 (s, 9H), 0.13 (s,
3H), 0.11 (s, 3H); 13C NMR (CDCl3)  ;HRMS (ESI) calcd. for C19H33O4Si: 353.2142 [M+H]+,
found, 353.2147; Anal. calcd. for C19H32O4Si: C, 64.73, H, 9.15; found C, 64.92, H, 9.29.
Synthesis of (1R,4aR)-3,4,6,7-tetrahydro-1H-1,4a-ethanonaphthalen-2(5H)-one (3.44)
To a solution of (1R,4aR,8aS)-8a-hydroxyhexahydro-1H-1,4a-ethanonaphthalen-2(5H)-one
(470.0mg, 2.419 mmol) in anhydrous benzene was added at once Burgess Reagent (865 mg, 3.63
mmol). The resulting solution was refluxed under argon for 4 hrs or until completion of the
reaction as indicated by TLC. After reaction was complete RM was diluted with ethyl acetate
and washed with water followed by brine. The organic layer was dried over magnesium sulfate
and evaporated under vacuum. The product was purified by Flash column chromatography
(Hex:EtOAc 9:1) to give (1R,4aR)-3,4,6,7-tetrahydro-1H-1,4a-ethanonaphthalen-2(5H)-one
(365.0mg, 2.071 mmol, 86 % yield) 1H NMR (400 MHz, CDCl3) δ 5.52 (t, J = 3.6 Hz, 1H), 3.10
(d, J = 6.5 Hz, 1H), 2.68 – 2.47 (m, 1H), 2.29 (tdd, J = 27.5, 18.8, 8.7 Hz, 2H), 1.95 (ddd, J =
16.4, 7.7, 3.9 Hz, 6H), 1.80 (ddd, J = 18.1, 13.5, 6.7 Hz, 4H), 1.66 – 1.58 (m, 3H), 1.58 – 1.44
(m, 3H).13C NMR (101 MHz, CDCl3) δ 211.16, 136.39, 118.07, 77.36, 77.04, 76.73, 58.48,
40.58, 36.46, 34.93, 33.53, 27.55, 26.92, 25.03, 19.97. HRMS (ESI) calcd. for C12H16NaO:
199.1099 [M+Na]+, found, 199.1143

(1R,2S,4aR)-2,3,4,5,6,7-hexahydro-1H-1,4a-ethanonaphthalen-2-ol

(3.50)

To

a

stirred

solution of (1R,4aR)-3,4,6,7-tetrahydro-1H-1,4a-ethanonaphthalen-2(5H)-one (330.0mg, 1.872
mmol) at 0°C was carefully added sodium borohydride (70.8 mg, 1.872 mmol) keeping the
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temperature below zero. Reaction was slowly brought to and stirring for 2hrs or until the
completion of the reaction (monitored by TLC). Reaction was again cooled to 0°C and quneched
with dropwise addtion of water. Methanol was evaporated and crude obtained was dissolve in
ethyl acetate. Oragnic layer was wahed with saturated ammonium chloride solution, brine and
then was dried over magensium sulfate. After concentartion of organic solvent colorless oily
liquid was obtained. Crude was purified using flash colum chromatography (Hexane:EtoAc 7:3)
to furnish
Polar-(1R,2R,4aR)-2,3,4,5,6,7-hexahydro-1H-1,4a-ethanonaphthalen-2-ol
NonPolar-(1R,2S,4aR)-2,3,4,5,6,7-hexahydro-1H-1,4a-ethanonaphthalen-2-ol

(3.49)

and
(3.50)

(72.0mg, 0.404 mmol, 21.57 % yield) 1H NMR (500 MHz, CDCl3) δ 5.39 (t, J = 3.5 Hz, 1H),
3.85 – 3.66 (m, 1H), 2.61 – 2.50 (m, 1H), 1.95 (dd, J = 10.9, 6.2 Hz, 2H), 1.90 – 1.82 (m, 1H),
1.82 – 1.73 (m, 1H), 1.71 – 1.61 (m, 3H), 1.61 – 1.52 (m, 3H), 1.52 – 1.43 (m, 2H), 1.43 – 1.32
(m, 2H), 1.28 (dd, J = 12.3, 6.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 147.48, 114.09, 77.25,
77.00, 76.75, 73.87, 49.44, 39.69, 36.51, 36.19, 34.08, 28.75, 24.98, 22.06, 20.24. ESI+ (M+1)
179.2
Polar-(1R,2R,4aR)-2,3,4,5,6,7-hexahydro-1H-1,4a-ethanonaphthalen-2-ol (3.49) (198.0mg,
1.111 mmol, 59.3 % yield) 1H NMR (500 MHz, CDCl3) δ 5.64 – 5.30 (m, 1H), 3.71 (s, 1H), 2.63
– 2.37 (m, 1H), 2.05 – 1.94 (m, 2H), 1.91 (s, 1H), 1.88 – 1.77 (m, 3H), 1.77 – 1.68 (m, 2H), 1.67
– 1.49 (m, 5H), 1.49 – 1.39 (m, 2H), 1.39 – 1.32 (m, 2H), 1.20 (dd, J = 11.9, 5.3 Hz, 1H). 13C
NMR (126 MHz, CDCl3) δ 145.79, 117.14, 77.25, 77.00, 76.75, 72.05, 48.64, 40.53, 35.84,
34.63, 34.59, 27.10, 25.66, 24.96, 20.08. ESI (M+Na) 201.13
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Polar(3.51)

(1aR,4aR,7R,8S,8aR)-octahydro-4a,8-ethanonaphtho[1,8a-b]oxiren-7-ol

and

Nonpolar (1aR,4aR,7R,8S,8aS)-octahydro-4a,8-ethanonaphtho[1,8a-b]oxiren-7-ol (3.52)
To stirred solution of (1R,2R,4aR)-2,3,4,5,6,7-hexahydro-1H-1,4a-ethanonaphthalen-2-ol (250.0
mg, 1.402 mmol) in DCM at was added sodium carbonate (130 mg, 1.543 mmol) and mCPBA
(346 mg, 1.543 mmol) at once. After stirring for 1 hr the starting material disspeared,
monoitotring by TLC. The reaction mixture was filtered through celite and celite was washed
with 10ml additional DCM. Combined DCM was washed with 2.0M sodium bicarbonate and 0.1
NaOH to remove m-Chlorobenzoic acid. The organic layer was then washed with brine and dried
over magnesium sulfate. DCM was evaporated under vacuum to give crude epoxide whihc was
purified by column chromatogarphy to give colorless oil Nonpolar 3.52 (1aR,4aR,7R,8S,8aS)octahydro-4a,8-ethanonaphtho[1,8a-b]oxiren-7-ol (170.0 mg, 0.875 mmol, 62.4 % yield) 1H
NMR (400 MHz, CDCl3) δ 4.20 – 4.03 (m, 1H), 3.16 (d, J = 5.3 Hz, 1H), 2.14 – 1.84 (m, 6H),
1.76 – 1.57 (m, 5H), 1.57 – 1.44 (m, 3H), 1.44 – 1.32 (m, 3H), 1.28 (dd, J = 24.6, 8.6 Hz, 2H),
1.13 – 0.99 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 77.36, 77.04, 76.72, 70.06, 69.07, 58.62,
46.58, 36.50, 34.40, 29.82, 28.59, 28.26, 24.57, 19.22, 16.91. . ESI+ (M+Na) 217.10
and Polar 3.51(1aR,4aR,7R,8S,8aR)-octahydro-4a,8-ethanonaphtho[1,8a-b]oxiren-7-ol (50.0mg,
0.257 mmol, 18.35 % yield) 1H NMR (400 MHz, CDCl3) δ 3.90 (d, J = 8.8 Hz, 1H), 3.45 (d, J =
3.2 Hz, 1H), 1.99 – 1.79 (m, 7H), 1.70 – 1.63 (m, 1H), 1.63 – 1.50 (m, 7H), 1.52 – 1.44 (m, 3H),
1.29 (dd, J = 16.7, 8.9 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 77.33, 77.01, 76.69, 71.44, 70.72,
57.34, 47.63, 38.97, 33.37, 30.88, 29.14, 27.86, 22.15, 20.93, 16.41. ESI+ (M+Na) 217.13
(1S,2R,4aR,8aS)-octahydro-1H-1,4a-ethanonaphthalene-2,8a-diol (3.53)
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To as stirred solution of (1aR,4aR,7R,8S,8aS)-octahydro-4a,8-ethanonaphtho[1,8a-b]oxiren-7-ol
(54.0 mg, 0.278 mmol) at-20°C in THF (Volume: 1.0 ml) was added dropwise 3.5M LAH (0.199
ml, 0.695 mmol). The reaction was slowly brought to RT and was stirred until completion of
reaction (Monitored by TLC). After completion of reaction mixture was again cooled to -20°C
and quenched with 500 μl of MeOH followed by 500 μl rochelle salt solution. The reaction was
stirred vigorously till solid precipitate was seen. The precipitate was filtered through celite. The
celite was washed with 5.0ml ethyl acetate. The combined organic extract was washed with
saturated ammonium chloride solution and brine. The organic layer was dried over magnesium
sulfate and evaporated under vacuum. Crude was purified by column chromatography to give
(1S,2R,4aR,8aS)-octahydro-1H-1,4a-ethanonaphthalene-2,8a-diol (38.5 mg, 0.196 mmol, 70.6 %
yield) 1H NMR (400 MHz, CDCl3) δ 4.05 – 3.85 (m, 1H), 2.40 (s, 3H), 1.98 (d, J = 6.0 Hz, 1H),
1.89 (dd, J = 12.2, 5.5 Hz, 1H), 1.84 (d, J = 4.9 Hz, 1H), 1.79 (dd, J = 12.8, 5.6 Hz, 2H), 1.74 –
1.63 (m, 3H), 1.64 – 1.57 (m, 2H), 1.55 (d, J = 8.3 Hz, 1H), 1.48 (d, J = 9.0 Hz, 2H), 1.38 (tt, J =
12.4, 6.1 Hz, 3H), 1.04 (dd, J = 13.6, 6.9 Hz, 1H), 0.97 – 0.81 (m, 1H). 13C NMR (101 MHz,
CDCl3) δ 80.37, 77.36, 77.04, 76.72, 69.10, 52.24, 42.98, 33.99, 30.95, 30.65, 28.07, 27.47,
20.77, 20.58, 20.54. ESI+ (M+1) 197.14
(1S,4aS,8aS)-8a-hydroxyhexahydro-1H-1,4a-ethanonaphthalen-2(5H)-one (3.22)
To a stirred solution of (1S,2S,4aR,8aS)-octahydro-1H-1,4a-ethanonaphthalene-2,8a-diol
(38.0mg, 0.194 mmol) in DCM (Volume: 1.0 ml) was added DMP (82 mg, 0.194 mmol)at RT.
The reaction was complete with in 30mins. DCM was recovered and diethyl ether was added to
the residue. The suspension was filtered through celite and the organic layer was washed with
saturated sodium bicarbonate solution, brine and dried over magnesium sulfate. Concentration of
ether under vacuum afforded crude ketone which was purified by column chromatography to
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give

(1S,4aS,8aS)-8a-hydroxyhexahydro-1H-1,4a-ethanonaphthalen-2(5H)-one 3.22 (35.0mg,

0.178 mmol, 92 % yield) CHCl3/max cm-1 3389, 2915, 2850, 1690, 1159 1H NMR (500 MHz,
CDCl3) δ 2.52 (q, J = 14.8 Hz, 2H), 2.24 – 2.03 (m, 3H), 1.94 – 1.87 (m, 1H), 1.82 (dd, J = 13.8,
6.1 Hz, 1H), 1.68 (dt, J = 13.2, 8.4 Hz, 3H), 1.62 – 1.46 (m, 8H), 1.40 (dd, J = 13.1, 9.9 Hz, 1H).
13

C NMR (126 MHz, CDCl3) δ 213.42, 81.79, 77.25, 77.00, 76.75, 61.51, 44.38, 33.98, 33.81,

30.75, 29.92, 29.52, 26.11, 20.32, 20.23.HRMS (ESI) calcd. for C12H19O2Na: 212.1204
[M+Na]+, found, 212.1213.

(1S,2R,4aR,8aS)-2-methyl-2,5,6,7,8,8a-hexahydro-1H-1,4a-ethanonaphthalene-2,8a-diol
(3.19)
To

a

stirred

solution

of

the

(1R,4aR,8aS)-8a-hydroxy-6,7,8,8a-tetrahydro-1H-1,4a-

ethanonaphthalen-2(5H)-one (20.0 mg, 0.104 mmol) in THF (Volume: 1.0 ml)at RT was added
methyllithium (0.195 ml, 0.312 mmol) at once. (Note: adding methyl lithium at 0°C results in
two products) Aftre stirring for 15min or till the starting material disappeared the reaction was
quenched by addition of saturated ammonium chloride solition. The reaction mixture was diluted
by ethyl acetate and organic layer was washed with brine. The organic extract was then dried
over magnesium sulfate and evaporated under vacuum to give crude diol. Crude was purified
using column chromatography ethyl acetate and hexanes (7:3) to afford (1S,2R,4aR,8aS)-2methyl-2,5,6,7,8,8a-hexahydro-1H-1,4a-ethanonaphthalene-2,8a-diol (16.2 mg, 0.078 mmol,
74.8 % yield) 1H NMR (400 MHz, CDCl3) δ 5.62 (d, J = 9.5 Hz, 1H), 5.40 (d, J = 9.3 Hz, 1H),
2.32 (dd, J = 20.5, 10.4 Hz, 2H), 2.13 – 1.97 (m, 3H), 1.76 – 1.46 (m, 15H), 1.42 (t, J = 9.1 Hz,
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4H), 1.32 (s, 3H). 13C NMR (126 MHz, MeOD) δ 139.54, 129.55, 80.19, 74.29, 55.66, 48.11,
47.94, 47.88, 47.77, 47.60, 47.43, 47.26, 47.09, 46.63, 34.16, 31.54, 30.44, 27.92, 22.90, 22.42,
20.87.
(1R,4aR,8aS)-8a-hydroxy-6,7,8,8a-tetrahydro-1H-1,4a-ethanonaphthalen-2(5H)-one (3.54)
To a stirred solution of (1R,4aR,8aS)-8a-hydroxyhexahydro-1H-1,4a-ethanonaphthalen-2(5H)one (20.0 mg, 0.103 mmol)of mixture of Toluene (Ratio: 2.0, Volume: 2.0 ml) and DMSO
(Ratio: 1.000, Volume: 1.000 ml) was added IBX (115 mg, 0.412 mmol). The reaction mixture
was stirred at 90°C for 3-4hrs (Reaction monitired by TLC). After completion of reaction it was
quenched with 2.0 ml water and extracted with ether. The organic layer washed with brine, dried
over magnesium sulfate and evaporated under vacuum to give crude enone. The crude was
carefully purified by column chromatography using ethyl actetae and hexanes. (8:2) to give
(1R,4aR,8aS)-8a-hydroxy-6,7,8,8a-tetrahydro-1H-1,4a-ethanonaphthalen-2(5H)-one
0.080 mmol, 77 % yield) White solid; mp 83-85 °C; IR cm-1; 1H NMR

1

(15.3mg,

H NMR (400 MHz,

CDCl3) δ 6.91 (d, J = 9.7 Hz, 1H), 5.98 (dd, J = 9.7, 1.3 Hz, 1H), 2.73 (d, J = 7.3 Hz, 1H), 2.48 –
2.29 (m, 1H), 1.96 (ddd, J = 11.9, 9.6, 5.1 Hz, 2H), 1.91 – 1.73 (m, 5H), 1.72 – 1.64 (m, 2H),
1.63 – 1.47 (m, 5H), 1.47 – 1.39 (m, 1H), 1.26 (qd, J = 11.4, 5.9 Hz, 1H). 13C NMR (101 MHz,
CDCl3) δ 203.59, 160.76, 127.99, 82.33, 77.35, 77.03, 76.71, 60.81, 51.10, 32.76, 29.55, 28.94,
23.45, 22.54, 20.35. 13C NMR (CDCl3)  202.5, 157.8, 127.9, 82.3, 60.3, 47.6, 31.9, 29.3, 26.8,
21.2, 20.9, 19.8; HRMS (ESI) calcd. for C12H17O2: 193.1229 [M+H]+, found, 193.1221;

(3S,4R,4aS,8aS)-4a-hydroxy-3-methyl-1-oxooctahydro-4,8a-ethanoisochromene-3carbaldehyde (3.10)
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A stream of ozone was carefully bubbled through a solution of (1S,2R,4aR,8aS)-2-methyl2,5,6,7,8,8a-hexahydro-1H-1,4a-ethanonaphthalene-2,8a-diol (16.0 mg, 0.077 mmol) in DCM
(Volume: 1.0 ml) at -78 °C until distinctive blue color of ozone was clearly observed. The
reaction was stirred at that temperature for 30mins. After 30 mins a stream of argon was passed
though the solution to displace the ozone. To this solution at -78 ° C was added DMS (0.011 ml,
0.154 mmol) and the reaction was allowed to warm up to RT and stirred for 6-8 hrs. Reaction
was monitored by TLC and no starting material was observed aftre 7 hrs. Organic solvent was
evaporated and crude lactol obtained was immediately dissolved in DCM. To a stirred solution
of

lactol;

(1R,3S,4R,4aS,8aS)-1,4a-dihydroxy-3-methyloctahydro-4,8a-ethanoisochromene-3

carbaldehyde (13.0 mg, 0.054 mmol, 70.4 % yield) in DCM (Volume: 1.0 ml) was added DMP
(32.6 mg, 0.077 mmol) at RT. The reaction was stirred no starting material was seen on TLC.
DCM was recovered and diethyl ether was added to the residue. The suspension was filtered
through celite and the organic layer was washed with saturated sodium bicarbonate solution,
brine and dried over magnesium sulfate. Concentration of ether under vacuum afforded crude
ketone which was purified by column chromatography to give colorless oily compound
(3S,4R,4aS,8aS)-4a-hydroxy-3-methyl-1-oxooctahydro-4,8a-ethanoisochromene-3-carbaldehyde
(9.3 mg, 0.039 mmol, 50.8 % yield)
1

H NMR (600 MHz, cdcl3) δ 9.57 (s, 1H), 2.39 (d, J = 6.8 Hz, 1H), 2.31 (d, J = 13.3 Hz, 2H),

2.23 – 2.15 (m, 2H), 1.98 (d, J = 14.1 Hz, 2H), 1.87 – 1.78 (m, 5H), 1.77 – 1.73 (m, 2H), 1.67 –
1.59 (m, 5H), 1.57 – 1.47 (m, 8H), 1.42 – 1.32 (m, 2H), 1.30 (s, 1H), 1.22 (s, 1H). 13C NMR (126
MHz, CDCl3) δ 201.62, 174.47, 86.70, 77.63, 77.30, 77.04, 76.79, 55.00, 48.85, 33.99, 32.49,
26.86, 23.95, 22.63, 22.01, 20.53.
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ethyl 2-oxocycloheptanecarboxylate (3.60) and ethyl 2-hydroxycyclohept-1-enecarboxylate
(3.60a)
ethyl 2-oxocycloheptanecarboxylate (3.60) (org.syn.coll. vol V p.198)
In a 100 mL 2 necked round-bottomed flask equipped with condenser and dropping funnel was
added sodium Hydride mineral oil dispersion (4.99 g, 125 mmol). NaH mineral oil dispersion
was then washed with benzene to remove mineral oil (2x50ml wash). Once the mineral oil was
removed, fresh Benzene (50.0 ml) was charged and then Diethyl Carbonate (10.80 ml, 89 mmol)
was added slowly and this mixture was heated to reflux. Cycloheptanone (5.26 ml, 44.6 mmol)
was added dropwise through a dropping funnel over 3-4 hrs. After the addition was complete
reflux was continued for another 30 mins and then reaction was cooled to RT. To the RM was
then added acetic acid dropwise to give a pasty white solid. (pH acidic). To the pasty solid was
added icecold water (exothermic reaction). The aqueous layer was extracted with ether and the
combined organic extracts were washed with 1M Sodium Bicarbonate and brine. The organic
layer was evaporated and crude oil obtained was purified by flash chromatography (1:10 EtOAc:
Hexanes) to afford ethyl 2-oxocycloheptanecarboxylate (5.89 g, 32.0 mmol, 71.7 % yield) Note:
Product obtained was mixture of Ketone 3.60 and its enol 3.60a. This mixture was carried
forward as such in the next reaction. 2927, 2256.20, 1739.85, 1704, 1637.54, 1239.51, 1309.11,
1048 cm–1; 1H NMR (400 MHz, cdcl3) δ 12.69 (s), 4.25 – 3.99 (m), 3.47 (dd, J = 10.3, 4.0 Hz),
2.63 – 2.45 (m), 2.45 – 2.24 (m), 2.08 – 1.94 (m), 1.94 – 1.74 (m), 1.71 – 1.63 (m), 1.61 – 1.50
(m), 1.49 – 1.35 (m), 1.22 (dt, J = 17.0, 7.1 Hz).

13

C NMR (101 MHz, ) δ 208.79, 179.34,

172.87, 170.36, 101.43, 77.32, 77.00, 76.68, 60.83, 60.11, 58.75, 58.72, 42.89, 35.17, 31.82,
29.47, 27.78, 27.39, 27.21, 24.45, 24.19, 14.07, 13.87. ESI+ ( M+Na) 207.11

ethyl 1-(but-3-en-1-yl)-2-oxocycloheptanecarboxylate (3.61)
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The ethyl 2-oxocycloheptanecarboxylate (2.0g, 10.86 mmol) was added dropwise to a stirred
solution of Potassium t-butoxide (1.267 g, 11.29 mmol) in dry DMSO (5.0 ml). After 1 4Bromo-1-butene (1.146 ml, 11.29 mmol) was added dropwise. After 5hrs at RT the solution was
diluted with water.The layers were separated, the aqueous layer was extracted with Ether (3 x 25
mL) and the combined organic layers were washed with brine and dried over Magnesium
Sulfate. Organic layer was evaporated under vacuum and crude oil obtained was purified by
column chromatography (Hexanes: Ethyl acetate 95:5) to afford ethyl 1-(but-3-enyl)-2oxocycloheptanecarboxylate (1.95 g, 8.18 mmol, 75 % yield) 1H NMR (500 MHz, CDCl3) δ 5.74
(ddt, J = 16.5, 10.4, 6.3 Hz, 1H), 4.94 (dd, J = 36.3, 13.6 Hz, 2H), 4.27 – 4.01 (m, 2H), 2.60
(ddd, J = 12.3, 8.7, 3.5 Hz, 1H), 2.42 (ddd, J = 22.8, 12.1, 7.5 Hz, 1H), 2.18 – 2.07 (m, 1H), 2.06
– 1.87 (m, 3H), 1.81 – 1.52 (m, 7H), 1.49 – 1.35 (m, 1H), 1.32 – 1.10 (m, 3H). 13C NMR (126
MHz, CDCl3) δ 209.27, 172.31, 137.96, 114.68, 77.35, 77.10, 76.84, 62.48, 60.97, 42.00, 34.56,
32.84, 29.83, 28.88, 25.51, 24.82, 14.06. ESI+ ( M+1) 239.17

ethyl 1-(but-3-en-1-yl)-2-methylenecycloheptanecarboxylate (3.62)
In a 100 mL round-bottomed flask, Sodium hydride 60% (0.554 g, 13.85 mmol) was added along
with 10ml DMSO and heated at 70°C for 1 hr. An additional 10ml DMSO was added followed
by Methyl triphenylphosphonium bromide (4.95 g, 13.85 mmol). After 20 mins Alkneylated
ketone (1.1g, 4.62 mmol) in (10 mL) DMSO was added slowly. RM stirred at this temperature
till completition of reaction. Reaction monitored by TLC. After completion of the reaction it was
diluted with water. The Aqueos layer was extarcted with ether and the combined organic layer
was washed with sat. ammonium chloride solution followed by brine. The organic layer was
dried over magnesium sulfate and evaporated under vacuum to give thick oil. The crude was
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purified by flash chromatography (Hexanes:Et2O 96:4) to afford ethyl 1-(but-3-enyl)-2methylenecycloheptanecarboxylate (755 mg, 3.19 mmol, 69.2 % yield) 1H NMR (500 MHz,
CDCl3) δ 7.35 (s, 1H), 5.83 (ddd, J = 16.7, 11.5, 6.5 Hz, 1H), 5.20 – 4.76 (m, 4H), 4.26 – 4.05
(m, 2H), 2.33 – 2.11 (m, 4H), 2.03 (ddd, J = 25.2, 16.9, 7.7 Hz, 4H), 1.58 (dddd, J = 33.0, 25.5,
16.9, 10.7 Hz, 11H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.64, 152.63,
138.74, 114.29, 113.16, 77.27, 77.02, 76.76, 60.37, 54.84, 37.58, 34.94, 34.69, 30.95, 30.28,
29.52, 24.54, 14.14. ESI+ ( M+1) 236.17
ethyl 2,3,3a,4,5,6,7,8-octahydroazulene-3a-carboxylate (3.63)
To a solution of ethyl 1-(but-3-enyl)-2-methylenecycloheptanecarboxylate (500 mg, 2.098
mmol) in degassed Toluene (2.0 ml) was added Grubbs Catalyst 2nd Generation (89 mg, 0.105
mmol) to give a yellow solution. Reaction mixture was refluxed for 5hrs. Toluene was
evaporated under vacuum and residue obtained was dissolved in DCM and loaded on to column
for purification using Hex:Et2O 95:5. to afford ethyl 2,3,3a,4,5,6,7,8-octahydroazulene-3acarboxylate (307 mg, 1.474 mmol, 70.3 % yield); 1H NMR (500 MHz, CDCl3) δ 5.53 (s, 1H),
4.16 (ddd, J = 14.1, 7.1, 2.4 Hz, 2H), 2.48 (dd, J = 12.1, 7.9 Hz, 1H), 2.41 – 2.29 (m, 2H), 2.29 –
2.13 (m, 3H), 2.03 (dd, J = 13.9, 7.2 Hz, 1H), 1.86 – 1.77 (m, 1H), 1.72 (dd, J = 13.9, 8.9 Hz,
3H), 1.68 – 1.61 (m, 3H), 1.50 – 1.33 (m, 4H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 176.92, 147.62, 128.24, 77.27, 77.01, 76.76, 60.35, 60.27, 37.55, 36.40, 30.35, 30.32,
29.96, 29.20, 24.95, 14.22. ESI+ ( M+1) 208.12
(1aS,3aS,8aR)-ethyl octahydro-1aH-azuleno[1,8a-b]oxirene-3a-carboxylate (3.64) and
(1aS,3aR,8aR)-ethyl octahydro-1aH-azuleno[1,8a-b]oxirene-3a-carboxylate (3.65)
To a stirred solution of ethyl 2,3,3a,4,5,6,7,8-octahydroazulene-3a-carboxylate (200 mg, 0.960
mmol) in aDCM (2.0 ml) was charged MCPBA (m-Chloroperoxybenzoic acid) (258 mg, 1.152
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mmol) to give a white suspension. Reation mixture was stirred for 2 hrs at RT. TLC showed
completion of reaction with formation of two new spots.Reaction mixture was diluted with water
and organic layer was separated. The DCM layer was washed with sat. NaHCO3 and brine and
then dried over magnesium sulfate. The organic layer was dried under vacuum and crude oil
obtained was purified using column chromatogarphy. Hex: Et2O (9:1) to afford (Non polar on
TLC) 3.64 (1aS,3aS,8aR)-ethyl octahydro-1aH-azuleno[1,8a-b]oxirene-3a-carboxylate (106mg,
0.473 mmol, 49.2 % yield) and (Slightly more Polar) 3.65 (1aS,3aR,8aR)-ethyl octahydro-1aHazuleno[1,8a-b]oxirene-3a-carboxylate (95.0 mg, 0.424 mmol, 44.1 % yield)
(1aS,3aS,8aR)-ethyl octahydro-1aH-azuleno[1,8a-b]oxirene-3a-carboxylate (3.64)
1

H NMR (400 MHz, CDCl3) δ 4.27 – 4.11 (m, 2H), 3.35 (s, 1H), 2.44 – 2.32 (m, 1H), 2.12 (dd, J

= 9.5, 3.6 Hz, 1H), 1.93 (dd, J = 13.6, 7.9 Hz, 1H), 1.84 (ddd, J = 5.8, 4.3, 1.6 Hz, 1H), 1.77 –
1.65 (m, 4H), 1.65 – 1.52 (m, 5H), 1.39 (ddt, J = 11.4, 9.0, 6.9 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H).
13

C NMR (101 MHz, CDCl3) δ 175.19, 77.34, 77.02, 76.70, 69.47, 64.72, 60.29, 54.78, 35.97,

32.80, 30.59, 27.07, 26.69, 26.30, 25.02, 14.20. ESI+ ( M+Na) 207.11

(1aS,3aR,8aR)-ethyl octahydro-1aH-azuleno[1,8a-b]oxirene-3a-carboxylate (3.65)
1

H NMR (400 MHz, CDCl3) δ 4.34 – 4.08 (m, 2H), 3.28 (s, 1H), 2.41 (dd, J = 14.1, 11.7 Hz,

1H), 2.18 – 1.85 (m, 3H), 1.83 – 1.57 (m, 8H), 1.56 – 1.41 (m, 4H), 1.28 (dd, J = 13.6, 6.5 Hz,
4H). 13C NMR (126 MHz, CDCl3) δ 13C NMR (101 MHz, CDCl3) δ 175.56, 77.35, 77.03, 76.72,
70.41, 63.77, 60.39, 55.56, 35.19, 34.07, 30.87, 28.12, 25.81, 25.00, 23.55, 14.22. ESI+ ( M+Na)
207.11
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CHAPTER 5
INTRODUCTION- CASPASE-1

Caspase-1-Introduction
Caspases represent a family of aspartate-specific cysteine dependent proteases involved in
the biochemical mechanisms underlying proinflammatory cytokine maturation and cellular
apoptosis. Initially, caspases' role in apoptosis was confirmed by studies performed on the
nematode worm Caenrohabditis elegans. Yuan’s research group showed CED-3 plays an
important role in programmed cell death and more importantly, CED-3 is homologous to human
protease caspase-1.68 Subsequently, studies revealed that caspase-1 is more involved in
maturation of inflammatory cytokines rather than in apoptosis. However, the finding of
homology between CED-3 and human caspase-1 led to the discovery of large class of CED3/caspase-1 like proteases in mammals as well as humans.69
To date, 15 mammalian caspases have been identified out of which 12 are present in
humans and have shown high phylogenetic conservation. Caspases play a crucial role in both
apoptosis and inflammation. Inflammatory caspases are involved in maturation of cytokines,
which in turn are responsible for several inflammatory disorders like rheumatoid arthritis,
multiple sclerosis osteoarthritis and septic shock. Apoptotic caspases are involved in
programmed cell death in multicellular organism and up-regulation (in Cancer) or downregulation (stroke or myocardial infarction) of apoptosis is warranted in several disease states.
Because of their important biological roles, these enzymes have been considered as good targets
in drug discovery process. 70, 71
All the caspases share several common features like similarity in amio acid residues, structure
and substrate specificity. They are expressed in cells as single chain zymogen 32-55 kDa
comprising of three domains; N-terminal prodomain, large subunit domain and a small subunit
domain.
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The inactive enzyme has to be proteolytically activated to its active form which is believed
to occur either via autoproteolysis, or via cleavage by other caspase or non-caspase proteases.
The active form of the enzyme is a heterodimer that is made up of 2 large subunits 17-20 kDa
(p20) and 2 small subunits (p10) 10-12 kDa. All of them have a cysteine residue in its active site,
which acts as a nucleophile, and most importantly they share a stringent requirement for
cleavage of their substrate after aspartic acid residue. The large and small subunits of human
caspases have 29 amino acid residues in common. Seven of these residues play a pivotal role in
substrate recognition and catalysis, while the remaining 22 residues are distributed throughout
the protein. It can be speculated that these 22 conserved residues may help to maintain the
structural integrity of active form of the enzyme. 71, 72
5.1 Classification of Caspases
Broadly, caspases can be divided into two categories based on their physiological functions:
inflammatory and apoptotic caspases. Caspase 2, 3 and 6-10 are involved in the apoptotic
processes; while caspase 1, 4, 5 and 12 are involved in maturation of cytokines, consequently
leading to the inflammatory response. Classification based on phylogenetic analysis puts caspase
into two major subfamilies caspase-1 type or the cell death gene CED type. Further they are
subdivided based on the long (more than 90 amino acid residue) or short (20-30 amino acid
residue) prodomain of the zymogen. Based on these criterion, mammalian caspases can be
divided in to three subclasses; Inflammatory caspases with large prodomain (caspase 1, 4, 5, 12,
13 & 14), Initiator caspase with long prodomain additionally having a (DED) death effector
domain (caspase 8 & 10) or a (CARD) caspase-recruitment domain (caspase 2 and 9) and the last
class is effector caspase with a short prodomain (caspase 3, 6 & 7).72-74
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5.2 Zymogen Activation
Zymogen activation (inactive procaspase) is tightly regulated and only occurs in response to
specific stimuli. Activation of procaspase takes place by proteolytic cleavage of a pro-domain
and separation of the large and small subunits of the active casapses. The cleavage is often
carried out by other caspases/proteases, with scission taking place at two distinct sites, each
containing aspartic acid residues (4 Asp containing peptide bonds). Most of the procaspases are
less active than the caspases though the difference in the activity between the zymogen and its
active form may vary. For example, procaspase 3 & 7 in 10,000 fold less active than caspase 3 &
7 while procaspase -9 is only 10 fold less active than caspase-9.75 There are some differences in
the mechanism of activation between inflammatory, effector and initiator caspases. The effector
casapases (-3, -6 & -7)76-78 are homodimers, which are activated by proteolysis, liberating the
active dimer from the prodomain. The initator and inflammatory caspases are activated by
“induced proximity model”, wherein the monomers are forced to dimerize and form multiprotien
complexes.79, 80

procaspase

N
-
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p20
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3-24 kDa
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Asp-cleavage
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Proteolytic cleavage
Active site
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Figure 5.1: maturation of Caspase-1
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5.3 Caspase-1 also know as interleukin 1-converting enzyme (ICE)
Caspase-1 also known as interleukin 1-converting enzyme (ICE) primarily localized in
monocytes, is one of the most studied caspases by both industry as well as academia. ICE was
the first human caspase to be identified in 1989 and was isolated in an effort to indentifying the
enzyme responsible for maturation of interleukin-1β (IL-1β). ICE is known to cleave inactive IL1β 31 kDa precursor to its active form 17.5 kDa which is then secreted by monocytes and
macrophages. Morever, ICE is also involved in processing of IL-18 and IL-1. It has been
established for years now that it plays a more prominent role in regulation of inflammatory
progression and is less involved in apoptotic pathways. 69, 81
5.4 Role of Caspase-1
Thornberry’s research group81, 82 indentified the importance of ICE in maturation of cytokines.
Activation of ICE leads to secretion of IL-1β by macrophages following an attack by exogenous
compounds either from bacteria or a virus. Interleukins-1 processing leads to myriad of events
ranging from initiation of fever to induction of inflammatory response to cellular activities like
proliferation,

differentiation

and

apoptosis.

Moreover,

IL-

mediated

induction

of

cyclooxygenase-2 in the central nervous system is responsible for pain and hypersensitivity
reactions. Secretion of other interleukins IL-18 and IL-33 mediated by ICE, suggest that it is
responsible for inflammatory processes as well as innate immunity. Gurcel et.al;83 suggested an
additional role of ICE in fortification of the injured cells. Bacterical pore forming toxins trigger
inflammasome (NALP3 and Ipaf) formation leading to activation of ICE, which in turn promotes
lipid metabolism (via activation of sterol regulatory element binding protein) to repair the
membrane damage. 84
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5.5 Activation of Caspase-1
ICE belongs to subclass of inflammatory caspases having a long N-terminal prodomain,
which is likely to be involved in protein-protein interaction leading to activation of the caspase1. The activation of ICE is very similar to that of initiator caspases. The N-terminal domain has a
“caspase activation and recruitment domain” (CARD) motif which is responsible for inducing
autocatalytic activation by bringing two or more proteins in very close proximity
Studies conducted on CASP-11-null mice indicate that caspase-11 is required for activation
of caspase-1. The mice lacking of caspase-11 were unable to produce any IL- similar to the
observation incase of ICE knockout mice.55 Currently, no human analog of murine caspase-11
has been found. However, caspase-4 & 5 show considerable sequence homology to the murine
caspase.85,

86

Moreover, studies have revealed upregulation of caspase-11 and caspase-5 in

response to lipopolysaccharide (LPS) challenege, suggesting role of caspase-5 in activation of
ICE.87
Activation of ICE has been studied by many research groups and a few mechanisms have
been put forward. Similar to other established caspase activation pathways, activation of ICE
should involve some adaptor molecule capable of inducing autocatalytic proteolysis. This
adaptor molecule should has a region that interacts with ICE, probably another CARD domain
capable of interacting with the ICE pro-domain. Additionally, it is likely that it also possesses an
oligomerization motif to facilitate caspase clustering.88 To date, several CARD containing
complexes have been shown to interact with CARD domain of procaspase-1, including
Rip2/RICK/CARDIAK (CARD-containing IL-1-converting enzyme associated kinase),89 (ICE
protein activating factor) Ipaf/CARDI2/CLAN, ASC/PYCARD and NALP1 (inflammasome)
complexes. Recent studies have shown that Rip2/RICK/CARDIAK complex is more involved in
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activation of nuclear factor kappa-light-chain-enhancer of activated B cells complex (NF-B)
and less involved with caspase-1.90,

91

Ipaf contains N-terminal CARD as well as

multiple

leucine rich repeats (LRR) at C-terminal, and it oligomerizes in the presence of procaspase-1.
LRR motif is also found in toll receptor family and is implicated in pathogen recognition. This
further confirms the role of Ipaf as a pathogen-recognizing molecule.92 Though Ipaf links with
ICE are strong, studies at physiological concentration of Ipaf are yet to be published. Apoptosisassociated speck-like protein with a CARD (ASC) has also been implicated as an ICE adaptor.
Bipartite ASC contains a CARD and a pyrin motif. Studies have shown that its CARD domain
interacts with ICE.93, 94 Lastly, NALP-1 which contains pyrin and CARD recruits caspase-1 via
ASC as well as caspase-5 through the CARD domain present in the C-terminus of NALP-1.
Tschopp and associates suggested that NALP-1 induces the formation of caspase-1/caspase-5
complex called “inflammasome”. The inflammasome is composed of caspase-1, ASC and
inflammasome component NALP1, NALP3 and Ipaf, which can sense foreign bodies (bacteria,
virus) This model is widely accepted for caspase-1 activation, however, what triggers
inflammasome activation is not completely clear yet.95-97
5.6. Structure of Caspase-1
Several crystal structures of caspase-1 enzyme bound to native ligand or inhibitor form have
been published in protein data bank. Cleavage of procaspase (p45) at four Asp-Xaa bonds (Asp
103-ser104, Asp 119-Asn 120, Asp 297-Ser 298 and Asp 316-Ala317) gives active ICE, which is
a tetramer comprising 2 large p20 subunits (residues 120-297) and 2 p10 small subunits (317-404
residues). Caspase is made up of six-stranded  sheets, forming the core of the enzyme. Five of
them lie parallel to each other while one is antiparallel (1, 164-170; 2, 199-205; 3, 230-236; 4,
278-283 7, 327-331 and 8, 388-393 residues respectively). The core is surrounded by six 
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helices which are roughly parallel to the beta sheet, and they prevent the core from water
molecules. Thelast seven residues from p20 and the first residues from p10 form two other antiparallel -sheets (5, 291-297 and 6, 317-323). The tetramers two subunits align themselves in
head-to-tail configuration with two identical active sites at the opposite end of the enzyme.81, 98, 99

Figure 5.2. : Cartoon representation of caspase-1
5.7 Active site of Caspase-1
One of the pioneering studies in the field of ICE research by Thornberry associates, was the
identification of tertiary protein structure of ICE and the ensuing discovery of the tetrapeptide;
Ac-YVAD-CHO possessing potent ICE inhibitory activity.81 Later on, Wilson and Associates
form Vertex Pharmaceuticals published x-ray crystal structures of ICE co-crystallized with
tetrapeptide aldehyde inhibitor (acetyl-Tyr-Val-Ala-Asp-H). Cys 285 was confirmed as a
nucleophile to which aldehyde is attached in covalent fashion.100, 101 Along with Cys 285, His
237 forms the catalytic diad in the active site. The analysis of enzyme-substrate complex reveals
that both the large and small subunits are required for ICE activity. The inhibitor occupies S1-S4
subsite of ICE wherein S1 is present in p20 subunit while S2-S4 (Val 338 to Pro 343) is formed
by residues from p10. Subunits p10 and p20 play role in recognition of aspartic acid of the
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substrate (at S1 subsite) by contributing residues Arg 179 (p20) and Arg 341 (p10) for salt bridge
interactions. Arg 179-Asp interaction seems to be more important based on hydrogen bonding
distances. P1 carboxylate (Asp residue) is stabilized by Arg (179, 341) and Gln 283, while P2
and P3 are solvent exposed. P4 of the inhibitor (Tyrosine) makes hydrophobic interaction with
residues His 342, Val 348 and Arg 383 in S4 subsite.81, 99, 101

Figure 5.3.: cartoon depiction of caspase-1 active site with cysteine 285 covalently attached to
the inhibitor
The Romanowski research lab carried out X-ray crystallographic studies on both ligand free and
malonate-bound human caspase-1 in order to unravel the mechanism of substrate binding.102 The
aim of this study was to investigate the conformational changes in active site upon binding of
substrate to aspartate recognition site. The analysis of empty enzyme suggests that there is a
major structural rearrangement in ligand free and ligand bound caspase-1, especially in three
well defined regions; loop 2 (minor changes), loop 3 (most changes) and loop 4 (minor changes).
Furthermore, the empty enzyme is not accessible to the substrate scaffold largely due to its
closed (or partially closed) active site conformation. This is due to a major shifting of loop 3 (by
4.9 Å) of the p10 subunit occluding the catalytic cleft of ICE in the ligand-free form. Foremost
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changes occur within the 15 residues of loop 3 containing critical residue Arg 341 of the P1
substrate recognition pocket. In the ligand free ICE the Arg 341 and Trp 340 is present on the
surface. Binding of the aspartate containing ligand to the protein, transfers the Arg 341 from
surface to S1 pocket and Trp 340 to S2 pocket of the ICE active site. In this transition of the loop
3, Arg 341 is rotated by 180 degrees from surface to oxyanion hole with proline 335 and 343
serving as pivot points. Romanowski et.al suggest that the binding of aspartate moiety of the
substrate to S1 pocket is essential to bring about conformational change with subsequent opening
of the active site which is now capable of catalysis.102

5.8 Allosteric site in Caspase-1
Wells, Romanowski and associates by the aid of X-ray crystallography discovered an allosteric
circuit in ICE.103,

104

In corroboration with their (Romanowski group) earlier105 findings, they

found that the protease exists in two distinct states: on-state/open state when the active site is
occupied and an off-state/closed state when enzyme is not occupied. In this study, they found
that there is allosteric binding site at the dimer interface, 15 Å away from the active site of the
enzyme. More importantly, when the allosteric site is occupied by a synthetic small molecule the
enzyme remains in off-state. Going from on-state to off-state of the enzyme, a network of 21
hydrogen bonds from nine side chain residues connecting the active and allosteric site, change
partners. Out of these nine side chains, Arg286 and Glu390 form salt bridge interactions and are
most crucial for retaining catalytic activity. 104, 105

189

Figure 5.4: Allosteric site of Caspase-1

5.9. Catalytic mechanism of caspase-1 mediated hydrolysis of peptide bond
Mechanism of the cleavage of the peptide bond by caspases is similar to that of other cysteine
proteases. The active site of the enzyme was confirmed by solving the crystal structure of the
caspase-1 covalently bound to its inhibitor via the sulphydryl group of the cysteine residue (Cys285). The active site contains a catalytic dyad comprising of a cysteine 285 100 residue which acts
as nucleophile and histidine 237 acting as a base. Both these residues are harbored in the p20
large subunit of the tetramer. The histidine residue not only enhances the nucleophilicity of
cystiene residue in the active site but also activates water molecule which plays important role in
hydrolysis of the peptide bond. The mechanism of hydrolysis is delineated in the figure 5.5.
given below. The aspartic acid moiety in substrate is anchored by the Arg341 and Ser347 from
p10 subunits, while Arg179 and Gln283 from p20 subunits. This helps orienting the carbonyl
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group of the substrate so that it is easily accessible for the nucleophilic attack. The hydrolytic
mechanism proceeds by attack of the Cys 285 on the electrophilic carbonyl group of the
substrate molecule forming a tetrahedral intermediate. Two possible geometries are suggested for
the tetrahedral intermediate of the substrate, one in which oxyanion hole is in contact with His
237 instead of Cys 285 and second one in which oxyanion hole is stabilized by Cys285 and
Gly238. However, the tetrahedral intermediate stabilized by oxyanion hole formed by Cys285
and Gly238 is the more likely one. The tetrahedral transition state collapses, liberating the free
amine and the acyl enzyme. The acyl-enzyme is then attacked by water molecule to give another
tetrahedral intermediate, which subsequently disintegrates giving free acid and regenerating the
Cys285 residue. Though the overall mechanism of hydrolysis of substrate is similar in all
caspases; however, their catalytic activity varies among the family members.81, 100, 101
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Figure 5.5.: Detailed Mechanism of hydrolysis of peptide bond catalyzed by Caspase-1
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5.10. Caspase-1 and Diseases
5.10.1 Epilepsy and ICE
Selected anti-inflammatory drugs displayed anticonvulsant activity in epileptic syndromes
that were unresponsive to classical second generation anti-epileptic drugs. This observation was
the first indication of possibility of role of inflammation in epilepsy. Several studies showed
fluctuations in cytokine levels in CSF and serum of epileptic patients. Moreover, epileptogenic
brain specimens surgically removed from epileptic patients (drug-resistant epilepsy with
differing origins) showed increased levels of proinflammatory cytokines (IL-1 and IL-1 recepor
type 1) in the glia, neurons and endothelial cell of the blood brain barrier. IL-1 is induced in the
brain following injuries like seizures. In control brains from normal patients, no such increase in
cytokine levels was observed.106-108
Biochemical studies showed that IL-1 activates Src family of tyrosine kinase which in
turn phosphorylates NMDA receptors. This results in NMDA receptor mediated calcium influx
in to the neurons.
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The influx of calcium plays role in (over) excitation of neurons and

seizures. 110-112
The role of inflammatory mediators in the etiology of epilepsy was further confirmed by use of
several animal models. The animal model studies resulted in three important findings
1) Pre-existing proinflammatory changes in the brain increased seizure susceptibility and
treatment of animals with anti-inflammatory drugs blocked the proconvulsant effects
2) Inhibition of specific proinflammatory signals in the brain reduced frequency of seizures
3) Induced (chemically or electrically) seizures trigger a inflammatory response in the brain
suggesting that recurrent seizures can induce proinflammatory mechanisms in brain
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All of these taken together suggest that inflammatory molecules might be involved in the
etiopathogenesis of epilepsy, and inhibition of the inflammatory processes can be a novel target
in the treatment of epilepsy. 108, 110-112
ICE plays an important role in the maturation of IL-1, hence inhibitors of ICE may become an
attractive in the treatment of epilepsy. Two molecules from the vertex (Pralnacasan-VX-740 and
VX-765) were tested against inflammatory disorders. VX-765 demonstrated good anticonvulsant profile in rodents following systemic administration. It also reduced frequency and
duration of seizure in mice, which were resistant to classical anti-convulsant drugs. Currently,
VX-765 is in phase 2b clinical trial stage for treatment of seizures.113, 114
5.10.2. ICE and multiple sclerosis
Multiple sclerosis is an immune-mediated demyelinating disease characterized by CNS white
matter plaques. The neuropathological characteristic of the disease is the presence of
inflammatory infiltrates containing few T cells within CNS. It is noted that TNF-α, IFN-γ, and
IL-1β are present in MS plaques. IL-1β has also been shown to induce experimental autoimmune
encephalomyelitis (EAE) in an MS animal model. Furlan and associates' findings suggest that
the ICE mRNA blood levels are elevated and are at peak at the time of maximal EAE severity. 115
Dowling et.al. established that there is marked up regulation of
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in MS plaques (acute as well

as chronic). Moreover, ICE deficient mice demonstrated reduced EAE incidence. Similar results
were obtained with pharmacological blockade of ICE in animal models. However, the ICE
inhibitor only reduces EAE incidence in the preventive protocol and not in the therapeutic
protocol, suggesting that ICE plays a crucial role in early stage of immune-mediated
inflammatory process finally leading to EAE. All these results taken together indicate that the
ICE plays a pivotal role in regulation of proinflammatory cytokines and inhibition of the ICE is a
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potential therapeutic target for treatment of immune mediated inflammatory diseases.115

5.10.3. ICE and Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disorder characterized by
inflammation of various tissues. In RA patients, procytokines levels were higher in the synovial
fluid (TNF-α, IL-1β IL-6 and 1L-18) form the joints irrespective of therapy. These cytokines are
capable of inducing various inflammatory responses along with cartilage breakdown. ICE is to
known to play an important role in maturation of IL-1β and IL-18, which are involved in
mediation of RA. Researchers have demonstrated that ICE inhibitors were able to reduce the
cytokine levels and subsequently alleviate symptoms of RA in animal models. Pralnacasan, an
ICE inhibitor has shown to reduce cartilage damage and bone degradation in murine models.
Pralnacasan initially showed promise in clinical trials against RA, however, was discontinued in
phase IIb due to Pralnacasan induced liver fibrosis.117-119 Though ICE inhibitors have shown
some potential in treatment of RA, safety in long term usage (required in treatment of
inflammatory disease) is to yet to be assessed. In order to develop a successful ICE inhibitor for
treatment of inflammatory disorders it is necessary to develop a very specific inhibitor of ICE
with good safety profile. 120, 121
5.10.4. ICE and other diseases
ICE has been implicated in sepsis but the exact mechanism of involvement of ICE is not known.
Pro IL-18 is processed by ICE to mature IL-18, which in turn induces TNF-production and Tcell polarization. Moreover, reduction in apoptosis of neutrophils as seen in sepsis is mediated by
production of IL-1. Both these observations suggest ICE inhibition might be a viable treatment
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option of sepsis. ICE has also been implicated in neurodegenerative disorders like Huntington’s
disease, Alzheimer's disease and Parkinson's disease. Though the regulation of ICE along with
other caspases (2, 3, 7 and 8) has been observed in many of such diseases, the exact role of ICE
has yet to be elucidated.122
5.11. Development of ICE inhibitors
ICE plays an important role in the maturation of proinflammatory cytokines, which in turn play a
role in various immune mediated inflammatory disorders. Researchers over the years, utilizing
ICE knockout animal models and ICE pharmacological inhibitors, have proved that it is possible
to regulate cytokine levels by inhibition of ICE. ICE-deficient mice exhibit a shift in the
transport of several proinflammatory cytokines like IL-1β, IL-1α, IL-6 and TNF-α. These studies
clearly indicate that ICE inhibitors have great potential to be developed in drugs for use against
several inflammatory disorders. Due to its high therapeutic potential, pharmaceutical companies
have invested time and money in pursuing this target for treatment of immune mediated
inflammatory disorders.123, 124
ICE has been the most well studied inflammatory caspases. One of the pioneering studies in field
of ICE research by Thornberry associates was the identification of the tertiary protein structure
of ICE and ensuing discovery of the tetrapeptide Ac-YVAD-CHO possessing potent ICE
inhibitory activity.100 Later on, X-ray crystal structures of ICE co-crystallized with various
inhibitors have been published. As a result of extensive structural studies over the years, precise
pharmacophoric requirement of ICE inhibitors have been identified. The substrate can be divided
in to four portions P1, P2, P3 and P4 (figure 5.6). Out of these requirements at P1 and P4 are
very stringent, while wide ranges of substitutions are tolerated in P2 and P3.
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81, 122, 124, 125

P1 ( Cysteine trap)
Figure 5.6.: Typical caspase-1 inhibitor
5.11.1 Substrate Specificity for caspase-1
Prerequisites for the substrates of ICE inhibitors are generally well accepted and are as follows:
1) Presence of L-Aspartic acid residue in the P1 site that emulates the cleavage site (AspAla) of the pro form of IL-1his distinctive feature confers specificity to caspases over
other cysteine proteases (calpains, cathepsins etc) Additionally, the aspartate residue
forms crucial salt bridge interactions with Arg179, Gln283 and Arg341 thus anchoring the
ligand in appropriate orientation exposing the adjoining electrophilic warhead group to the
nucleophilic Cys285.99, 100
2) Presence of electrophilic warhead groups in the P1 site to which Cys285 forms a covalent
bond. His237 stabilizes the oxyanion of the warhead group suggesting its involvement in
the catalytic cascade. Depending upon the nature of substituent adjacent to the
electrophilic center (usually carbonyl group) the inhibitor can be reversible or
irreversible.123, 126
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Figure 5.7.:Types of caspase-1 inhibitiors
Variety of both reversible and irreversible warhead groups have been identified in an
effort to optimize the potency, selectivity, cell permeability, safety and ADME properties
of ICE inhibitors. Some examples of cysteine traps used in ICE inhibitor design are shown
below. Bioisosteric replacement of acid group (e.g. sulphonamide) to improve cell
permeability has also been reported. Presence of an additional hydrophobic P1′ subsite
adjacent to P1 has also been explored.127 Till date, most successful cystiene trap is
hemiacetal prodrug which is found in inhibitor in clinical trials (VX-740= Pralnacasan and
VX-765)
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Figure 5.8.: Different warhead groups used in caspase-1 inhibitors
3) P2-P3 requirements are not very stringent and most of the variation is seen in the design of
ICE inhibitors is in this region. Dolle and coworkers employed N-methyl scan of substrate
amide (ICE inhibitor) to determine crucial H-bond interaction of the amides of the
tetrapetide (P2-P3 region) with caspase-1 active site. Dolle et.al. later
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indentified cyclic

motifs that would retain these key hydrogen bonding interactions in P2-P3.129, 130
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Figure 5.9.: Crucial hydrogen bonding interaction in P2-P3 region of caspase-1 inhibitor

Further optimizations on Pyridazinondiazepine scaffold led to the discovery of Vertex’s
molecule pralnacasan, which was first ICE inhibitor in clinical trial

4) Finally P4 requirement is very precise and is the determinant of specificity amongst
different caspases (Karannewsky et.al). For caspase-1, hydrophobic aromatic groups are
generally tolerated well.131
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Figure 5.10. shows P1-P4 regions of Ac-YVAD-CHO inhibitor in the caspase-1 active
site (S1-S4). All the crucial hydrogen bonding interactions are shown in green.

Figure 5.10.: Depiction of active site of Caspase-1 with bound inhibitor Ac-YVAD-CHO, as
reported in the co-crystal structure.
5.12. Caspase-1 Inhibitors in literature
Using precise knowledge of the active site and crucial protein ligand interactions of ICE, many
research groups, both from industry and academia have reported several ICE inhibitors till date.
Especially with advent of Pralnacasan clinical trials (stopped at phase-II), and VX-765 clinical
trials for treatment of drug resistant epilepsy (just cleared in Phase IIa and Phase IIb will start
later in 2011) and psoriasis (completed phase II) have continued interest of scientist in
development of novel ICE inhibitors for the treatment of immune mediated inflammatory
diseases. Moreover, anakinra (Kineret®) that modulates IL-1levels is approved for the
treatment of some inflammatory disorders further suggest need for development of new ICE
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inhibitors. Review of inhibitors developed till date is summarized in table given below which
suggests that peptidomimetic design is still favored. Recently, several approaches have been
undertaken by proctor and gamble to simplify the peptidic scaffold (table 5.1) and to modulate
pharmacokinetic properties of ICE inhibitors.
Several non-peptidic ICE inhibitors have been reported but none of them have been continued
further in drug development program.134
Problems associated with development of Caspase-1 inhibitors
Even after several years of caspasse-1 research, only two candidates (Pranlacasan and VX-765)
have reached clinical trials. This clearly indicates that there are some problems associated with
caspase-1 drug development. One of the major problems associated with ICE inhibitor
development is obtaining specificity amongs several human cysteine proteases. 134, 135
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Table 5.1: Caspase-1 Inhibitors from literature
P4

P2-P3

P1

Notes

Refer
ences

Ac-Y

VA

D-CHO

One of the first successful tetrapetide with

81

ICE-1 inhibition activity with IC-50 2-5 nM
VA

Epoxide as Cysteine trap high caspase

136, 137
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selectivity

None

Designed to explore P3 region (Ki= 90 nM)

138

Pfizer

139

Diphenyl ether sulfonamide analog designed
to

increase

interaction.

potency

via

Identification

hydrophobic pocket

hydrophobic
of

P1

prime

(Ki= 100 nM)
Pralnacasan-Vertex

140

First ICE inhibitor to reach the clinical trails,
however discontinued in phase IIb clinical
trails for the treatment of Rheumatoid
arthritis due to liver toxicity at high dose
(IC50 5nM)
VX-765-Vertex

140 134

,

II on treatment resistant patients using VX765. Preliminary endpoint shows VX-765 to
be Safe and tolerable. Secondary endpoint
suggest need for longer duration phase IIb
trails. VX-765 inhibits acute and chronic
seizures in preclinical models that do not
respond to standard anti-epileptic drugs.
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Vertex Pharmaceutical just completed phase

141

Pfizer
P1 Sulfonamides analogs as ICE inhibitors,
designed

to

enhance

the

potency

via

intramolecular hydrogen bonding (Ki= 4 nM)
Sunesis Pharmaceutical

142

Disulfide tethering used to find reversible
ICE inhibitor. Novel tricyclic molecular
fragment recognized binding specifically to
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S4. Substituion of peptidomimetic P2-P3
region with thienyl alkyl ester
(Ki= 5 nM)
Procter and Gamble Pharmaceutical
Diazocan derivative, P2-P3 cyclic probe. R=
Substituted Phenyl ring
Most potent analog; R = Ph(3-OMe)
10,000 fold selective over caspase 3 & 8

143

Intended to increase cell permeability

144

IC 50 1 nM, Whole cell assay (THP-1) 3 nM

P & G Pharmaceutical

145

8, 6 fused bicyclic peptidomimetic (P2-P3).
Designed to maximize interactions at S2
pocket of the active site. IC50 of 1 nM. Most
of the derivatives were 10,000 fold more
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selective than caspase 3 and 8
Whole cell assay (THP-1) 46-100 nM
P & G Pharmaceutical

146

Monocyclic Thiazepine derivative with IC50
of 30 nM of most active compound in the
series. 10,000 foldmore selective than caspase
3 and 8
P & G Pharmaceutical
Pyrrolopyrimidinone as dipeptide mimetic

147

(P2-P3) IC50=14 nM
Whole cell assay (THP-1) 500nM 252 nM
P & G Pharmaceutical

148

1-(2-acylhydrazinocabonyl)-cycloalkyl
carboxamide derivative as ICE inhibitor
IC50 = 30 nM Whole cell assay (THP-1)
500nM
First example of noncovalent potent selective

149

aldehyde by benzylamine. Ki = 47 nM
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ICE inhibitor. Replacement of eletrophilic

CHAPTER 6
SYNTHESISANDBIOLOGICALEVALUATION OF
BERKELEYAMIDE A AND ITS DERIVATIVES

6.1. Introduction
Caspase-1 inhibitors have been highly pursued by industry as well as academia due to
their immense therapeutic potential. However, even after decades of painstaking research, only
few candidates have reached clinical trials. Moreover, none of them have made it to the market
yet. This suggests that there is a continuous need to search for novel ICE inhibitors for the
possible treatment of inflammatory disorders due to their tremendous potential. Over the years,
many natural products isolated from varied natural sources have served as leads in the drug
discovery process. With that perspective, we decided to explore some natural product leads for
development of ICE inhibitors. 150, 151
Recently, several interesting secondary metabolites have been isolated from rare
microbes evolved in extreme ecosystems such as Berkeley Pit Lake system in Montana using
bioactivity guided fractionation. These secondary metabolites have shown an array of biological
activity, ranging from anticancer to antimicrobial activity. One such secondary metabolite,
berkeleyamide A (6.1), was isolated from the fungi Pencillium rubrum. The fungus was one of
the first microbes to be studied and was isolated from a water sample taken from 885 feet of the
lake. Crude chloroform extracts inhibited caspase-1 and matrix metalloproteinase-3 (MMP-3) in
low micromolar range. After extensive purification, isolation and subsequent structure
elucidation (using techniques like IR, NMR 1D & 2D, HRMS) of several compounds, they
discovered four new amides; berkeleyamide A, B, C and D. All these compounds were active
against caspase-1 and MMP-3. berkeleyamide A exhibited greatest potency amongst all the
novel compounds and inhibited both casapase-1 and MMP-3 with IC50 of 330 nM.152
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6.2 Structure of Berkeleyamide A

Figure 6.1. Possible diastereomers of berkeleyamide
The structure of berkeleyamide A was elucidated using detailed NMR studies. It has a
core pyrrolidone scaffold with isobutyl chain substitution at 14-position, β-hydroxy-ketone side
chain appended at 11 position and three stereogenic centers; C-10, C-11 and C-14. The absolute
stereochemistry at C-10 was assigned as 10S using modified mosher ester analysis. There was
ambiguity regarding the configuration of the C11 and C14 stereogenic centers at the time of
isolation. However, it was known that they share a trans relationship, which was established by
the use of NOESY 2D NMR studies. With this information at disposal, it is evident that
berkeleyamide A can have either 10(S), 11(R) & 14 (S) absolute stereochemistry or 10(S), 11(S)
and 14 (R). Intriguing biological properties and ambiguity of the absolute stereochemistry at C11
and C14 prompted us to initiate the total synthesis of 6.1. The overall objective of this project
was to accomplish the total synthesis of 6.1, perform detailed structure activity relationship
studies and apply structure based design approach in the quest of novel potent caspase-1
inhibitors based on 1 scaffold.152
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6.3.

Route-1 proposed synthesis for berkeleyamide A
Berkeleyamide A has a disubstituted pyrrolidone scaffold with three stereogenic centers.

Our proposed synthetic scheme is depicted in scheme 1, which relies on synthesis of the crucial
pyrrolidone synthon followed by installation of the -hydroxy ketone side chain. Assuming 1 is
biosynthesized from naturally occurring L-leucine, it was logical to use commercially available
Boc-L-Leucine for the construction of disubstituted pyrrolidone. The -hydroxy ketone side
chain can be appended by functional group manipulation of the X group. All the obtained
diastereomers have been separated by either column chromatography or preparative HPLC.

Scheme 6.1: Proposed synthesis of berkeleyamide A
Proposed reactions a) synthesis of aldehyde b) Knoevenagel condensation and Hydrogenation d)
one pot Boc-deprotection followed by cyclization e) Functional group manipulations
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Scheme 6.2: Synthesis of disubstituted Pyrrolidone scaffold
Reagents and Conditions: a) N, O dimethylamine hydrochloride, N-methyl morpholine, EDCI
DCM b) 2.4 M LAH in THF solution, THF c) Ethyl cyanoacetate, 10% Silica gel CHCl 3 d) 10%
Pd/C, H2 e) LaCl3.7H2O water:acetonitrile (9:1) f) Grignard, THF and then HCl
According to the retrosynthetic analysis of 6.1, formation of pyrrolidone scaffold was the
key step towards the total synthesis of this natural product. To achieve this objective,
commercially available N-Boc-L-Leucine 6.2 was converted into Weinreb amide 6.3, using
standard peptide coupling conditions. Weinreb amide obtained (96%) was then subjected to
reduction using lithium aluminium hydride (LAH) solution (2.4M) to give an aldehyde in 90%
yield. The next crucial step in our scheme was homologation of the aldehyde fragment and we
decided to employ Knoevenagel condensation for the same. Knoevenagel reaction is a
modification of aldol reaction and involves a nucleophilic attack of active methylene group
containing compound (like diethyl malonate or meldrum’s acid) on an aldehyde followed
subsequent dehydration to give a unsaturated compound. Having aldehyde in hand next step
was Knoevenagel condensation of the aldehyde with diethyl malonate (active methylene
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containing compound) in presence of an appropriate catalyst. Unfortunately, after exploring
different reaction conditions for the Knoevenagel reaction, it did not proceed as anticipated.
Given below (Table 6.1) is the summary of various reaction conditions and different catalysts.
The failure of the reaction was attributed to the polymerization of the aldehyde N-Boc-LLeucinal and may have been caused because of the inability of diethyl malonate to carry out the
nucleophilic attack on the aldehdye. Hence diethyl malonate was replaced with more reactive
ethyl cyanoacetate as an active methyelene component of the Knoevenagel condensation.
Accordingly, N-Boc-L-Leucinal was treated with catalytic amounts of piperidine acetate in
presence of ethyl cyanoacetate in benzene to give the desired  unsaturated ester albeit with
poor yields. After screening for several different catalysts, silica gel was found to be the best
catalyst for the Knoevenagel condensation yielding approximately 70% of the required product.
Table 6.1: Different catalyst and reaction conditions for Knoevenagel reaction
Substrate

Catalyst

Reaction conditions

Results

Diethyl malonate

Piperidne acetate

Reflux in benzene using dean stark

No reaction

Diethyl malonate

p-Toluene sulfonic

Reflux in benzene using dean stark

No reaction

acid
Diethyl malonate

Piperdine

Stirring at RT in ethyl acetate

No reaction

Diethyl malonate

Triphenyl phosphine

Stirring at RT in THF

No reaction

Diethyl malonate

s-Proline

Stirring at RT in ethanol

No reaction

Ethyl cyanoacetate

Piperdine

Stirring at RT in ethyl acetate

≤ 20% yield

Ethyl cyanoacetate

s-Proline

Stirring at RT in ethanol

≤10% yield

Ethyl cyanoacetate

Triphenylphosphine

Stirring at RT in THF

No reaction

Ethyl cyanoacetate

30% Silica

Stirring at RT in Ethyl acetate

55-70% yield
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Once the Knoevenagel condensation condition was set, the next step in the proposed
sequence was formation of the five membered lactam. Reduction of the -unsaturated ester
(cis-trans) using palladium over carbon catalyst and hydrogen under balloon pressure proceeded
smoothly, furnishing a saturated -amino ester derivative. We envisioned one pot deprotection of
Boc group followed by cyclization to form pyrrolidone scaffold from the saturated cyanoester
6.8. Deprotection of the Boc group by either HCl or TFA required longer exposure times and
resulted in incomplete conversion and/or product degradation. Alternatively, deprotection of the
boc group in water using microwaves required only minutes for completion of the reaction. Upon
exposure of ester 6.7 to microwaves at 100°C, two products were isolated; 5-isobutylpyrrolidin2-one 6.9 and 5-isobutyl-2-oxopyrrolidine-3-carbonitrile 6.10. When the reaction was carried out
in the presence of catalytic amounts of mild Lewis acid like lanthanum chloride hepta-hydrate
(Table 6.2), only 5-isobutyl-2-oxopyrrolidine-3-carbonitrile was isolated with moderate yields.
Table 6.2: Reaction conditions for cyclization (All reactions carried out in Microwave at normal
absorption)
Catalyst

Reaction
conditions

Tempe-

Ratio of 10:9

rature in

Overall
Yield

o

C

10

9

%

No catalyst

Water

100

50

50

40

No catalyst

Water:ACN (9:1)

100

50

50

38

No catalyst

ACN

60

NR

NR

-

ScOTf (10 mol %)

Water:ACN (9:1)

65

70

30

36

LaCl3. 7H2O (10 mol %)

Water:ACN (9:1)

65

90

10

53%

YbCl3.6H2O (10 mol %)

Water:ACN (9:1)

65

80

20

41%
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Though we were successful in synthesizing the disubstituted pyrrolidinone derivative, 5isobutyl-2-oxopyrrolidine-3-carbonitrile was racemized (optical rotation and NMR). This was a
minor setback in our progress, but we decided to move forward with racemic material and
address this issue later.
With the pyrrolidinone scaffold in hand, appending -hydroxy ketone side chain was the
final hurdle. According to our proposed synthetic route, either the cyano functional group of
compound 6.10 can be subjected to grignard addition or the compound 6.9 can be subjected to an
aldol type reaction. Grignard added to the cyano functional group was very sluggish and gave
many inseparable products (needed HPLC purification). After several attempts, we were unable
to homologate the cyano functional group. With this failure and earlier racemization problems
we decided to switch to a more robust asymmetric route for synthesis of 6.1.
6.4

Need for asymmetric route of synthesis of berkeleyamide A
We were simultaneously working on an asymmetric synthetic protocol, which would

obviate the need for meticulous chromatographic separations of diastereomeric mixtures. The
overall goal of this project was development of an efficient, enantioselective and scalable route
for total synthesis of 6.1. To achieve this specific objective, we designed an asymmetric route for
the synthesis 6.1, amenable for detailed structure activity relationship (SAR) studies and
determination of absolute configuration of the natural product. Discussed below is our
asymmetric route for synthesis of 6.1 and it diastereomers. We were also able to confirm the
absolute configuration of the natural product to be 10S, 11R, 14S. This was in accordance with
work simultaneously published by Brimble et al.153
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6.5

Prior work
During the course of our work, Brimble and coworkers confirmed the absolute

stereochemistry of 6.1 by co-eluting an authentic sample (obtained from Sterile et.al) and a
synthetic sample in HPLC as 10S, 11R, 14S. Given below is their retrosynthetic scheme (Scheme
3), which relies on the application of a crucial [3+2]-dipolar cycloaddition towards completion of
total synthesis of 6.1. They visualized the formation of isoxazoline 6.13 by reaction between the
dipolar nitrile oxide 6.15 and the dipolarophile chiral alkene 6.14.

Scheme 6.3: Retrosynthetic analysis for berkeleyamide A by Brimble et al
Synthesis of chiral alkene 6.14 was carried out in 10 steps, starting from L-leucine.
unsaturated ester 6.16 was synthesized from L-leucine in four steps in a straightforward
manner. Reduction of the double bond and lactamization were carried out in one pot and the
obtained lactam was protected by Boc group to give compound 6.17. The lactam 6.17 was then
subjected to alkylation with acetaldehyde followed by mesylation mediated dehydration to give
internal alkene 6.18. The internal alkene was then subjected to acid mediated kinetic protonation
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to furnish the key chiral alkene . Next, they turn their attention toward the synthesis of nitirile
oxide. Initial attempts of synthesis of 6.13 from nitroalkane failed due to homodimerization of
nitrile oxide and isomerization of chiral alkene. Hence the authors decided to utilize
dehydrohalogenation of a hydroxyiminoyl halide at lower temperatures for the synthesis of
nitrile oxide.

Scheme 6.4: synthesis of chiral alkene 6.14
Reactions and conditions : a) NaBH4, H2SO4, THF b) K2CO3, BnBr c) Swern oxidation d)
NaH, triethylphosphonoacetate e) Pd(OH)2, MeOH, AcOH f) (Boc)2O, DMAP f) LiHDMS,
THF, Acetaldehyde g) MsCl, TEA then DBU i) KHMDS j) AcOH
Treatment of oxime 6.20 with N-cholorsuccinimide afforded iminoyl chloride 6.21 which on
reaction with chiral alkene in the presence of a base gave mixtures of oxazoline cycloadduct
products (6.13:6.13a:6.13b) in ratio 2.1:1:1 (2.1 is the required diastereomer and is shown in a
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box, scheme ). Berkeleyamide A was obtained from cycloadduct in two steps; molybdenum
chloride mediated reductive cleavage of oxazoline scaffold and deprotection of group.153

Schemes 6.5: Completion of synthesis of Berkeleyamide A by Brimble
Reagents and conditions: a) NCS, py, DCM b) TEA c) Mo(CO)6, MeCN:H2O d) TFA
Brimble and Associates completed the total synthesis of 6.1 in about 14 steps with 3 % overall
yield. Their crucial cycloaddition reaction suffered from poor diastereoselectivity (2.1:1:1) and
lower yield (~35%) of the required diastereomer. Though they confirmed the absolute
stereochemistry of the molecule, their route is not amenable to scale up and SAR studies. This
warrants development of asymmetric route, which is scalable and accessible for a structure
activity relationship study.

216

6.6

Route-2 Total synthesis of Berkeleyamide A

Scheme 6.6 : Route-2 retrosynthetic analysis of 6.1
We deliberated the use of a modular asymmetric synthetic approach for the synthesis of
6.1 and its diastereomers. Our plan was to employ Evans’ aldol154 reaction as a key step for C-C
bond formation between chiral imide 6.23 (shown in red) and aldehyde 6.24 (shown in blue).
The crucial asymmetric aldol reaction will facilitate the introduction of the required chirality at
C10 and C11 (Scheme 6.6). As depicted in the retrosynthetic analysis, crucial N-acyl-4R-benzyl
oxazolidin-2-one 6.23 was envisioned from L-leucine by assuming the natural L-configuration in
the biosynthetic pathway. The other aldol coupling partner, aldehyde 6.24, was envisioned from
-keto ester 6.25, which can be made in two steps starting from meldrums acid. Our
disconnection approach not only offered an enantioselective route to 6.1 but also presented us a
flexible strategy to synthesize all possible diastereomers of 6.1, for SAR studies, by simply
incorporating either L or D–amino acid and adopting Evans’ (or) non Evans’ syn/anti-aldol
synthetic approach.155-157
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6.6.1 Synthesis of Aldehyde 6.24
As shown in Scheme 6.6, the aldehyde 6.24 was synthesized from commercially
available Meldrum’s acid. Meldrum’s acid was converted to -ketoester by typical acylation
using phenyl acetylchloride followed by decarboxylative methanolysis.158 The ketone
functionality was then protected as the 1,3-dioxalane using 1,2-bis(trimethylsilyloxy)ethane and
TMSOTf to give ketal 6.25.159 The corresponding ester was then converted to the required
aldehyde 6.24 by a standard two step protocol; complete reduction of the ester to the alcohol by
LAH followed by Dess-Martin-Periodinane mediated oxidation. We were able to synthesize the
aldehyde 6.24 precursor alcohol 6.26

in multigram quantities with overall good yield.160

However, unstable aldehyde (prone to oxidation to corresponding acid) was always prepared
fresh before the aldol condensation reaction (scheme 6.7).

Scheme 6.7: Synthesis of aldehyde fragment 6.24
Reagents and Conditions: a) Phenylacetyl chloride, Pyridine, CH2Cl2, 0°C-rt b) Methanol, reflux
c) 1,2-bis(trimethylsilyloxy)ethane, TMSOTf, CH2Cl2, rt, 8h, 95%; d) 2.3M LiAlH4 in THF,
THF, 0 °C-rt, 2h, 78%; e) Dess-Martin-Periodinane, CH2Cl2, rt, 1h, 92%.
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6.6.2 Synthesis of Chiral imide
Next, commercially available N-Boc-L–leucine was converted to N-Boc-L–leucinal 6.2
following a standard two-step protocol. Conversion of the N-Boc-L–leucine to mixed anhydride
using isobutrylchlorformate and N-methyl morpholine and then transforming the mixed
anhydride to weinreb amide by treating it with N,O-dimethylhydroxylamine hydrochloride. The
weinreb amide formed was then converted to aldehyde using lithium aluminium hydride. The
resulting aldehyde 6.2 was subjected to Horner-Wadsworth-Emmons (HWE) olefination using
triethylphosphonoacetate and Lithium bis(trimethylsilyl)amide as base.161,
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Due to known

potential of  unsaturated ester 6.27 to undergo racemization, the ester was directly subjected
to hydrogenation without purification. The  unsaturated ester was reduced using 5%
palladium over carbon catalyst under hydrogen pressure of 20 psi to give aminoester 6.28 in 85%
yield Subsequent ester hydrolysis of 6.28 furnished -N-Boc-amino acid 6.29 in good yield.
Large scale synthesis of 6.29 was achieved obviating the need for chromatographic purification.
The free acid obtained was then converted to chiral imide using standard coupling protocol to
give N-Boc chiral imide 6.30 (scheme 6.8).
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Scheme 6.8: Synthesis of -N-Boc-oxazolidinone fragment 6.30
Reagents and Conditions: a) (i) isobutrylchlorformate, N-methyl morpholine, -20°C (ii) N,Odimethylhydroxylamine hydrochloride, CH2Cl2, 0°C; b) 2.3 M LAH in THF, Ether -20°C; c) (i)
Triethylphosphonoacetate, 1M LiHDMS in THF, THF, 0°C, 6.2, -20 to 0°C, 0.5h; d) 5% Pd/C,
H2, 20 psi, EtOAc, 1.5h, 85%; e) LiOH.H2O, THF:MeOH:H2O (9:2:1), rt, 2h, 79%; f) pivaloyl
chloride, TEA, LiCl, 4(R)-benzyl-2-oxazolidinone, THF, -20°C-rt, 6h, 75%.
To carry out aldol reaction in asymmetric fashion, we envisaged use of Evans’ aldol
chemistry for installation of two stereogenic centers C10 and C11. However, our earlier attempts
of an aldol reaction using chiral imide of N-boc -amino acid 6.29 and aldehyde fragment 6.24
failed

to

furnish

any

required

product

under

standard

Evans’

aldol

conditions;

dibutylborontriflate and diisopropylethylamine (DIPEA)/ Triethylamine. Furthermore, our
efforts of using titanium tetrachloride and DIPEA/Triethylamine in aldol reaction were also
futile.155
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We attributed this failure of the aldol reaction due to presence of enolizable Boc (carbamate) 163
functionality in chiral imide .

Scheme 6.9 : Synthesis of aldol adduct 6.31
Reagents and Conditions: a) i., Bu2BOTf, Triethyl amine, DCM, -78 ºC ii. Aldehyde 6.24 or b)
i. TiCl4, DIPEA, DCM, -78 ºC ii. Aldehyde
The enolizable N-Boc carbamate functionality in 6.29 was then converted into the azide
in unique two step protocol; Boc deprotection followed by azido transfer reaction using shelf
stable imidazol-1-sulfonyl azide164 to furnish -azido acid 6.32 in 77% yield. The azide transfer
reagent was prepared according to the procedure reported in the literature. Reevaluation of the
asymmetric aldol reaction using the chiral imide of 6.12 was then pursued. Accordingly, acid
6.18 was coupled with the 4(R)-benzyl-2-oxazolidinone chiral auxillary using a standard
procedure in order to obtain the correct stereochemistry in the aldol reaction based on literature
precedents.154
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Scheme 6.10: Synthesis of Azido chiral imide derivative 6.33
Reagents and conditions: a) 4.0M HCl in 1,4 dioxane, 0°C to rt, 12h; b) imidazol-1-sulfonyl
azideHCl, K2CO3, CuSO4.5H2O, MeOH, rt, 14h, 77%; c) pivaloyl chloride, TEA, LiCl, 4(R)benzyl-2-oxazolidinone, THF, -20°C-rt, 6h, 75%.
6.6.3 Asymmetric aldol reaction
With the required fragments 6.24 and 6.33 in hand, our plan was to use an asymmetric
Evans’ aldol reaction to couple these segments and to set the C10 and C11 stereochemistry.
Evans’ aldol reaction using standard conditions; dibutylboron triflate and TEA did not give any
expected product. However, the asymmetric aldol reaction using a chiral imide derived from acid
6.32, TiCl4 and DIPEA gave the required aldol product, albeit with poor yield. To improve the
yield further, two key features were taken in to consideration. First, the side product arising from
the aldol reaction was a result of polymerization of aldehyde and second, in standard Evans’
aldol protocol, usually more than two equivalents of aldehdye are used. With this in mind,
Crimmin’s modified aldol protocol, which uses only 1.0 equivalent of aldehdye and (-)-sparteine
as base, was selected as the method of choice. As anticipated, the best conversion was achieved
with Crimmin’s modification of Evans’ aldol protocol using ()-sparteine as base. As shown
Scheme 6.11, chiral imide 6.33 was treated with TiCl4/(-)-sparteine to generate Z-enolate A,
which was treated with aldehyde 6.24 to afford the aldol product 6.34. One of the most
significant feature of this reaction was that not only high yields were obtained, but more
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importantly, exclusively single diastereomer was produced.165The (-)-sparteine is thought to
serve as a bidentate ligand though exact role of this chiral base is not yet fully understood. It is
however very clear that it does not play any role in chiral induction.

Scheme 6.11: Crimmin’s Aldol protocol
Reactions and Conditions: a) TiCl4, (-)-sparteine, 6.24, CH2Cl2, 0°C, 3h, 74%
The stereochemical outcome of the aldol reaction can be rationalized using a
Zimmerman-Traxler six membered chair-like transition state (Scheme 11). As anticipated, the
facial selectivity of the aldehyde was directed by the chiral auxiliary of the enolate resulting in
re-face attack to deliver Evans’ syn aldol product. The absolute configuration of obtained alcohol
was deduced using Mosher’s method.
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6.7

Moshers’s method: Stereochemistry Assignment of C-10 hydroxy of aldol adduct
Determination of the absolute configuration of organic compounds is an important aspect

for natural product chemist. Although there are several methods used to determine the absolute
stereochemistry of organic molecules, Mosher’s method, which uses 2-methoxy-2-phenyl-2(trifluoromethyl)acetic acid (MTPA) esters has been extensively used, especially for secondary
alcohols. The prototype protocol begins with the esterification of the secondary alcohol with the
(R) and (S) enantiomers of MTPA followed by acquiring and comparing the NMR data for
resulting diastereomers. One important thing to note is that MTPA is available in two forms:
MTPA acid and MTPA acid chloride (MTPACl). Derivatization of the alcohol with the (R)MTPA acid leads to the corresponding (R)-MTPA ester while the (R)-MTPA chloride leads to
the (S)-MTPA ester. Mosher’s approach depends on the anisotropic effects exerted by the
aromatic ring on the substituents (L1 and L2). Mosher suggested that, in solution, the  C-H
bond, carbonyl group of the ester and trifluoromethyl group of the MTPA ester derivative are in
one plane (Figure 6.2). When the MTPA is placed in appropriate conformation as described by
Mosher, the 1H –NMR shift of L1 of the (R)-MTPA ester show upfield signals relative to that of
(S)-MTPA ester due to the diamagnetic effect of the phenyl ring. These differential shielding
effects are represented as ΔSR , calculated by measuring chemical shift differences between the
certain protons in the (S)-MTPA ester and (R)-MTPA derivative. All the protons shielded in the
(R)-MTPA have a positive ΔSR value, whereas those shielded in the (S)-MTPA derivative will
have a negative ΔSR value. Based these values and postulated position of Mosher ester, the
absolute configuration is determined.166
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Figure 6.2. Configurational correlation model for (R)-MTPA and (S)-MTPA derivatives
The aldol adduct 6.34 was converted to (R) and (S) MTPA esters using (S) and (R) MTPACl
respectively (scheme 11). 1H-NMR spectra were recorded for both the diastereomers and
differences in protons in ppm were calculated. Shown below in the figure 6.3.

Scheme 6.12: Mosher ester synthesis
Reactions and Conditions: a) (R)-MTPACl or (S)-MTPACl, DMAP, TEA, DCM, RT 30mins
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Figure 6.3: Mosher ester analysis confirming the S-configuration of the aldol adduct
The absolute configuration of the resulting alcohol at the C10 position was further confirmed by
Mosher ester analysis to be 10S as in the natural product 1. Furthermore, the syn selectivity of
the aldol product was confirmed by 1H NMR analysis of Mosher ester derivatives (J10-11, 2.95
Hz). With aldol product in hand total synthesis of berkeleyamide A was just couple of steps
away.

Scheme 6.13: Synthesis of 6.1
Reactions and Conditions: a) 5% Pd/C, ammonium formate, MeOH, 1h, 85%; b)
Pd(CH3CN)2Cl2, acetone, H2O, rt, 4h, 77%.
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The transformation of the aldol adduct 6.34 into the natural product 6.1 required azide
reduction, lactamization and ketal deprotection. Gratifyingly, after a few attempts, transfer
hydrogenation using 5% Pd/C directly provided the lactam 6.35 in one pot from 6.34 in 85%
yield Moreover, chiral auxiliary was recovered without loss of its optical purity. Finally, ketal
deprotection of 6.35 was then successfully achieved with Pd(CH3CN)2Cl2 in moist acetone to
yield (6.1) in 77% yield.167 The 1H NMR of our synthetic compound was in accordance with
spectral details reported by isolation chemists further confirming the absolute configuration of
6.1 to be 10S, 11R, 14S. The spectral and other data of 6.1 were in full agreement with the
reported data of the natural product. The 2D-NOESY correlations of 6.1 were also consistent as
reported.
6.8

Crystal structure of berkeleyamide A derivative

Berkeleyamide A is liquid and hence has to be derivatized (in to solid) for X-ray crystal structure
analysis. The absolute configuration of berkeleyamide A was further confirmed by derivatizing
the ketal 6.35 in to di-dinitrobenzoyl derivative 6.38. Single crystal was grown by slow
evaporation of methanolic solution of 6.38 and analyzed using Bruker X-ray crystallography
machine.
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.
Scheme 6.14: Dinitrobenzoyl derivative of Ketal
Reagent and conditions a) 3,5 dinitrobenzoyl chloride, DMAP, TEA and DCM
Given below is the ORTEP diagram of X-ray crystal structure of derivative 6.38,

Figure 6.4: ORTEP representation of crystal structure of derivative of berkeleyamide A
In summary, a concise synthesis of the caspase-1 inhibitor 1 has been achieved in 9 steps
starting from N-Boc-L-leucinal with 18% overall yield. Our synthetic endeavor of 1 is very
efficient, scalable and highly diastereoselective with the flexibility to develop various analogues
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of the natural product. Using this modular approach, synthesis of remaining the diastereomers
was carried out.
6.9

Synthesis of Diastereomers of berkeleyamide-A
In order to accomplish effective analoging, it is imperative to recognize the affinities of

all the diastereomers of 6.1 towards ICE and subsequent identification of the most potent
diastereomer. This not only confirms the role of chirality in affinity of the ligand towards the
enzyme but also helps further to confirm the absolute configuration. Therefore, we proposed to
synthesize all the possible diastereomers of the natural product and evaluate them for biological
activity. As mentioned above, our approach is suitable for the synthesis of all the possible
diastereomers of 6.1. All the diastereomers can easily be obtained by either switching the chiral
auxillary from 4(R)-benzyl-2-oxazolidinone to 4(S)-benzyl-2-oxazolidinone or exchanging the
starting precursor from N-Boc-L-leucine to N-Boc-D-leucine .
Instead of starting the synthesis with N-Boc-D-leucine, we decided to racemize Boc-Lleucine. After few initial attempts, we were able to achieve racemization by using longer reaction
times at the HWE homologation step. After racemization of the N-Boc ester, all the steps in
scheme were followed up until the -azido acid derivative (determined by optical rotation). The
azido acid derivative was then coupled with 4(R)-benzyl-2-oxazolidinone to yield an inseparable
mixture of chiral imides. The racemic mixture of chiral imides was then subjected to aldol
reaction, giving rise to two aldol products, which were then easily separated using column
chromatography. Both aldol products were then converted into berkeleyamide diastereomers by
following lactmization and deketalization protocol.
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Scheme 6.15: Synthesis of berkeleyamide A and its epimer; 6.42
Reactions and Conditions: a) pivaloyl chloride, TEA, LiCl, 4(R)-benzyl-2-oxazolidinone, THF, 20°C-rt, 6h, b) TiCl4, (-)-sparteine, CH2Cl2, 0°C, 3h 60-70% overall yield (1:1 diastereomer
yield) c) 5% Pd/C, ammonium formate, MeOH, 1h, 85%; d) Pd(CH3CN)2Cl2, acetone, H2O, rt,
4h, 77%.
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Similarly, other diastereomers using 4(S)-benzyl-2-oxazolidinone chiral auxillary and aldehyde
were prepared.

Scheme 6.16: Synthesis of Diastereomers of berkeleyamide A
Reactions and Conditions: a) pivaloyl chloride, TEA, LiCl, 4(R)-benzyl-2-oxazolidinone, THF, 20°C-rt, 6h, b) TiCl4, (-)-sparteine, CH2Cl2, 0°C, 3h 60-70% overall yield (1:1 diastereomer
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yield) c) 5% Pd/C, ammonium formate, MeOH, 1h, 85%; d) Pd(CH3CN)2Cl2, acetone, H2O, rt,
4h, 77%.
6.10 Anti-aldol reaction
The synthesis of diastereomers arising from anti aldol reaction was very challenging.
Initial attempts of applying modified Evans’ anti aldol156protocol (scheme) as well as Oppolzer’s
anti aldol157 methodology (scheme) were unsuccessful. In both the cases starting material we
recovered at the end of the reaction.
Anti aldol reactions

Scheme 6.17: Oppolzer’s protocol
Reactions and Conditions: a) Camphorsultam, PivCl, TEA, LiCl THF, 0°C to RT b) DIPEA
TiCl4, 6.24, CH2Cl2, -78 °; c) Triethyl borane in 1 M hexanes, Trifluoro methanesulfonic acid
(freshly distilled) 1 h, in DCM, DIPEA, -5°C 0.5 h and then 6.24 at -78 °C for 3 h. Reaction
quenched by addition of extra DIPEA and phosphate buffer pH 7.0
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Scheme 6.18: Evans anti-aldol protocol
Reactions and Conditions: a) 6.24, MgCl2 10 mol% TEA, TMSCl, NaSbF6 30 mol% in EtOAc,
RT.
After a thorough literature search, we found that Ghosh’s anti aldol reaction has wide
applications and might work in our substrate. Delightfully, use of Ghosh’s anti-aldol protocol168
provided anti aldol product, albeit, with poor diastereoselectivity; 3:1 syn : anti product with a
70% yield. Ghosh’s protocol uses of tosyl amino indanol as chiral auxillary, TiCl4 and Hunigs
base, scheme 8. The anti-aldol formation can be rationalized by a six membered transition state
Zimmerman-Traxler type model. Following are the assumptions for the formation of anti-aldol
product 1) Chiral ester 6.53 on treatment with TiCl4 forms Z enolate and formed enolate attacks
the aldehdye on Si-face, 2) the titanium enolate forms a seven-membered metallocycle with a
chair like conformation involving metal coordination with tosyl-amino functional group; 3) a
second titanium metal is chelated to indanyloxy oxygen as well as to the aldehyde carbonyl
forming another six-membered chair like transition state. Precomplexation of the aldehdye with
TiCl4 is necessary for the success of anti-aldol reaction, suggesting that there is involvement of
two titanium metal in the transition state.
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Though we were able to isolate the required anti-aldol product, the reaction suffered from
poor diastereoselection. One of the reasons for the reduced disastereoselection is the presence of
relatively large R1 group which might not allow for the formation of the chair like seven
membered ring and the Z-enolate formed attacks the aldehdye from re-face giving rise to
majority of syn-aldol product.

Scheme 6.19: Synthesis of diastereomer of berkeleyamide using Ghosh’s Methodology
Reactions and Conditions: a) p-toluenesulfonyl chloride, dimethylamino pyridine, Triethyl
amine, DCM, 2h at RT 80% b) 6.32, DCC, Triethylamine 10h RT c) TiCl4, iPr2NEt, 23 °C then
6.24 and TiCl4 DCM, -78 °; d) 5% Pd/C, ammonium formate, MeOH, over night, 60%; (Note
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Aldol product obtained was hard to characterize hence was immediately converted to respective
ketals) e) Pd(CH3CN)2Cl2, acetone, H2O, rt, 4h, 75%

Figure 6.5: Rationale for anti-aldol product.
Overall, we were able to develop and implement a highly diastereoselective route for the
total synthesis of berkeleyamide A and its diasteremers. All five diastereomers (including
berkeleyamide A), along with azido acid and chiral imides were submitted for biological
evaluation to our collaborators.
With total synthesis of the natural product and its disatereomer accomplished, our next
aim was to design ICE inhibitors based on berkeleyamide scaffold. berkeleyamide was chosen as
a lead as it was reported to inhibit ICE with IC50 of 300 nM. We conducted molecular modeling
docking studies (disclosed in next section) in order to investigate the mode of binding of 6.1 and
it diastereomers in ICE active site, while we were waiting on the biological results.
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6.11 Design of Caspase-1 inhibitors based on berkeleyamide A scaffold
6.11.1 Background
ICE has been the most well studied inflammatory caspases and is key mediator of cytokines IL1 and IL-18 pathways. Due to its high therapeutic potential, pharmaceutical companies have
pursued this target for treatment of immune mediated inflammatory disorders. One of the
pioneering studies in field of ICE research by Thornberry associates was the identification of
tertiary protein structure of ICE and ensuing discovery of the tetrapeptide Ac-YVAD-CHO
possessing potent ICE inhibitory activity.81 Later on, a few x-ray crystal structures of ICE as well
as ICE co-crystallized with various inhibitors have been published.132With comprehensive
knowledge of the active site and precise understanding protein-ligand interactions in ICE,
structure based drug design seem to be a rational approach for design of novel inhibitors of ICE.
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6.11.2 ICE active site –Quick Summary
Pro-ICE is activated to active ICE by assemblage of multiprotein complex called inflammasome.
ICE in its active form is an oligomeric enzyme containing two subunits denoted p20 (residues
120-297) and p10 (residues 317-404 Prerequisites for the substrates of ICE inhibitors are
generally well accepted and are as follows:
1) Presence of L-Aspartic acid residue in the P1 site. The aspartate residue forms crucial salt
bridge interactions with Arg179, Gln283 and Arg341 thus anchoring the ligand in
appropriate orientation exposing the adjoining electrophilic warhead group to the
nucleophilic Cys285.
2) Presence of electrophilic warhead groups (aldehyde, ketone, haloketone, Michael
acceptors, etc) in the P1 site to which Cys285 forms a covalent bond
3) P2-P3 requirements are not very stringent and that’s where most of the variation is seen in
the design of ICE inhibitors. However, it is necessary to retain certain hydrogen bonding
interactions 128
4) Finally P4 requirement is very precise and is the determinant of specificity amongst
different caspases. For caspase-1 large hydrophobic groups are generally tolerated well.
Figure 4 shows P1-P4 regions of Ac-YVAD-CHO inhibitor in the caspase-1 active site.126,
132, 133
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Figure 6.6: Depiction of active site residues of Caspase-1 with bound inhibitor Ac-YVAD-CHO,
as reported in the co-crystal structure. Active site divided according to substrate specificity in P1,
P2, P3 and P4. Catalytic diad; Cys285 and His237 are circled for clarity and are represented in
magenta. All crucial hydrogen bonds are depicted in green.
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6.11.3 Rational design of Caspase-1 inhibitor
With the pharmacophoric features essential for ICE inhibition well known and several crystal
structures of ICE co-crystallized with ICE inhibitors available, we utilized a structure-based
design approach for the design of ICE inhibitors based on berkeleyamide-A scaffold. Docking is
one of the most important, versatile and widely used computational tools in structure-based drug
design and development process. Molecular docking involves orientation of a ligand into the
active site of the receptor, which in turn helps to elucidate crucial ligand-receptor interactions.
Docking studies were performed in order to investigate the key protein-ligand interactions
between ICE and 6.1. Additionally, all the remaining seven diastereomers of 6.1 were also
subjected to docking to examine effect of stereochemistry on the nature of protein-ligand
interaction.134
6.11.4 Molecular docking protocol
Docking studies were performed using Glide (Schrödinger) with extra-precision (XP) settings to
predict the binding mode of 6.1 and its diastereomers in the active site of ICE. ICE enzyme (pdb
code: 2HBQ)169 along with co-crystallized inhibitor Z-VAD-FMK were retrieved from the
protein data bank. Obtained enzyme was subjected to protein preparation using protein
preparation wizard of Maestro. As a part of protein handling, all the water molecules were
removed, hydrogen atoms were added and finally the enzyme was minimized using an
OPLS2005 force-field. The second step of molecular docking is defining the active site by grid
generation around the known bound ligand. The binding site was defined as the residues located
within 12 Ǻ distance of the bound ligand. A relatively larger active site was selected to check if
there were any additional binding pockets around the active site. Once the grid was generated,
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the next step was preparing the ligands that were to be docked into the active site. All the eight
diastereomers of 6.1 were sketched using Maestro, visually inspected and minimized utilizing an
OPLS2005 force-field from the macromodule of Schrodinger. Default settings were used for
performing the docking of 6.1 and its diastereomers into the active site of 2HBQ. The final
ligand poses were selected based on the Glide empirical docking scores (GlideScore) and Emodel
score.

6.11.5 Pose Validation
Pose validation study is one of the most important evaluation parameters in molecular docking
studies as it validates the reproducibility of the binding pose of the native ligand. Pose validation
was carried out in order to evaluate the performance of Glide. The native ligand Z-VAD-FMK
was docked in 2HBQ active site using Glide. Glide was able to reproduce the binding pose of ZVAD-FMK in the active site very similar to that in the crystal structure with excellent root mean
squared deviation (RMSD) of 0.4. Ligplot depiction of Z-VAD-FMK in the ICE active site is
shown below in figure 6.7. As projected, the aspartate moiety of the ligand in P1 shows salt
bridge interactions with Arg179 and Arg341. The nucleophilic residue Cys285 is covalently
bound to the warhead group and oxyanion thus formed is stabilized by Gln283 and His237. The
P4 portion of the molecule is surrounded by hydrophobic amino acid residues, namely His, Trp
Val and Pro. Moreover, all the crucial hydrogen bonding interactions of residues Arg341 and
Ser339 with the ligand are retained.
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Figure 6.7: Ligplot depiction of Z-VAD-FMK in the Caspase-1 active site in the co-crystal
structure 2HBQ.
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Figure 6.8: Pose validation studies. Ligand in green is the native ligand which was extracted and
docked in the active site. Ligand in pink is the native ligand which is covalently attached to
cysteine residue in the active site.

Once pose validation was completed, 6.1 was docked in similar fashion using Glide.
Docking studies revealed that the 6.1 only partially occupied the ICE active site. The docking
pose of 6.1 superimposed with native ligand Z-VAD-FMK in ICE active site is depicted in figure
6.8 given below. It can be clearly seen that the pyrrolidone scaffold of the molecule is occupying
S2 site with the carbonyl of the lactam ring pointing towards the S3 pocket. The S1 pocket is not
occupied, while S3 and S4 pockets of the enzyme are occupied by the -hydroxy ketone moiety
and the aromatic phenyl ring respectively. We then generated 10 docking poses of the naturally
occurring diastereomer of 6.1. The natural product, 8 out of ten times was docked in a similar
fashion. Based on the insights from these docking studies, structural modifications will be
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implemented in the design of inhibitors of ICE. Similarly seven diastereomers of the natural
product were docked in the active site. It is important to note that six of them were docked
differently from the natural product. Only the SSS diastereomer was docked in a similar fashion
as the natural product, insinuating that the natural product and it epimer SSS might be the most
active compounds. Overlay of docked 1 and the remaining diastereomers is shown below figure
6.9 (for clarity the active site residues are not shown).

Figure 6.9: Overlay of 6.1 (docked in ICE active site) shown in magenta with Z-VAD-FMK
shown in green in the ICE active site
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Figure 6.10: The overlay of 6.1 (magenta) and Z-VAD-FMK (green) in the active site of ICE.
The active site is shown as van der Waals surface.

Figure 6.11: Overlay of all eight diastereomers docked in to the ICE active site. 6.1 is shown in
green and SSS diastereomer is shown in magenta
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6.12 Design of ICE inhibitors
We assumed that the natural product might be the most active diastereomer and applied
rational design approach to 6.1 in the quest for novel ICE inhibitors. Based on our docking
results and literature precedents for ICE inhibitors, we were intrigued by the fact that in spite of
the natural product lacking the crucial P1 portion, berkeleyamide still showed potent caspsae-1
inhibitory activity. We postulated that 6.1 exhibited ICE inhibitory activity by binding tightly to
S2-S3 portion in the active site and occlude the entry of its natural substrate. Another hypothesis
is that 6.1 may bind to allosteric site of the enzyme and modulate the conformation of the
enzyme and its active site, making it inaccessible to its substrates. Figure 6.10 shows the overlay
of the native inhibitor Z-VAD-FMK with Berkeleymide A in the enzyme active site. From
overlay it is pretty evident that 6.1 occupies mostly S2, S3 and S4 pocket while the crucial S1
pocket is only partially occupied.
This presents us with an opportunity to install an aspartic acid motif along with an electrophilic
warhead via an appropriate linker. The aspartic acid residue will strongly anchor the molecule
within the active site and help orient the electrophilic warhead group in close proximity to
nucleophilic cysteine residue. To carry out this modification, we can take advantage of the free
amide nitrogen in 6.1 molecule, type A derivatives. We also decided to substitute the phenyl end
of the molecule with aspartic acid in case the ketone moiety functioned as the electrophilic war
head group type B derivatives. Other variations incorporated are deoxo-derivatives and ketone
moietly protected as ketal to explore if these functional groups are essential of ICE activity. The
designed derivatives of 6.1 are enlisted in the table 6.3 given below.
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Table 6.3: Structures of proposed novel ICE inhibitors based on 1 scaffold
SJK 1

SJK 2

SJK 3

SJK 4

SJK 5

SJK 6

SJK 7

SJK 8

SJK 9

SJK 10
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Docking studies of the Designed molecules
Docking was carried out in a similar fashion as explained above. The enzyme was prepared by
removing the water molecules and the native ligand. Hydrogen atoms were added and protein
preparation wizard’s protocol was followed for preparation of the protein. All the designed
molecules were sketched using ligand builder module from Maestro. All the molecules were
minimized and visually checked for correctness. Grid was generated around the active site (12Å)
and all the molecules were docked in active site using docking protocol shown in figure 6.12.

Figure 6.12: General protocol for docking
SJK-1 SJK-2, SJK-6 and SJK-7 had very good docking scores. It is important to note that SJK-1,
SJK-2 and SJK-5 are prodrugs and their active form (free acid and aldehyde) was used for
docking studies. All the above mentioned molecules occupied the S1 site of the enzyme and
more importantly showed salt bridge interactions with Arg341 and Arg179. All these molecules
also retained all the crucial hydrogen bonding interactions between Arg341 and Ser 339 require
for ICE inhibitory activity. Given below in figure 6.13 is the overlay of the native ligand Z247

VAD-FMK shown in green and SJK-1 shown in magenta. It is evident from the figure 6.13 that
both ligands are almost superimposed over each other in the active site. Moreover, the SJK-1
designed ligand retained all the crucial hydrogen bonding interactions: salt bridge interaction
between aspartic acid residue and Arg341 and Arg179 as well as hydrogen bond interactions
between residues Arg341 and Ser 339. It is also important to note that Cys285 is in proximity to
the electrophilic aldehyde residue and the electrophilic war head group is oriented in such a way
that is susceptible to attack by thiol functional group of cysteine residue.

Figure 6.13: Overlay of SJK-2 (Magenta) and native ligand in Green in ICE active site shown as
van der waals surface
Almost all the designed inhibitors occupied the active site of ICE except for the type B
derivatives suggesting that type A derivative design is more appropriate. Shown below is the
ligand interaction diagram (generated by using a script from Maestro) of the ICE active site and
the ligand Z-VAD-FMK and ICE active site and SJK-1. Almost all the interactions, H-bond,
stacking interactions and even the solvent exposed areas of the both the ligands, are very
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similar.

Figure 6.14: Ligand Interaction Diagram for native ligand Z-VAD-FMK in ICE active site.
Amino acid residue colors denote; Green= hydrophobic, Cyan = Polar; Red = negative charges,
purple= positive charges. H-bond; solid lines for backbone interaction and dashed lines for side
chain. interaction is denoted by Green line. Solvent accessible surface area represented by
yellow atom background. Text; small font is further while large font is close
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Figure 6.15: Ligand Interaction Diagram for SJK-1 in ICE active site.
Amino acid residue colors denote; Green= hydrophobic, Cyan = Polar; Red = negative charges,
purple= positive charges. H-bond; solid lines for backbone interaction and dashed lines for side
chain. interaction is denoted by Green line. Solvent accessible surface area represented by
yellow atom background. Text; small font is further while large font is close
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In summary, our docking studies indicated that berkeleyamide A and its diastereomers only
partially occupied the ICE active site. Moreover, the crucial S1 subsite containing the catalytic
diad and the aspartic acid clamp (Arg179 and Arg341) were not occupied. According to our
docking results (glide score and visual inspection), it seems that 1 and its diastereomers might
have low affinity for the ICE active site. However, potent ICE inhibitory activity of
berkeleyamide reported by Stierle and coworkers made this case very interesting.
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6.13 Biological evaluation:
All the diastereomers, including berkeleyamide and some intermediates, were submitted for a
caspase-1 inhibition assay. The assay was performed by our collaborators in CORE C facility at
The University of Mississippi, under the guidance of Dr. Susan Manly. This is a fluorimetric
assay performed using a commercially available 96 well-plate kit; BML-AK701’ from Enzolife
sciences. The kit includes pure enzyme, buffers and a known inhibitor of caspase-1 as a
reference standard: YVAD-CHO.
Principle of the Assay
The ICE Drug Discovery Kit contains a fluorogenic substrate (YVAD-AMC). Cleavage of the 7amino-4-methylcoumarin (AMC) dye from the C-terminus of the peptide substrate by ICE shows
increased fluorescence intensity, which is measured at 460 nm. Stronger the enzyme inhibition
lesser would be the fluorescence intensity as compared to the blank.
Given below in table are the results obtained from this assay.
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Table 6.4: Biological evaluation of berkeleyamide A and their derivatives against Caspase-1
Compound

Inhibition

No.

pmol/min

6.48

5.18

6.47

5.21

6.1

5.23

6.45

5.59

6.34

5.54

6.46

5.36

6.35

5.35

6.42

5.19

6.29

5.52

6.53

5.62

Blank

6.68

Ac-YVAD-CHO

0.09

(control)

Unfortunately, none of the compounds submitted for the assay showed any activity against
caspase-1. These results, though very surprising, are in accordance with our docking studies,
which correctly predicted very weak affinity of these ligands with the ICE active. To eliminate
any error in the assay, these assays were performed in triplicate. This also suggests neither 6.1
nor its diastereomer modulate ICE allosterically.
We also submitted our samples for anti-malarial, anti-leishmanial and anti-fungal activity.
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Furthermore, we also evaluated their cytotoxic potential. None of the submitted compounds
showed any potential anti-malarial, anti-leishmanial or anti-fungal activity (Table 6.5, 6.6 and
6.7 a&b) nor they were cytotoxic.
Table:6.5 Biological evaluation of berkeleyamide A and its derivatives : Anti-leishmanial Assay
Compound No.

Plate type

IC50
(µg/ml)

IC90
(µg/ml)

6.1
6.48
6.47
6.38

LEM Sec
LEM Sec
LEM Sec
LEM Sec
LEM Sec
LEM Sec

NA
18
NA
NA
NA
NA

NA
>40
NA
NA
NA
NA

6.45a(ketal of 6.48)
6.46a(ketal of 6.47)

Table 6.6: Biological evaluation of berkeleyamide A and its derivatives: Anti-Malarial Assay
Compound No.
6.1
6.48
6.47
6.38

6.45a(ketal of 6.48)
6.46a(ketal of 6.47)

IC50
ng/ml

S. I.

NA
NA
NA
NA
NA
NA

-

IC50
ng/ml
NA
NA
NA
NA
NA
NA
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S. I.
-

Table 6.7a : Biological evaluation of berkeleyamide A and its derivatives : Anti-fungal Assay
Compound No.

6.1
6.48
6.47
6.38

6.45a(ketal of 6.48)
6.46a(ketal of 6.47)

Test Concen
-trations
(µg/mL)
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8

C.
C.
C.
A.
C.
albicans glabrata krusei fumigatus neofor
IC50
IC50
IC50
IC50
mans
IC50
-

Table 6.7b : Biological evaluation of berkeleyamide A and its derivatives : Anti-fungal Assay

Compound No.

6.1
6.48
6.47
6.38

6.45a(ketal of 6.48)
6.46a(ketal of 6.47)

Test
Concentr
ations
(µg/mL)
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8
20, 4.0, 0.8

S.
aureu
s IC50

MR
S
IC50

E.
coli
IC50

-

-

-
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P.
M.
aeruginos intracellular
a IC50
e IC50
-

-

Table 6.8: Standards used for Antifungal assay
Microorganism

Drug Control

IC50 (µg/ml)*

Candida albicans ATCC 90028 (Ca)
Candida glabrata ATCC 90030 (Cg)
Candida krusei ATCC 6258 (Ck)
Aspergillus fumigatus ATCC 90906
(Afu)
Cryptococcus neoformans ATCC
90113 (Cn)
Staphylococcus aureus ATCC 29213
(Sa)
Methicillin-resistant
S.
aureus
ATCC 33591 (MRS)
Escherichia coli ATCC 35218 (Ec)
Pseudomonas aeruginosa ATCC
27853 (Pa)
Mycobacterium intracellulare ATCC
23068 (Mi)

Amphotericin B
Amphotericin B
Amphotericin B
Amphotericin B

0.23
0.23
0.68
0.74

MIC
(µg/ml)**
0.63
0.63
1.25
1.25

Amphotericin B

0.19

0.63

Ciprofloxacin

0.10

0.50

Ciprofloxacin

0.09

0.25

Ciprofloxacin
Ciprofloxacin

0.004
0.078

0.008
1.000

Ciprofloxacin

0.56

1.00

*The concentration (mg/ml) that affords 50% inhibition of growth
**MIC (Minimum Inhibitory Concentration) is the lowest test concentration (mg/ml) that allows
no detectable growth
Table 6.9: Biological evaluation of berkeleyamide A and its derivatives for Cytotoxicity Assay
Compound No.
6.1
6.48
6.47
6.38
6.45a(ketal of 6.48)
6.46a(ketal of 6.47)

TC50 ng/ml
NC
NC
NC
NC
NC
NC
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6.14

Conclusion
In conclusion, we were able to develop and implement a highly diastereoselective route

for total synthesis of berkeleyamide A. Asymmetric synthesis of the natural product was
completed in a modular fashion in 9 steps, starting from N-Boc-Leucinal with an overall 18%
yield. The salient feature of this route is that it is easily scalable and amenbale to structural
modifications for a structure activity relationship study. Furthermore, this route was successfully
applied to the synthesis of four diastereomers (three syn and one anti with respect to stereogenic
centers 10C and 11C).
After completion of the total synthesis of berkeleyamide A, we carried out molecular
docking studies using GLIDE module of Schrodinger molecular modeling suite. Our docking
studies indicated that berkeleyamide A and its diastereomers only partially occupied the ICE
active site. Moreover, the crucial S1 subsite containing the catalytic diad and aspartic acid clamp
(Arg179 and Arg341) was not engaged in salt bridge interactions with argentine residues.
According to our docking results (glide score and visual inspection), we postulated that 6.1 and
its diastereomers might have low affinity for ICE active site. However, potent ICE inhibitory
activity of berkeleyamide reported by Stierle and coworkers made this case very interesting. We
postulated that the natural product can either bind to an allosteric site or a distinct site in caspase1 and exert its inhibitory effect.
Based on the literature precedent and our docking results, we designed novel ICE
inhibitors based on a berkeleyamide scaffold and docked them in ICE active site. All the
designed derivative showed better docking results than the natural product. Newly designed
derivative containing the cysteine trap, occupied the S1 site in a similar fashion to reported ICE
inhibitors. Moreover, the designed compounds also retained all crucial hydrogen bonding
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interactions required for potent ICE inhibitory activity. Our docking results of the deigned
molecules indicate that they have good potential to be potent ICE inhibitors.
However, a major setback to our program was the biological results. We tested
berkeleyamide A and its derivatives for ICE inhibitory activity and none of the compounds
showed any significant activity. Moreover, we also tested these compounds for anti-fungal, antimalarial and anti-leishmanial activity. Unfortunately, none of the tested derivatives, including the
natural product, exhibited any significant activity.
Our biological evaluation of berkeleyamide A and its derivatives reveal that these
compounds lacked caspase-1 inhibitory activity. One of the possible reason for the discrepancy
in the activity reported by Steirle et al may be due to the presence of some impurity in the
authentic sample, which possesses a high affinity for caspase-1. This is very unlikely, however,
and an error in assaying the compounds cannot be completely ruled out.
The natural product and its derivatives did not exhibit any caspase-1 inhibitory activity,
which was correctly predicted by our docking studies. This result validates our docking protocol
to a certain extent. As our docking study indicated that newly designed molecules may show
promising ICE inhibition, we plan on synthesizing and testing a short library our designed
molecules.
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CHAPTER 7
EXPERIMENTAL- BEREKELEYAMIDE A

General Experimental
1

H and

13

C NMR spectra were measured in CDCl3 or C6D6 on Bruker 400 MHz (100 MHz) or

500 MHz (125 MHz) machines. Chemical shifts were reported in ppm downfield from
tetramethylsilane (δ) as the internal standard and coupling constants are in hertz (Hz).
Assignment of proton resonances were confirmed by correlated spectroscopy. IR spectra were
recorded using a universal attenuated total reflection sampling accessory with a Zinc Selenide
crystal on a Perkin-Elmer Spectrum 100 FT-IR spectrometer. The high-resolution mass spectra
(HRMS) were recorded on a Micromass Q-Tof Micro mass spectrometer with lock spray source.
Optical rotations were measured on an Autopol V automatic polarimeter, from Rudolph
Research Analytical in a 1 dm or a 5 dm cell. Melting points were measured on an OptiMelt ®
V.1.061 (Stanford Research systems) instrument and were uncorrected. The reaction progress
was monitored on precoated silica gel G or GP Analtech TLC plates. Spots were visualized
under 254 nm UV light and/or by dipping the TLC plate into a solution of 2 ml anisaldehyde and
10 ml glacial acetic acid and 5 ml H2SO4 in 340 ml MeOH followed by heating with a hot gun.
Column chromatography was performed with Dynamic Adsorbents Inc. silica gel 60 (230-400
mesh). All the solvents (hexane, ethyl acetate, CH2Cl2, Et2O) were distilled prior to use. All
reactions were performed under an atmosphere of argon using oven-dried glassware and standard
syringe/septa techniques. The solvents THF and Et2O were distilled from sodium-benzophenone,
toluene, cyclohexane, benzene from sodium. CH2Cl2 was dried over P2O5. DMF, NEt3, iPr2NH
and iPr2NEt and were distilled from CaH2.
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(R)-tert-butyl (1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (Weinreb
Amide)
To a stirred solution of Boc-leucine (10.0 g, 43.2 mmol) in 150 ml anhydrous DCM was added
N-Methylmorpholine (14.26 ml, 130 mmol) at -10°C. The reaction mixture was stirred for
30mins. After 30 mins stirring at -10°C, N,O dimethylhydroxylamine (5.06 g, 51.9 mmol), and
EDC (9.95 g, 51.9 mmol) was added successively to give a yellow solution. The reaction mixture
brought to RT over 1 hour and was stirred at this temperature for 2-3hrs. The reaction was
monitored by TLC. After completion of the reaction 50.0 ml of water was added to quench the
reaction. The organic layer was washed with 0.5N HCl, saturated NaHCO3 followed by brine.
The organic layer was dried over magnesium sulfate and then concentrated vacuum to furnish
weinreb amide, which was carried forward into next reaction without purification. (10.9g, 92%)
Colorless liquid;

max

2958(s), 1715(s), []23 -23 (c =1.0 in methanol)

1

H NMR (500 MHz,

CDCl3) δ 9.58 (s, 1H), 5.03 (s, 1H), 4.23 (s, 1H), 1.81 – 1.72 (m, 1H), 1.65 (s, 2H), 1.50 – 1.38
(m, 11H), 0.96 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 200.40, 155.57, 79.93, 77.25,
77.00, 76.75, 68.47, 58.33, 38.01, 28.20, 24.58, 23.01, 21.85.

N-tert-Butoxycarbonyl-L-leucinal (6.3)
To a stirred solution of weinreb amide (780 mg, 2.84 mmol) in a 25 mL round-bottomed flask
in THF (10.0 ml) at to -78°C was charged LAH 1.0 M (2.84 ml, 2.84 mmol), very slowly.
Resulting solution was stirred for 2.0 hrs at same temperature. After completion of reaction
(monitored by TLC), a saturated solution of NaCl was added slowly followed by Rochelles salt.
Reaction mixture was stirred vigourously for 30mins and the residue formed was filtered through
celite. THF was concentrated to give oily residue which was further dissolve in ethyl acetate.
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The organic layer was washed with brine, dried over magnesium sulfate and concentrated under
vacuum to give crude 3. The crude leucinal was purified by flash column chromatography using
Hexanes:EtOAc (8:2). (520.0 mg, 85%). Colorless liquid;

max 2958(s),

1735(s), 1700(b)

[]23 -45 (c =1.0 in methanol) 1H NMR (500 MHz, CDCl3) δ 9.58 (s, 1H), 5.03 (s, 1H), 4.23 (s,
1H), 1.81 – 1.72 (m, 1H), 1.65 (s, 2H), 1.50 – 1.38 (m, 11H), 0.96 (d, J = 6.5 Hz, 6H). 13C NMR
(126 MHz, CDCl3) δ 200.40, 155.57, 79.93, 77.25, 77.00, 76.75, 68.47, 58.33, 38.01, 28.20,
24.58, 23.01, 21.85.

General procedure for Knoevenagel reaction
In a 5 mL round-bottomed flask was charged 3 (50.0 mg, 0.232 mmol), Diethyl malonate (0.053
ml, 0.348 mmol), acetic acid (2.66 µl, 0.046 mmol) and Piperidine (4.60 µl, 0.046 mmol in
Toluene (1.0 ml). The reaction mixture was stirred at RT for 1hr and then water was removed
azeotropically using dean stark. Reaction was monitored by TLC. No new spot was observed
after 5 hrs. Reaction was discontinued after 24 hrs due to considerable degradation.

(S,E/Z)-ethyl 4-((tert-butoxycarbonyl)amino)-2-cyano-6-methylhept-2-enoate (6.7)
In a 5.0 mL round-bottomed flask ethyl 2-cyanoacetate (228 mg, 1.061 mmol) was charged
followed by N-Boc-Leucinal (100mg, 0.884 mmol) in Chloroform. To the resulting solution
silica gel (106.0 mg, 1.768 mmol) was added as a catalyst. Reaction was stopped after no starting
material was remaining; confirmed by TLC. After completion of reaction chloroform was
evaporated to give silica impregnated compound which was further purified using flash column
chromatography. (EtOAc:Hexanes 7.25:2.75) (161.0 mg, 58%) Yellow liquid;

max

2878(s),

1715(s), 2200 (s); 1H NMR (500 MHz, CDCl3) δ 7.47 (s, 1H), 4.60 (s, 1H), 4.34 (dd, J = 14.1,
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7.0 Hz, 2H), 1.71 (dt, J = 19.8, 6.7 Hz, 1H), 1.58 (dd, J = 19.2, 11.2 Hz, 2H), 1.52 – 1.41 (m,
10H), 1.38 (t, J = 7.1 Hz, 3H), 1.12 – 0.92 (m, 7H).

13

C NMR(126 MHz, CDCl3) δ 163.19,

161.12, 154.85, 113.05, 108.78, 80.22, 77.25, 77.00, 76.75, 62.64, 50.12, 42.62, 28.31, 24.71,
22.88, 21.90, 14.04. LC MS ESI(M+1) 311.23 (Note: Spectra provided only for one of the
geometrical isomer. Geometrical isomers Cis and Trans not separated and carried forward to
next reaction without purification)
ethyl 4-((tert-butoxycarbonyl)amino)-2-cyano-6-methylheptanoate (6.8)
To a stirred solution of 7 (50.0mg, 0.161 mmol) in Ethyl acetate (2.0 ml) was carefully added
Palladium 10% on carbon (17.14 mg, 0.161 mmol). A balloon of hydrogen gas was then used
carry out the reduction under ballon pressure. The reaction was stirred 5-8 hrs and then filtered
through celite. The ethyl acetate was recovered under vacuum and crude obtained was purified
by column chromatography (EtOAC: Hexane 7:3) (39.0mg, 77%) Yellow liquid;

max

2878(s),

1745(s), 2210 (s) 1H NMR (500 MHz, CDCl3) δ 4.27 (d, J = 9.0 Hz, 1H), 4.12 (dd, J = 13.1, 6.8
Hz, 2H), 3.70 – 3.51 (m, 1H), 2.36 (t, J = 7.6 Hz, 2H), 1.90 – 1.80 (m, 1H), 1.71 – 1.55 (m, 2H),
1.42 (s, 8H), 1.25 (t, J = 7.1 Hz, 3H), 0.90 (d, J = 6.5 Hz, 6H).

13

C NMR (126 MHz, CDCl3) δ

173.74, 155.61, 78.94, 77.31, 77.26, 77.06, 76.80, 60.38, 48.47, 45.15, 31.00, 28.39, 24.89,
22.99, 22.28, 14.21. LC MS ESI (M+Na) 335.30

5-isobutyl-2-oxopyrrolidine-3-carbonitrile and 5-isobutylpyrrolidin-2-one (6.10 and 6.11)
To a suspension of 8 (100.0mg, 0.320 mmol) in water:ACN (9:1) mixture was added Lanthanum
chloride heptahydrate (0.320 mmol). The reaction mixture was place in a microwave tube and
the solution was irradiated with microwave at normal absorption at 80°C. After 10 mins reaction
was complete (starting material exhausted). Reaction mixture was extracted with EtOAC 5.0 ml
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and organic layer was washed with brine. The organic layed was dried over magnesium sulfate
and concentrated under vacuum. TLC showed presence of two products. Both these products
were purified using column chromatography.

5-isobutyl-2-oxopyrrolidine-3-carbonitrile (6.11)
Thick oil solidifies on standing liquid film ;

max

2242, 1689, 1H NMR (400 MHz, CDCl3) δ 6.76

(s, 1H), 3.80 – 3.69 (m, 1H), 3.57 – 3.46 (m, 1H), 2.77 – 2.65 (m, 1H), 2.11 – 1.95 (m, 1H), 1.77
– 1.63 (m, 2H), 1.63 – 1.52 (m, 1H), 1.43 (dd, J = 13.7, 6.3 Hz, 1H), 0.96 (d, J = 6.5 Hz, 6H) 13C
NMR (126 MHz, CDCl3) δ 168.80, 116.96, 77.30, 77.04, 76.79, 51.39, 45.26, 33.51, 33.25,
25.27, 22.75, 22.34. LS-MS ESI- [M-H] 165.12
5-isobutylpyrrolidin-2-one (6.10)

Thick oil solidifies on standing liquid film ;

max

2956, 1684.70 1H NMR (400 MHz, CDCl3) δ

3.69 – 3.55 (m, 1H), 2.23 (ddd, J = 7.9, 5.9, 3.8 Hz, 1H), 2.18 – 2.08 (m, 1H), 1.61 (d, J = 6.4
Hz, 2H), 1.44 – 1.31 (m, 2H), 1.25 – 1.16 (m, 1H), 0.83 (dd, J = 6.6, 3.2 Hz, 6H). 13C NMR (101
MHz, CDCl3) δ 178.75, 77.47, 77.15, 76.84, 52.84, 45.90, 30.39, 28.30, 27.58, 25.02, 22.84,
22.32. LS-MS ESI- [M+H] 142.51

Methyl (2-benzyl-1,3-dioxolan-2-yl)acetate (6.25)
To a solution of 6.25a beta-ketoester (8.0 g, 41.6 mmol) and 1,2-bis-[trimethylsilyl(oxy)]ethane
(10.74 g, 52.0 mmol) in anhydrous dichloromethane (100 ml) was added TMSOTf (1.5 ml, 8.32
mmol) drop wise slowly at 0 °C. The mixture was allowed to warm to room temperature. After
8h, the reaction was quenched with TEA (1.2 ml, 8.54 mmol) and washed with 5% aqueous
NaHCO3 solution, water, brine, and dried over magnesium sulfate. The residue obtained after
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concentration was used for next reaction without any further purification (9.3 g, 95%). Colorless
liquid; max (CHCl3)/cm-1 3031, 2953, 1736, 1436, 1205, 1095, 1032; 1H NMR (400 MHz,
CDCl3) δ 7.36 – 7.22 (m, 5H), 3.99 – 3.89 (m, 2H), 3.80 – 3.69 (m, 2H), 3.73 (s, 3H), 3.13 (s,
2H), 2.67 (s, 2H);

13

C NMR (126 MHz, CDCl3) δ 169.99, 136.06, 130.77, 128.01, 126.60,

109.00, 65.28, 51.76, 43.77, 42.48; HRMS (ESI+) Calc. for C13H16O4Na 259.0946; Found
259.0956.

2-(2-Benzyl-1,3-dioxolan-2-yl)ethanol (6.26)
To a solution of methyl (2-benzyl-1,3-dioxolan-2-yl)acetate (9.3 g, 39.4 mmol) in anhydrous
THF (200 ml) was added 2.3M LiAlH4 solution (18 ml, 41.6 mmol) drop wise at 0 °C. The
mixture was allowed to room temperature. After 2h, excess of LiAlH4 was quenched with EtOAc
followed by saturated brine solution at 0 °C. The slurry obtained was passed through pad of
celite and concentrated. The crude obtained was dissolved in ethyl acetate (100 ml) and washed
with 1N HCl, water, brine, dried over magnesium sulfate and concentrated. The residue was
purified on silica gel column chromatography (EtOAc:hexanes, 1:3) to afford pure alcohol
product (6.4 g, 78%). Colorless liquid; max (CHCl3)/cm-1 3432, 2956, 2886, 1121, 1030, 699;
1

H NMR (400 MHz, CDCl3) δ 7.31 – 7.19 (m, 5H), 3.93 – 3.83 (m, 2H), 3.78 – 3.66 (m, 4H),

3.19 (s, 1H), 2.92 (s, 2H), 1.90 (t, J = 5.9 Hz, 2H);

13

C NMR (101 MHz, CDCl3) δ 136.29,

130.55, 128.01, 126.50, 111.42, 65.03, 58.36, 43.76, 39.21; HRMS (ESI+) Calc. for C12H16O3Na
231.0997; Found 231.0991.

(2-Benzyl-1,3-dioxolan-2-yl)acetaldehyde (6.24): To a stirred solution of 2-(2-benzyl-1,3dioxolan-2-yl)ethanol (1.0 g, 4.8 mmol) in dichloromethane (30 ml) was added Dess Martin
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Periodinane (3.0 g, 7.2 mmol) portion wise at room temperature. After 1h, the mixture was
concentrated, re-dissolved in ether and passed through celite. The residue obtained after
concentration was purified by column chromatography using ether:hexanes (1:3) to afford 4
(0.91 g, 92%) as a colorless liquid; max (neat)/cm-1 3030, 2890, 1720, 1127, 1082, 1044; 1H
NMR (400 MHz, CDCl3) δ 9.67 (t, J = 2.8 Hz, 1H), 7.37 – 7.15 (m, 5H), 3.95 – 3.86 (m, 2H),
3.84 – 3.75 (m, 2H), 2.96 (s, 2H), 2.63 (d, J = 2.8 Hz, 2H);

13

C NMR (101 MHz, CDCl3) δ

199.86, 135.57, 130.59, 128.13, 126.79, 109.20, 65.20, 50.78, 44.55.

Ethyl (2E,4S)-4-[(tert-butoxycarbonyl)amino]-6-methyl-hept-2-enoate (6.27): To a solution
of triethyl phosphonoacetate (16.4 g, 73.0 mmol) in THF (200 ml) was added solution of 1.0 M
NaHMDS (65.7 ml, 65.7 mmol) slowly at 0 °C. The resulting orange solution cooled to -20 °C
and a solution of freshly prepared N-Boc-L-leucinal (15.72g, 73.0 mmol) in THF (50 ml) was
added dropwise at the same temperature. After addition, the mixture was warmed to 0 °C and
stirred under argon for additional 30 min and then quenched with saturated aqueous ammonium
chloride solution at 0 °C. The organic layer was separated, concentrated, and the residue was
dissolved in EtOAc (200 ml), washed with water and brine, dried over MgSO4 and filtered. The
filtrate was partially concentrated and subjected to reduction without further purification. As a
pale yellow oil; [20D= -23 (c 1.50, MeOH); max (CHCl3)/cm-1 3354, 2959, 1701, 1691, 1657,
1519, 1367, 1282, 1167, 1045; 1H NMR (500 MHz, CDCl3) δ 6.81 (dd, J = 15.4, 4.9 Hz, 1H),
5.90 (d, J = 15.6 Hz, 1H), 4.50 (d, J = 7.9 Hz, 1H), 4.32 (bs, 1H), 4.17 (q, J = 7.0 Hz, 2H), 1.67
(dt, J = 13.1, 6.5 Hz, 1H), 1.42 (s, 9H), 1.36 (m, 2H), 1.26 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.6
Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 166.4, 155.0, 148.9, 120.4, 77.3, 60.4, 49.8, 43.8, 28.4,
24.7, 22.7, 14.2; HRMS (ESI+) Calc. for C15H27NO4Na 308.1838; Found 308.1827.
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Ethyl (4R)-4-[(tert-butoxycarbonyl)amino]-6-methylhep-tanoate (6.28): To the solution of
6.27 in EtOAc (100 ml) was added 5% Pd/C catalyst (1.0 g) and the reaction mixture stirred
under H2 atmosphere for 30 min at 20psi in Parr shaker. The catalyst was removed by filtration
through a pad of Celite and the organic solvent was evaporated under reduced pressure. Then the
crude obtained was purified by column chromatography using Et2O:hexanes (1:5) to afford 6.28
(18.0 g, 85%) as colorless thick liquid; [20D= -6.20 (c 1, MeOH); max (CHCl3)/cm-1 3357,
2957, 1712, 1689, 1519, 1450, 1390, 1366, 1248, 1168, 1044, 1028; 1H NMR (500 MHz,
CDCl3) δ 4.25 (d, J = 9.0 Hz, 1H), 4.10 (q, J = 6.8 Hz, 2H), 3.71 – 3.56 (m, 1H), 2.33 (t, J = 7.6
Hz, 2H), 1.80 (m, 1H), 1.58 (m, 2H), 1.40 (s, 9H), 1.28 (m, 2H), 1.23 (t, J = 6.8 Hz, 3H), 0.88 (d,
J = 6.5 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 173.7, 155.6, 78.9, 60.4, 48.5, 45.2, 31.0, 28.4,
24.9, 23.0, 22.3, 14.2; HRMS (ESI+) Calc. for C15H29NO4Na 310.1994; Found 310.2002.

(4R)-4-[(tert-Butoxycarbonyl)amino]-6-methylheptanoic acid (6.29): To a solution of 6.28
(16.0 g, 55.7 mmol) in THF:MeOH (400 ml, 5:1) was added aqueous solution of 2M LiOH (84
ml, 168 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature and
stirred for additional 2h. The mixture was concentrated to remove organic solvents, diluted with
Et2O (100 ml), separated the layers and the aqueous layer was carefully acidified with 1N HCl at
0 °C, extracted with methylene chloride (3x50 ml) and the combined organic layers were washed
with brine, dried over MgSO4 and concentrated to afford 6.29 as a white solid (11.46 g, 79%).
M.p. 110-111 oC; [20D= -6.60 (c 1.06, MeOH); max (neat)/cm-1 3331, 2948, 1709, 1657, 1534,
1454, 1394, 1365, 1276, 1253, 1167, 1116, 1026, 901, 872, 847; 1H NMR (500 MHz, MeOD) δ
3.61 (bs, 1H), 2.33 (t, J = 7.5 Hz, 2H), 1.79 (ddd, J = 12.2, 8.1, 3.9 Hz, 1H), 1.72 – 1.63 (m, 1H),
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1.63 – 1.51 (m, 1H), 1.46 (s, 9H), 1.42 – 1.33 (m, 1H), 1.28 – 1.18 (m, 1H), 0.99 – 0.87 (m, 6H);
13

C NMR (126 MHz, MeOD) δ 175.9, 156.9, 78.3, 44.3, 30.9, 30.2, 27.4, 24.7, 22.2, 21.1;

HRMS (ESI+) Calc. for C13H26NO4 260.1862; Found 260.1856.

(4R)-4-Amino-6-methylheptanoic acid hydrochloride (6.29a): To a solution of 6.29 (10.24 g,
39.5 mmol) in anhydrous 1,4-dioxane (20 ml) was added 4M HCl in dioxane (50 ml, 200 mmol)
at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 12h
under argon to yield thick slurry. The mixture was concentrated and resulting solid was dispersed
in anhydrous ether and filtered under inert atmosphere to furnish 6.29a as a white solid, m.p.
147-148 oC; [20D = -4.41 (c 0.64, MeOH); max (neat)/cm-1 2873, 1724, 1702, 1602, 1503,
1438, 1298, 1234, 1121, 896; 1H NMR (400 MHz, D2O) δ 3.35 – 3.26 (m, 1H), 2.46 (t, J = 7.5
Hz, 2H), 1.95 – 1.78 (m, 2H), 1.68 – 1.56 (m, 1H), 1.49 – 1.36 (m, 2H), 0.84 (dd, J = 6.5, 3.0 Hz,
6H); 13C NMR (126 MHz, D2O) δ 177.2, 49.5, 41.0, 29.6, 27.5, 23.8, 21.7, 21.2; HRMS (ESI+)
Calc. for C8H18NO2 160.1338; Found 160.1342.

1H-imidazole-1-sulfonyl azide hydrochloride

Sulfuryl chloride (16.26 ml, 200 mmol)was added drop-wise to an ice-cooled suspension of
sodium azide (13.00 g, 200 mmol) in MeCN (250 mL) and the mixture stirred overnight at room
temperature. imidazole (23.83 g, 350 mmol)was added to the ice-cooled mixture and the
resulting slurry stirred for 3 h. at room temperature. The mixture was diluted with EtOAc
(100mL) and H2O (100mL) and the aqueous layer separated and discarded. The organic layer
was washed with H2O (10 mL) then saturated aqueous NaHCO3 (2 × 15 mL), dried over
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MgSO4 and filtered. Concentration of the filtrate and flash chromatography (EtOAc/Hexanes,
1:3) gave 1 as a colourless liquid (0.62 g, 72%). IR ν max. (film) 2168, 1379 and 1173 cm-1 1H
NMR (500 MHz, CDCl3) δ = 7.1 (dd, 1 H, J = 0.7, 1.6 Hz, H-4), 7.35 (dd, 1 H, J = 1.4, 1.7 Hz,
H-5), 7.96 (dd, 1 H, J = 0.8, 1.4 Hz,)

13

C NMR (101 MHz, CDCl3) δ = 117.3, 131.09, 136.7

HRMS (EI): m/z = 173.0013;

(4R)-4-azido-6-methylheptanoic acid (6.32): The reagent imidazole-1-sulfonyl azide
hydrochloride (3.86 g, 18.40 mmol) was added to the to the suspension of 6.29a (3.0 g, 15.33
mmol), potassium carbonate (7.84 g, 56.7 mmol) and copper(II) sulfate pentahydrate (0.380 g,
0.153 mmol) in 80 ml MeOH. After stirred for 14h, the resulting gray colored mixture was
concentrated, diluted with water and adjusted the pH to 2 with conc. HCl at 0 °C. The resulting
aqueous layer was extracted with ethyl acetate (3x30 ml) and the combined organic layer was
washed with water, brine, dried over magnesium sulfate and concentrated. The residue was
purified by column chromatography (hexanes: EtOAc, 9:1) to afford 6.32 (2.2 g, 77%) as a
colorless liquid; [20D= +10.77 (c 1.17, MeOH); max (neat)/cm-1 2959, 2873, 2097, 1707, 1416,
1369, 1267, 1245, 1172, 922; 1H NMR (500 MHz, CDCl3) δ 3.38 (ddd, J = 13.6, 8.9, 4.6 Hz,
1H), 2.51 (m, 2H), 1.98 (m, 1H), 1.75 (m, 2H), 1.52 (ddd, J = 14.4, 8.7, 5.9 Hz, 1H), 1.32 (m,
1H), 0.94 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 178.7, 60.0, 43.3, 30.5, 29.5, 25.0,
22.9, 22.1; HRMS (ESI+) Calc. for C8H15N3O2 186.1243; Found 186.1247.

4R)-3-[(4R)-4-azido-6-methylheptanoyl]-4-benzyl-1,3-oxazolidin-2-one (6.33): To a stirred
solution of 6.32 (1.0 g, 5.4 mmol) in THF (40 ml) was added TEA (1.52 ml, 10.8 mmol)
followed pivaloyl chloride (0.66 ml, 5.4 mmol) at -20 oC. After stirring for 2h, LiCl (275 mg,
6.48 mmol) and 4(R)-benzyl-oxazolidin-2-one (860 mg, 4.86 mmol) were added, the mixture
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was allowed to warm to 0 oC and then to room temperature slowly and stirred for additional 4h.
The mixture was concentrated and residue was partitioned between 5% aqueous KHSO4 (20 ml)
and ethyl acetate (50 ml). The organic layer was washed with 1M sodium bicarbonate (2x10 ml),
brine (10 ml) and then dried over magnesium sulfate and concentrated. The residue was purified
by column chromatography (EtOAc: hexanes, 3:17) to yield 6.33 (1.4 g, 75%) as a viscous
liquid; [20D= -73.48 (c 1.14, MeOH); max (neat)/cm-1 2958, 2097, 1777, 1698, 1454, 1386,
1351, 1210, 1106, 1050, 745, 701; 1H NMR (400 MHz, CDCl3) δ 7.32 (t, J = 7.2 Hz, 2H), 7.29 –
7.23 (m, 1H), 7.19 (d, J = 6.9 Hz, 2H), 4.67 (ddd, J = 10.7, 7.0, 3.2 Hz, 1H), 4.23 – 4.14 (m, 2H),
3.47 – 3.38 (m, 1H), 3.28 (dd, J = 13.4, 3.3 Hz, 1H), 3.14 – 2.98 (m, 2H), 2.77 (dd, J = 13.4, 9.5
Hz, 1H), 1.95 (dtd, J = 11.4, 7.5, 4.2 Hz, 1H), 1.79 (ddt, J = 20.2, 8.1, 6.1 Hz, 2H), 1.54 (ddd, J =
14.5, 8.8, 5.9 Hz, 1H), 1.34 (ddd, J = 13.7, 8.3, 5.2 Hz, 1H), 0.94 (dd, J = 6.6, 1.4 Hz, 6H); 13C
NMR (101 MHz, CDCl3) δ 172.5, 153.4, 135.3, 129.4, 128.9, 127.3, 66.3, 60.1, 55.1, 43.4, 37.8,
32.2, 29.1, 25.1, 22.9, 22.1; HRMS (ESI+) Calc. for C18H25N4O3 345.1927; Found 345.1937.

(4R)-3-{(2R,4S)-4-azido-2-[(1S)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl]-6methylheptanoyl}-4-benzyl-1,3-oxazolidin-2-one (6.34): To a stirred solution of 6.33(280 mg,
0.81 mmol) in dichloromethane (4 ml) was added freshly distilled TiCl4 (94 µl, 0.85 mmol)
slowly at 0 °C. After 15 min, to this yellow suspension was added the (-)-sparteine (374 µl, 1.6
mmol) drop wise to give a dark red solution, which was stirred for 1h at same temperature. Then
a solution of 6.24 (184 mg, 0.89 mmol) in dichloromethane (2 ml) was added dropwise at 0 °C.
After 2h, the mixture was quenched with half saturated aqueous solution of NH4Cl. The organic
layer was separated and aqueous layer was further extracted with dichloromethane. The
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combined organic layer was washed with water, brine, dried over magnesium sulfate and
concentrated. The residue was purified using column chromatography (hexanes:EtOAc, 3:1) to
give the aldol product 6.34 (330 mg, 74%) as a colorless viscous liquid; [a]20D = -50.3 (c 1.2,
MeOH); max (neat)/cm-1 3506, 2958, 2103, 1779, 1693, 1386, 1350, 1210, 1196, 1110, 702; 1H
NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.3 Hz, 2H), 7.30 – 7.20 (m, 8H), 4.64 (ddd, J = 10.2, 6.6,
3.0 Hz, 1H), 4.28 (ddd, J = 10.4, 5.3, 2.9 Hz, 1H), 4.23 – 4.17 (m, 1H), 4.15 – 4.05 (m, 2H), 3.93
(dq, J = 12.1, 6.9 Hz, 2H), 3.75 (ddd, J = 9.2, 4.8, 2.4 Hz, 1H), 3.71 – 3.63 (m, 2H), 3.41 (dd, J =
11.2, 6.1 Hz, 1H), 3.35 (dd, J = 13.3, 3.2 Hz, 1H), 2.95 (q, J = 13.9 Hz, 2H), 2.69 (dd, J = 13.2,
10.1 Hz, 1H), 2.21 (ddd, J = 14.2, 10.6, 3.7 Hz, 1H), 1.85 (dd, J = 11.0, 6.8 Hz, 2H), 1.82 – 1.73
(m, 1H), 1.70 (ddd, J = 14.1, 8.7, 2.8 Hz, 1H), 1.55 (ddd, J = 14.4, 8.4, 6.4 Hz, 1H), 1.36 (ddd, J
= 13.7, 7.7, 5.7 Hz, 1H), 0.93 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 173.9, 153.2,
135.9, 135.5, 130.7, 129.4, 129.0, 128.1, 127.3, 126.6, 111.4, 68.9, 65.9, 65.3, 64.9, 59.3, 55.7,
44.8, 43.8, 43.5, 40.6, 37.7, 32.1, 25.1, 22.7, 22.3; HRMS (ESI+) Calc. for C30H39N4O6
551.2870; Found 551.2875.

(1S,2R,4S)-4-azido-1-[(2-benzyl-1,3-dioxolan-2-yl)methyl]-2-{[(4R)-4-benzyl-2-oxo-1,3oxazolidin-3-yl]carbonyl}-6-methylhep-tyl(2R)-3,3,3-trifluoro-2-methoxy-2phenylpropanoate [(R)-MTPA ester of (6.34)]: To a stirred solution of 6.34 (3 mg, 5.45 µmol),
TEA (1.5 µl, 10.9 mol) in anhydrous dichloromethane (1.7 ml) was added S-(-)- MTPA-Cl (1.4
mg, 0.054 mmol). After 30 min, the reaction mixture washed with water, brine, dried over
magnesium sulfate and concentrated. The residue was purified by preparative TLC using
hexanes: EtOAc (3:1) to afford R-MTPA ester of 2 (2.9 mg, 70%). 1H NMR (400 MHz, CDCl3)
δ 7.59 (d, J = 7.5 Hz, 2H), 7.41 – 7.30 (m, 5H), 7.30 – 7.22 (m, 6H), 7.19 (d, J = 7.2 Hz, 2H),
5.75 – 5.68 (m, 1H), 4.58 – 4.49 (m, 1H), 4.27 (dt, J = 10.4, 2.6 Hz, 1H), 4.18 (t, J = 8.2 Hz,
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1H), 4.15 – 4.09 (m, 1H), 3.95 (dd, J = 13.4, 6.6 Hz, 1H), 3.88 (dt, J = 12.3, 6.1 Hz, 1H), 3.73
(dd, J = 12.2, 6.7 Hz, 1H), 3.67 (t, J = 6.6 Hz, 1H), 3.53 (s, 3H), 3.31 – 3.23 (m, 2H), 2.90 (dd, J
= 33.3, 13.9 Hz, 2H), 2.74 (dd, J = 13.2, 9.9 Hz, 1H), 2.17 (dd, J = 15.4, 7.5 Hz, 1H), 2.10 – 2.01
(m, 2H), 1.71 (tt, J = 13.5, 6.9 Hz, 1H), 1.58 (s, 1H), 1.53 – 1.44 (m, 1H), 1.44 – 1.35 (m, 1H),
1.32 – 1.23 (m, 2H), 0.92 (d, J = 6.6 Hz, 6H).

(1S,2R,4S)-4-azido-1-[(2-benzyl-1,3-dioxolan-2-yl)methyl]-2-{[(4R)-4-benzyl-2-oxo-1,3oxazolidin-3-yl]carbonyl}-6-methylhep-tyl(2S)-3,3,3-trifluoro-2-methoxy-2phenylpropanoate [(S)-MTPA ester of (6.34)]: Prepared as described above. 1H NMR (400
MHz, CDCl3) δ 7.58 – 7.53 (m, 2H), 7.40 – 7.31 (m, 5H), 7.30 – 7.18 (m, 8H), 5.80 (dd, J = 5.7,
3.1 Hz, 1H), 4.54 (t, J = 8.5 Hz, 1H), 4.30 (dd, J = 16.8, 8.5 Hz, 2H), 4.15 (dd, J = 8.9, 2.1 Hz,
1H), 3.83 (dd, J = 12.7, 6.7 Hz, 1H), 3.74 (dd, J = 13.1, 6.7 Hz, 1H), 3.64 – 3.56 (m, 4H), 3.52
(dd, J = 12.6, 6.5 Hz, 1H), 3.30 (dd, J = 13.3, 3.1 Hz, 2H), 2.88 – 2.75 (m, 3H), 2.24 – 2.14 (m,
1H), 1.98 (d, J = 6.3 Hz, 2H), 1.82 – 1.69 (m, 1H), 1.52 (ddd, J = 16.3, 13.7, 4.9 Hz, 2H), 1.39 –
1.29 (m, 2H), 0.94 (d, J = 6.6 Hz, 6H).

(3R,5S)-3-[(1S)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl]-5-isobutylpyrrolidin-2-one
(6.35): To a solution of 6.34 (160 mg, 0.291 mmol) in MeOH (15 ml) was added ammonium
formate (366 mg, 5.81 mmol), 5% Pd/C (60 mg) and stirred for 1h at room temperature. The
mixture was concentrated and residue dissolved in ethyl acetate, washed with water, brine, dried
over magnesium sulfate, and concentrated. The residue was purified by column chromatography
(isopropanol: hexanes, 1:9) to afford 6.35 (86 mg, 85%) as a colorless viscous liquid; [20D = 11.4 (c 0.35, MeOH); max (CHCl3)/cm-1 3224, 2925, 2954, 1687, 1454, 1269, 1128, 1030, 820,
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735; 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.20 (m, 5H), 6.04 (s, 1H), 4.44 (d, J = 9.7 Hz, 1H),
4.00 – 3.91 (m, 2H), 3.77 – 3.63 (m, 3H), 2.96 (dd, J = 30.2, 13.9 Hz, 2H), 2.36 (dd, J = 15.2, 6.5
Hz, 2H), 1.82 (dt, J = 14.6, 12.2 Hz, 2H), 1.71 – 1.64 (m, 1H), 1.64 – 1.55 (m, 1H), 1.43 – 1.35
(m, 1H), 1.32 – 1.23 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H);

13

C NMR (126 MHz, CDCl3) δ 177.7,

136.1, 130.6, 128.1, 126.6, 111.5, 66.5, 65.3, 65.0, 51.0, 46.5, 46.4, 43.9, 41.7, 27.7, 25.3, 22.9,
22.4; HRMS (ESI+) Calc. for C20H30NO4 348.2175; Found 348.2176.

(-)-Berkeleyamide A (6.1): To a solution of 6.35 (23 mg, 0.066 mmol) in acetone (0.5 ml) and
water (24 l, 1.3 mmol) was added bis (acetonitrile) dichloropalladium (II) (3.43 mg, 0.013
mmol). The mixture was stirred for 4h and concentrated. The residue was purified by column
chromatography (isopropanol: hexanes, 1:9) to afford 6.1 (15 mg, 77%) as a colorless viscous
liquid; [a]20D = -34.2 (c 0.48, MeOH), [a]20D = -31.1 (c 0.11, MeOH); max (CHCl3)/cm-1 3257,
2955, 2927, 1704, 1686, 1454, 1367, 1271, 1077, 1030, 734; 1H NMR (400 MHz, CDCl3) δ 7.33
(t, J = 7.2, 3H), 7.30 – 7.24 (m, 1H), 7.24 – 7.17 (d, 2H), 6.11 (s, 1H), 4.37 (ddd, J = 8.8, 5.3,
3.4, 1H), 3.74 (s, 2H), 3.65 (td, J = 11.9, 7.7, 1H), 3.12 (s, 1H), 2.85 (dd, J = 17.3, 3.2, 1H), 2.71
(dd, J = 17.3, 8.9, 1H), 2.52 – 2.42 (m, 1H), 2.31 (dt, J = 13.0, 7.6, 1H), 1.72 (ddd, J = 13.2, 9.3,
4.2, 1H), 1.60 (td, J = 13.4, 6.6, 1H), 1.44 – 1.34 (m, 1H), 1.28 (dt, J = 13.7, 7.0, 1H), 0.91 (d, J
= 6.6, 6H); 13C NMR (101 MHz, CDCl3) δ 208.5, 177.2, 133.6, 129.5, 128.7, 127.1, 66.9, 50.8,
50.7, 46.4, 46.1, 45.5, 28.8, 25.3, 22.8, 22.3; HRMS (ESI+) Calc. for C18H26NO3 304.1913;
Found 304.1902.
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(S)-3-((2S,4S)-4-azido-2-((R)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl)-6methylheptanoyl)-4-benzyloxazolidin-2-one (6.45) and (S)-3-((2S,4R)-4-azido-2-((R)-2-(2benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl)-6-methylheptanoyl)-4-benzyloxazolidin-2-one
(6.46):

To a stirred solution of 6.44+6.43 (100.0 mg, 0.290 mmol) in dichloromethane (4 ml) was added
freshly distilled TiCl4 (33.6 µl, 0.305 mmol) slowly at 0 °C. After 15 min, to this yellow
suspension was added the (-) Sparteine (167 µl, 0.726 mmol) drop wise to give a dark red
solution, which was stirred for 1h at same temperature. Then a solution of 6.24 2-(2-benzyl-1,3dioxolan-2-yl)acetaldehyde (65.9 mg, 0.319 mmol) in dichloromethane (2 ml) was added
dropwise at 0 °C. After 2h, the mixture was quenched with half saturated aqueous solution of
NH4Cl. The organic layer was separated and aqueous layer was further extracted with
dichloromethane. The combined organic layer was washed with water, brine, dried over
magnesium sulfate and concentrated. The residue was purified using column chromatography
(hexanes:EtOAc, 3:1) to give the mixture of aldol products Aldol 6.45 (48.0 mg, 0.087 mmol,
30.0 % yield) and Aldol 6.46 (53.0mg, 0.096 mmol, 33.1 % yield) as a colorless viscous liquid

(S)-3-((2S,4S)-4-azido-2-((R)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl)-6methylheptanoyl)-4-benzyloxazolidin-2-one (6.45)
[a]20D = 30.3 (c 1.0, MeOH); max (neat)/cm-1 3500, 2955, 2100, 1769, 1683, 1350, 1210, 730 1H
NMR (500 MHz, CDCl3) δ 7.37 (t, J = 7.3 Hz, 2H), 7.29 (dd, J = 13.2, 6.8 Hz, 6H), 7.26 – 7.21
(m, 2H), 4.57 (td, J = 7.7, 2.4 Hz, 1H), 4.32 – 4.26 (m, 1H), 4.19 – 4.08 (m, 2H), 4.05 (dd, J =
16.2, 8.2 Hz, 1H), 4.01 – 3.94 (m, 2H), 3.88 – 3.78 (m, 2H), 3.78 – 3.70 (m, 1H), 3.52 – 3.41 (m,
2H), 2.97 (s, 2H), 2.66 (dd, J = 13.1, 10.8 Hz, 1H), 2.06 – 1.99 (m, 1H), 1.98 – 1.72 (m, 4H),
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1.57 (ddd, J = 14.4, 9.0, 5.7 Hz, 1H), 1.38 (ddd, J = 13.7, 8.5, 5.0 Hz, 1H), 1.28 (t, J = 7.1 Hz,
1H), 0.96 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 174.30, 153.47, 135.94, 135.77,
130.64, 129.48, 128.98, 128.10, 127.26, 126.66, 111.43, 77.41, 77.15, 76.90, 69.56, 65.83, 65.28,
64.91, 60.41, 55.98, 46.30, 43.76, 43.68, 40.04, 37.17, 34.02, 25.04, 23.03, 22.07, 14.24. (ESI+)
for C30H39N4O6= 551.30
(S)-3-((2S,4R)-4-azido-2-((R)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl)-6methylheptanoyl)-4-benzyloxazolidin-2-one (6.46):
[a]20D = 30.3 (c 1.6, MeOH); max (neat)/cm-1 3506, 2958, 2103, 1779, 1693, 1386, 1350, 1210,
1

H NMR (500 MHz, CDCl3) δ 7.40 – 7.35 (m, 2H), 7.34 – 7.23 (m, 9H), 5.31 (s, 1H), 4.76 –

4.56 (m, 1H), 4.31 (dd, J = 10.3, 2.7 Hz, 1H), 4.27 – 4.22 (m, 1H), 4.19 – 4.08 (m, 2H), 4.02 –
3.91 (m, 2H), 3.83 – 3.77 (m, 1H), 3.76 – 3.68 (m, 2H), 3.49 – 3.41 (m, 1H), 3.38 (dd, J = 13.2,
2.9 Hz, 1H), 2.98 (q, J = 13.9 Hz, 2H), 2.73 (dd, J = 13.1, 10.2 Hz, 1H), 2.25 (ddd, J = 14.1,
10.7, 3.5 Hz, 1H), 1.88 (dd, J = 10.8, 7.0 Hz, 2H), 1.84 – 1.77 (m, 1H), 1.76 – 1.71 (m, 1H), 1.63
– 1.52 (m, 1H), 1.43 – 1.36 (m, 1H), 0.96 (d, J = 6.6 Hz, 7H)

13

C NMR (126 MHz, CDCl3) δ

173.86, 153.19, 135.92, 135.50, 130.68, 129.45, 129.01, 128.10, 127.35, 126.65, 111.43, 77.40,
77.15, 76.89, 68.92, 65.87, 65.35, 64.92, 59.27, 55.68, 44.70, 43.79, 43.50, 40.54, 37.70, 32.08,
25.08, 22.77, 22.30. (ESI+) for C30H39N4O6= 551.29
(R)-3-((2R,4R)-4-azido-2-((S)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl)-6methylheptanoyl)-4-benzyloxazolidin-2-one (6.41)
[a]20D = -40.3 (c 1.9, MeOH); max (neat)/cm-1 3516, 2948, 2113, 1778, 1693, 1386; 1H NMR
(500 MHz, CDCl3) δ 7.37 (t, J = 7.3 Hz, 2H), 7.29 (dd, J = 13.4, 7.1 Hz, 6H), 7.25 – 7.20 (m,
1H), 4.57 (td, J = 7.7, 2.5 Hz, 1H), 4.30 (ddd, J = 9.7, 6.7, 2.8 Hz, 1H), 4.19 – 4.09 (m, 2H), 4.06
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(d, J = 8.0 Hz, 1H), 4.04 – 3.91 (m, 3H), 3.89 – 3.66 (m, 3H), 3.57 – 3.37 (m, 2H), 2.97 (s, 2H),
2.66 (dd, J = 13.1, 10.8 Hz, 1H), 2.06 – 1.70 (m, 6H), 1.57 (ddd, J = 14.3, 8.9, 5.7 Hz, 1H), 1.38
(ddd, J = 13.7, 8.4, 5.0 Hz, 1H), 1.29 (dd, J = 8.3, 5.9 Hz, 1H), 1.05 – 0.84 (m, 6H). 13C NMR
(126 MHz, CDCl3) δ 174.30, 153.44, 135.95, 135.78, 130.63, 129.45, 128.97, 128.08, 127.24,
126.64, 111.43, 77.35, 77.09, 76.84, 69.56, 65.83, 65.26, 64.90, 60.40, 55.96, 46.31, 43.78,
43.70, 40.11, 37.21, 34.02, 25.05, 23.00, 22.07. (ESI+) C30H39N4O6= 551.28.
(3S,5S)-3-((R)-1-hydroxy-3-oxo-4-phenylbutyl)-5-isobutylpyrrolidin-2-one (6.48)
To a solution of Ketal 6.48a (18.0 mg, 0.052 mmol) in acetone (0.5 ml) and Water (12.13 µl,
0.673 mmol) was added bis (acetonitrile) dichloropalladium (II) (2.06 mg, 0.008 mmol). The
mixture was stirred for 4h and concentrated. The residue was purified by column
chromatography (isopropanol: hexanes, 1:9) to afford Isomer I_RSS_6.48 (10.0mg, 0.033 mmol,
63.6 % yield) as a colorless viscous liquid ; [a]20D = -33.2 (c 0.7, MeOH), max (CHCl3)/cm-1
3250, 2965, 2917, 1700, 1687, 1360, 1201; 1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 7.3 Hz,
2H), 7.29 (t, J = 7.3 Hz, 2H), 7.22 (d, J = 7.1 Hz, 2H), 6.26 (s, 1H), 4.43 (d, J = 3.5 Hz, 1H),
3.83 – 3.72 (m, 3H), 3.61 (dt, J = 14.0, 6.7 Hz, 2H), 3.48 (d, J = 2.2 Hz, 1H), 2.88 (dd, J = 17.1,
3.4 Hz, 1H), 2.73 (dd, J = 17.1, 8.9 Hz, 1H), 2.52 (ddd, J = 10.6, 9.0, 5.1 Hz, 1H), 2.20 (ddd, J =
12.6, 8.6, 6.8 Hz, 1H), 1.74 – 1.59 (m, 3H), 1.47 (dt, J = 13.9, 7.0 Hz, 2H), 1.39 – 1.32 (m, 2H),
0.94 (d, J = 2.3 Hz, 3H), 0.93 (d, J = 2.3 Hz, 4H).13C NMR (126 MHz, CDCl3) δ 208.45, 177.09,
133.69, 129.52, 128.77, 127.16, 77.30, 77.05, 76.79, 66.36, 50.68, 50.62, 46.84, 46.41, 45.81,
29.69, 25.32, 22.72, 22.59. ESI+ (M+Na) C18H25NNaO3 326.18
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(3S,5R)-3-((R)-1-hydroxy-3-oxo-4-phenylbutyl)-5-isobutylpyrrolidin-2-one (6.47)
To a solution of 6.47a (24.00 mg, 0.069 mmol) in acetone (0.5 ml) and Water (16.18 µl, 0.898
mmol) was added bis (acetonitrile) dichloropalladium (II) (2.69 mg, 0.010 mmol). The mixture
was stirred for 4h and concentrated. The residue was purified by column chromatography
(isopropanol: hexanes, 1:9) to afford (3S,5R)-3-((R)-1-hydroxy-3-oxo-4-phenylbutyl)-5isobutylpyrrolidin-2-one (16.0 mg, 0.053 mmol, 76 % yield) 6.47 as a colorless viscous liquid
(solidifies after few weeks) ; [a]20D = +34.2 (c 0.9); max (CHCl3)/cm-1 3259, 2945, 2927, 1701,
1686, 1455, 1364, 1270, 1077, 1030, 734; 1H NMR (500 MHz, CDCl3) δ 7.64 – 6.83 (m, 42H),
6.51 (s, 8H), 4.42 (s, 7H), 3.76 (s, 14H), 3.67 (d, J = 11.4 Hz, 17H), 2.85 (d, J = 3.2 Hz, 2H),
2.83 – 2.58 (m, 12H), 2.58 – 2.10 (m, 16H), 1.98 (s, 2H), 1.72 (ddd, J = 13.1, 9.4, 4.0 Hz, 6H),
1.67 – 1.19 (m, 28H), 0.97 (s, 3H), 0.93 (d, J = 6.6 Hz, 46H). 13C NMR (126 MHz, CDCl3) δ
208.65, 177.52, 133.67, 129.52, 128.77, 127.16, 77.32, 77.07, 76.81, 66.69, 50.76, 50.69, 46.47,
46.09, 45.61, 28.57, 25.23, 22.92, 22.32. ESI (M+1) 304.19
(3R,5R)-3-((S)-1-hydroxy-3-oxo-4-phenylbutyl)-5-isobutylpyrrolidin-2-one (6.42)
Procedure same as for compound 6.47
[a]20D = +39.1 (c 2.0, MeOH) max (CHCl3)/cm-1 3247, 2907, 1700, 1682, 1454, 1H NMR (500
MHz, CDCl3) δ 7.37 (t, J = 7.3 Hz, 2H), 7.29 (dd, J = 13.4, 7.1 Hz, 6H), 7.25 – 7.20 (m, 1H),
4.57 (td, J = 7.7, 2.5 Hz, 1H), 4.30 (ddd, J = 9.7, 6.7, 2.8 Hz, 1H), 4.19 – 4.09 (m, 2H), 4.06 (d, J
= 8.0 Hz, 1H), 4.04 – 3.91 (m, 3H), 3.89 – 3.66 (m, 3H), 3.57 – 3.37 (m, 2H), 2.97 (s, 2H), 2.66
(dd, J = 13.1, 10.8 Hz, 1H), 2.06 – 1.70 (m, 6H), 1.57 (ddd, J = 14.3, 8.9, 5.7 Hz, 1H), 1.38 (ddd,
J = 13.7, 8.4, 5.0 Hz, 1H), 1.29 (dd, J = 8.3, 5.9 Hz, 1H), 1.05 – 0.84 (m, 6H). 13C NMR (126
MHz, CDCl3) δ 174.30, 153.44, 135.95, 135.78, 130.63, 129.45, 128.97, 128.08, 127.24, 126.64,
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111.43, 77.35, 77.09, 76.84, 69.56, 65.83, 65.26, 64.90, 60.40, 55.96, 46.31, 43.78, 43.70, 40.11,
37.21, 34.02, 25.05, 23.00, 22.07. ESI (M+1) 304.19

N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-4-methylbenzenesulfonamide (6.52)

To a stirred suspension of 1R, 2S-cis-amioindan-2-ol, p-toluenesulfonyl chloride and DMAP in
DCM was added TEA. After stirring for 2 h at 23 oC, the resulting solution was washed with
water, brine and was dried over anhydrous magnesium sulfate. Solvent was reduced under
vacuum to afford crude product. The crude was purified using column chromatography over
silica gel (4:6 EtOAc:Hexanes) to give p-toluenesulfonamide cream colored solid obtained (m.p.
130-133) 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.20
(dt, J = 19.0, 7.1 Hz, 2H), 7.09 (d, J = 7.3 Hz, 1H), 5.26 (d, J = 9.1 Hz, 1H), 4.70 (dd, J = 9.1,
4.8 Hz, 1H), 4.34 (dd, J = 4.9, 3.5 Hz, 1H), 3.06 (dd, J = 16.7, 5.1 Hz, 1H), 2.89 (d, J = 16.6 Hz,
1H), 2.46 (s, 3H), 1.78 – 1.63 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 143.79, 139.48, 137.57,
129.87, 128.51, 127.26, 127.20, 125.35, 124.56, 77.36, 77.05, 76.73, 72.84, 61.31, 39.29, 21.59.

(R)-(1R,2S)-1-(4-methylphenylsulfonamido)-2,3-dihydro-1H-inden-2-yl4-azido-6methylheptanoate (6.53)

To a stirred solution of N-tosyl-1-aminoindan-2-ol (213 mg, 0.702 mmol), DMAP (42.9 mg,
0.351 mmol) and (R)-4-azido-6-methylheptanoic acid (130.0 mg, 0.702 mmol) in DCM was
added DCC (217 mg, 1.053 mmol) . The resulting slurry was stirred at 23°C for 18h.The slurry
was filterd through pad of celite and concentrated to afford residue which was purified by silica
gel chromatography to yield ester 91% yield max (CHCl3)/cm-1 3278, 2957, 2100, 1737, 1336 1H
NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.25 (dd, J = 12.3,
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3.4 Hz, 3H), 7.18 (d, J = 6.1 Hz, 1H), 5.20 (t, J = 4.6 Hz, 2H), 4.99 (dd, J = 10.1, 5.2 Hz, 1H),
3.31 (dt, J = 8.8, 4.3 Hz, 1H), 3.11 (dd, J = 17.3, 4.9 Hz, 1H), 2.92 (d, J = 17.3 Hz, 1H), 2.46 (s,
3H), 2.32 (t, J = 7.4 Hz, 2H), 1.85 – 1.71 (m, 3H), 1.65 (dt, J = 14.3, 7.3 Hz, 1H), 1.53 – 1.44
(m, 1H), 1.27 (ddd, J = 13.5, 8.2, 5.3 Hz, 2H), 0.93 (dd, J = 6.6, 1.9 Hz, 6H).

13

C NMR (101

MHz, CDCl3) δ 171.91, 143.83, 139.58, 138.54, 137.87, 129.87, 128.69, 127.46, 126.99, 125.03,
124.24, 77.33, 77.02, 76.70, 75.03, 59.94, 59.51, 43.24, 37.37, 30.58, 29.49, 24.99, 22.84, 22.07,
21.57.

(3R,5S)-3-((R)-2-(2-benzyl-1,3-dioxolan-2-yl)-1-hydroxyethyl)-5-isobutylpyrrolidin-2-one
(6.54)
To a stirred solution of Tos Aminoidanol aux Azido acid (127.0 mg, 0.270 mmol) in dry CH 2Cl2
was added 1M TiCl4 (35.7 µl, 0.324 mmol) CH2Cl2 solution dropwise under argon at 0 oC. The
resulting solution was allowed to warm to 24 oC and stirred for another 15-20 mins. DIPEA (179
µl, 1.026 mmol) was added in a dropwise fashion to this solution at the same temperature, giving
brown color solution. After stirring for additional 1 hr at 24 oC, the resulting solution was taken
in a syringe and was added very slowly using a syringe pump over 15mins into a solution of 2(2-benzyl-1,3-dioxolan-2-yl)acetaldehyde (120 mg, 0.580 mmol) and TiCl4 (8.93 µl, 0.081
mmol) at -78 oC. The reaction mixture was stirred at -78 oC for 1hr and then quenched by
addition of ammonium chloride solution. The layers were separated and the aqueous layer was
washed with 10.0ml of DCM. Combined organic layers were washed with brine and then dried
over magnesium sulfate to furnish crude aldol products. The crude products were separated using
column chromatography (hexanes:EtoAc 7:3) The aldol product obtained were immediately
cyclized using same procedure as in 6.47 [20D = -12.4 (c 0.85, MeOH); max (CHCl3)/cm-1
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3222, 2929, 2954, 1689, 1454, 1269; 1H NMR (500 MHz, CDCl3) δ 7.47 – 7.18 (m, 6H), 6.54 (s,
1H), 4.37 (s, 1H), 4.14 (dd, J = 9.3, 6.2 Hz, 1H), 3.94 (s, 2H), 3.69 (dd, J = 17.4, 6.6 Hz, 3H),
3.02 (q, J = 14.0 Hz, 2H), 2.51 (dd, J = 15.8, 6.8 Hz, 1H), 2.21 – 2.02 (m, 2H), 1.88 – 1.77 (m,
2H), 1.70 – 1.56 (m, 1H), 1.46 – 1.36 (m, 1H), 1.35 – 1.22 (m, 2H), 0.93 (d, J = 6.5 Hz, 6H). 13C
NMR (126 MHz, CDCl3) δ 178.36, 136.32, 130.75, 127.94, 126.42, 111.19, 77.31, 77.05, 76.80,
69.38, 65.32, 64.94, 50.83, 46.09, 45.22, 43.99, 41.46, 30.98, 25.26, 22.97, 22.23. HRMS (ESI+)
Calc. for C18H26NO3Na 370.1994; Found 370.2002.
(3R,5S)-3-((R)-1-hydroxy-3-oxo-4-phenylbutyl)-5-isobutylpyrrolidin-2-one (6.55)
[a]20D = -40.1 (c 0.5, MeOH) 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 7.1 Hz, 1H), 7.35 – 7.27
(m, 3H), 7.23 (d, J = 7.1 Hz, 2H), 6.20 (s, 1H), 4.22 (s, 1H), 3.82 (s, 2H), 3.68 (s, 1H), 2.86 (dd,
J = 16.2, 8.5 Hz, 1H), 2.74 – 2.64 (m, 1H), 2.51 (d, J = 7.8 Hz, 2H), 2.13 – 2.02 (m, 1H), 1.85 (d,
J = 9.4 Hz, 1H), 1.69 – 1.56 (m, 1H), 1.47 – 1.37 (m, 1H), 1.30 (dd, J = 14.9, 8.7 Hz, 2H), 0.94
(d, J = 6.6 Hz, 6H).13C NMR (126 MHz, CDCl3) δ 208.05, 178.52, 133.99, 129.80, 128.81,
127.03, 69.86, 51.34, 51.06, 46.32, 45.73, 45.39, 44.18, 30.76, 25.31, 23.11, 22.12. HRMS
(ESI+) Calc. for C18H26NO3Na 326.1732; Found 326.1726.
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